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Abstract 
One of the most pressing issues in the clinical management of patients with idiopathic 
pulmonary fibrosis (IPF) is how a clinician can respond when asked “how long do I 
have?”  IPF has a varied clinical course and the only available treatments, aside from 
lung transplantation, are corticosteroids and immunosuppressants. The side effects of 
both corticosteroids and immunosuppressants may actually outweigh the benefits for 
use in IPF. Biomarkers of disease progression are often unable to predict acute lung 
function decline. This is possibly because the underlying mechanisms driving the 
disease are poorly understood and little attention has been paid to how intrinsic 
differences in resident lung fibroblasts may be contributing to this disease.  
In this thesis, extracellular matrix (ECM) molecules that are both found in the blood 
and released by resident lung fibroblasts were investigated for their utility as 
biomarkers of disease progression in IPF. The primary focus was on the ECM protein 
fibulin-1, an essential constituent of elastic fibres, which has not previously been 
studied in the context of interstitial lung disease. This thesis investigated the 
relationship between fibulin-1, and disease severity in patients with and without 
pulmonary fibrosis. In addition, the utility of fibulin-1 as a biomarker of disease 
progression was compared against other previously described components of the 
ECM, namely periostin, tenascin-C and fibronectin, in the same patients. Lastly, the 
effect of the profibrotic cytokine transforming growth factor-beta-1 (TGFβ1) on 
fibulin-1 levels in resident lung fibroblasts from patients with and without IPF was 
interrogated.  
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Patients with IPF had higher levels of serum, tissue and fibroblast-derived fibulin-1 
than patients without IPF. Serum fibulin-1 levels accurately discriminated between 
patients with IPF who progressed (whereby progression is defined as a decline in lung 
function) within one year of blood draw and those who remained stable. Neither 
periostin, tenascin-C or fibronectin levels were predictive of disease progression in 
patients with IPF. 
Increased ECM deposition leads to decreased lung function as the normal architecture 
is replaced by fibrotic tissue. Tissue fibulin-1 negatively correlated with lung function 
in patients with IPF. Importantly, while tissue periostin and total collagen were 
similarly increased in patients with IPF compared to patients without IPF, levels of 
periostin and total collagen did not correlate with lung function. This thesis highlights 
for the first time that fibulin-1 may be an important contributor to lung mechanical 
properties. Furthermore, fibulin-1 dysregulation may stem from altered fibulin-1 
production by fibroblasts derived from patients with IPF. Cell-secreted and cell-
associated fibulin-1 levels were increased in fibroblasts derived from patients with 
IPF compared to patients without IPF. TGFβ1 induced deposition of fibulin-1 was 
observed in fibroblasts derived from patients with IPF but not in fibroblasts derived 
from patients without IPF. 
In conclusion, the ECM profile is altered in patients with IPF compared to patients 
without IPF. While any of the 300+ proteins that constitute the lung ECM may be 
dysregulated in the context of IPF, fibulin-1 stood out as a novel biomarker of disease 
severity and may be an important target of the fibrotic process. 
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Chapter 1.    Introduction 
1.1 Interstitial lung disease 
1.1.1 Background 
The term interstitial lung disease (ILD) is an umbrella term that describes a large 
group of disorders that can affect men, women and children (Bradley et al. 2008). 
Most of the more than 150 different ILD disorders eventually lead to lung scarring, or 
pulmonary fibrosis (Selman and Pardo 2013). Causes of ILDs are varied and often 
hard to determine in the individual patient. Some patients could go many years 
without a definitive diagnosis and disease guidelines outline the need for a 
multidisciplinary approach for the most accurate diagnosis (Raghu et al. 2011).  
Diagnosis of ILD is challenging and there is an entire subgroup of ILDs of which the 
cause of the initial injury is ruled unknown. Idiopathic interstitial pneumonias (IIPs) 
encompass an equally varied spectrum of ILDs in which all typical causes of ILD 
have been ruled out, which puts a special emphasis on the need for a complete patient 
history in addition to baseline lung function measurements during the initial 
presentation. However, pulmonary fibrosis remains a common theme and a cause for 
concern in many ILDs.   
In pulmonary fibrosis, the alveoli that are responsible for efficient gas transfer are 
hindered by perpetual inflammation and damaged interstitium. When scarring occurs, 
it is generally not reversible (Paz and Shoenfeld 2010). Progressive fibrosis eventually 
leads to the destruction of the normal lung architecture, loss of lung function and 
eventually death (Araya and Nishimura 2010).  
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Changes in lung function parameters are often used to monitor patients with ILD. In 
patients with idiopathic pulmonary fibrosis (IPF), a small decline in lung function can 
indicate increased risk of death due to fibrosis. Pulmonary fibrosis is a consequence 
for which lung transplantation remains the only viable option of treatment in the end 
stages of different ILDs (Demedts et al. 2001; Raghu et al. 2011).  
Greater understanding of the mechanisms driving pulmonary fibrosis is critical in 
order to design treatments to slow or even reverse the fibrotic process. The 
extracellular matrix (ECM) is a key driver of the fibrogenesis (Tschumperlin et al. 
2012). Changes in ECM proteins signal states of active fibrogenesis in other diseases 
(Jourdan-LeSaux et al. 2010; Lopez-Hernandez and Lopez-Novoa 2012) and have 
recently also been shown to be important in IPF (Naik et al. 2012). 
1.1.2 Aetiology 
There are many different causes of ILD and identification of the causal agent is an 
essential component of the diagnostic strategy. Classification of ILD is based on 
aetiology (Figure 1.1) and the clinical course of ILD is largely determined by its 
underlying cause. Most commonly, ILDs will be associated with occupational or 
environmental exposures (eg. smoke, bird allergens) or due to an underlying 
connective-tissue disease (eg. scleroderma).  
Although some forms of ILD are untreatable, many forms do respond to treatment 
(Theodore et al. 2012). This makes accurate diagnosis of the specific ILD very 
important. ILDs can be grouped into categories where the initial insult is known, and 
those where the cause of the ILD is unknown, or idiopathic.  
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Figure 1.1 Classification of some Interstitial Lung Diseases (ILDs) 
The classification of ILDs is based primarily by aetiology. 
IIP idiopathic interstitial pneumonia, IPF idiopathic pulmonary fibrosis, LAM 
lymphangioleiomyomatosis 
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1.1.3 Diagnosis 
Diagnosis in ILD is difficult as the scores of disease entities all affect the lung 
interstitium and share similar clinical and radiological manifestations. Prior to 
diagnosis, a patient will often present with very diffuse respiratory symptoms 
(Kameda et al. 2011). These symptoms include shortness of breath (dyspnea) and a 
persistent but non-productive cough.  Upon taking a patient history, the clinician will 
need to determine if there have been any exposures to agents of ILD such as a history 
of smoking and even certain medications. The clinician also needs to investigate if the 
ILD is caused by an underlying connective-tissue disease. 
A thorough patient history is critical to identify the causal factor and if a patient is 
suspected to have an ILD, a detailed physical examination follows, again looking for 
potential underlying causes of ILD not easily elucidated from a patient’s memory.  
Lastly, a series of lung function tests and high-resolution computed tomography (HR-
CT) scans will be performed; not only for diagnosis, but also to assess the severity of 
the ILD at first presentation, as this is indicative of mortality in certain ILDs (Jegal et 
al. 2005).  
If a definitive diagnosis cannot be made following the routine examination, a surgical 
lung biopsy is then taken. However, this is an invasive procedure and it is possible 
that diagnosis can be made on the radiological features on HR-CT instead (Ryerson 
and Collard 2013).  
1.1.4 Treatment and Management 
Management in ILD is multifaceted. Often, for ILDs which have a known aetiology, 
correct identification of the causal agent is required at first consultation. Patients with 
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newly diagnosed ILD are all advised to cease smoking and undergo pulmonary 
rehabilitation which can improve or prevent the further decline of lung function.  
Monitoring of ILD patients is done through repeated lung function measurements.  
In most cases, if the causal agent is an allergen or environmental toxin, removal or 
limitation of exposure to the agent is recommended. If the causal agent is an 
underlying connective tissue disease, then the connective tissue disease is treated with 
the paramount aim of slowing of lung function decline. However, some instances of 
ILD, such as IPF, are relentlessly progressive and currently have no effective 
treatment beyond lung transplantation.  
1.1.5 Connective-tissue disease related interstitial lung disease 
Connective-tissue disease related ILD (CTD-ILD) accounts for about 15% of all ILDs 
(Fischer and du Bois 2012). Underlying connective tissue disease represents a 
difficult-to-treat sub-group of ILDs, including rheumatoid arthritis, systemic lupus 
erythematosus and systemic sclerosis. As with other ILDs, there is a lot of 
heterogeneity between CTD-ILDs and each is associated with particular clinical 
features. 
Most clinically relevant is the fact that CTD-ILD often has a more favourable 
prognosis compared to the other idiopathic ILDs. There have been substantial gains in 
the understanding of systemic sclerosis through the recent completion of two major 
clinical trials (Homer and Herzog 2010). Features of CTD are often seen in patients 
diagnosed with ILD as 13% of those meeting the diagnostic criteria for IPF also have 
undifferentiated CTD (Fischer and du Bois 2012).  
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1.1.6 Hypersensitivity pneumonitis 
Hypersensitivity pneumonitis (HP) is similar in presentation to IPF but is caused by 
repeated exposure to a particular allergen.  Inhalation of organic allergens is the most 
common cause, but inorganic chemicals can also cause HP (Hanak et al. 2007). 
Treatment mostly requires avoidance of the causal antigen. HP comes in three states; 
acute, subacute and chronic, and the majority of patients will present with a pattern 
that fits one of the three categories (Bradley et al. 2008). Despite this, patients with 
chronic HP are the most difficult to diagnose as careful patient history must be 
obtained to rule out IPF (Selman and Buendia-Roldan 2012). 
1.1.7 Sarcoidosis 
Sarcoidosis is an ILD that rarely progresses to pulmonary fibrosis and 55-90% of 
patients with stage I disease will undergo spontaneous remission (Bradley et al. 2008). 
Again, the natural history and progression of this disease is difficult to predict but 
most remissions will occur during the first six months. Due to the high rates of 
remission, treatment is not normally prescribed if the patient has normal or mildly 
abnormal lung function and normal oxygen saturation (Reich 2012). If the disease 
progresses, the overall mortality is 1-5%, mainly due to myocardial or central nervous 
system involvement (Bradley et al. 2008).     
1.1.8 Idiopathic interstitial pneumonias 
The IIPs includes seven clinico-radiologic-pathologic groups of ILDs: IPF, 
nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), 
acute interstitial pneumonia (AIP), respiratory bronchiolitis-associated interstitial lung 
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disease (RB-ILD), desquamative interstitial pneumonia (DIP), and lymphoid 
interstitial pneumonia (LIP).  
The availability of HR-CT allowed for the discrimination of a particular radiologic 
pattern known as usual interstitial pneumonia (UIP) from the other IIP patterns. UIP is 
the hallmark feature of IPF (Figure 1.2), with its presence determining IPF diagnosis 
with the greatest certainty (King et al. 2001). Of the seven disease entities, IPF 
remains the most common of the IIPs and has the greatest mortality (Flaherty et al. 
2003).  
 
Figure 1.2 High-resolution computed tomography (HR-CT) scans of a patient 
with usual interstitial pneumonia (UIP). 
HR-CT scans demonstrate the classic UIP pattern that defines idiopathic pulmonary 
fibrosis (IPF). (A) Axial and (B) coronal images show extensive fibrosis with basal 
predominance of the honeycombing pattern that is the hallmark feature of UIP 
(arrows).   
Reproduced with permission from (Raghu et al. 2011) 
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1.2 Idiopathic pulmonary fibrosis 
1.2.1 The problem of an unknown cause 
IPF occurs primarily in older adults and fibrosis is limited to the lungs. The diagnosis 
of IPF is determined by the exclusion of other known causes of ILD and a particular 
pattern of fibrosis that is seen on HR-CT scans or by surgical biopsy (Raghu et al. 
2011). In addition, many patients with IPF present with concomitant diseases such as 
pulmonary hypertension and emphysema, making both diagnosis and treatment 
difficult. 
IPF affects more males than females and smoking is a significant risk-factor for the 
development of the disease (Ryerson and Collard 2013). Progression in IPF is varied 
and unpredictable and the effect of co-morbidities has not been well-studied. Unlike 
other ILDs where allergen avoidance or medications can significantly improve lung 
function, a diagnosis of IPF has no such positives and clinicians and patients alike are 
often at a loss as to what are the next steps to take (Swigris et al. 2005).  
Current recommendations for treatment are limited to only oxygen therapy in the most 
severe patients (Raghu et al. 2011). Enrolment into clinical trials may be the only 
course of action, besides lung transplantation, but often strict inclusion criteria leave 
many patients without options.  
1.2.2 Clinical trials 
Treatment of IPF has been largely unsuccessful (Noble et al. 2011), partly due to 
incomplete knowledge of the mechanisms driving fibrogenesis. Pirfenidone ((5-
methyl-1-phenyl-2-[1H]-pyridone; Shionogi & Co., Ltd., Osaka, Japan; MARNAC 
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Inc., Dallas, TX, USA) is a synthetic molecule that acts on transforming growth 
factor-beta 1 (TGFβ1) and tumour necrosis factor (TNF)-α in vitro (Raghu et al. 
1999), cytokines thought to play major roles in the development of fibrosis (Leask 
and Abraham '2004).  
Phase 3 results from one of the most recent trials in IPF, the CAPACITY (Clinical 
Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of Efficacy 
and Safety Outcomes) programme, have just been published (King et al. 2014) and 
aimed to confirm the results of Phase 2 trials of the drug in patients with IPF. 
Previous studies in a Japanese cohort of patients with IPF indicated that pirfenidone 
was successful at increasing the progression-free survival time and improved forced 
vital capacity (FVC) in 163 patients compared to 104 patients who were in the 
placebo group (Taniguchi et al. 2011).  
In a bleomycin model of mouse fibrosis, pirfenidone suppresses the induced elevation 
of lung basic-fibroblast growth factor and prevents the downregulation of interferon-γ 
(Oku et al. 2008). It was hypothesized that by targeting the cytokines that were major 
drivers of the fibrotic environment that the development of chronic pulmonary failure 
could be slowed. However, in the CAPACITY study, they found that while overall 
there was a favourable outcome for the use of pirfenidone as a treatment in IPF, a 
substantial number of patients experienced significant side-effects including nausea, 
photosensitivity and rash, to name a few (Noble et al. 2011).  Furthermore, the 
greatest benefits of the drug, an increase in percentage predicted forced vital capacity 
(FVC%), was no longer significant at 72 weeks.   
One interpretation of this finding is that while able to suppress the acute pro-fibrotic 
effects of cytokines, which are largely non-specific to fibrosis, pirfenidone does not 
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act on the underlying mechanism that specifically drives excessive ECM deposition in 
the lung interstitium. Therefore, a greater understanding of what distinctively induces 
ECM deposition is needed and biomarkers of disease progression that reflect states of 
active lung fibrogenesis would be ideal targets for drug development in IPF.  
1.2.3 Biomarkers of progression 
Peripheral blood biomarkers of disease progression in IPF have been identified and 
are the most likely to achieve clinical utility because of their ease of sampling (Vij 
and Noth 2012). A biomarker of disease progression could tie the physical 
development of fibrosis (ie. excessive ECM deposition) with the cell type most 
responsible for the production of matrix components, the resident fibroblast. 
Of the known serum biomarkers in IPF, most are produced by alveolar epithelial cells 
or circulating immune cells (Richards et al. 2012; Vij and Noth 2012).  Those that are 
associated with mucus producing epithelial cells include the MUC5B gene 
polymorphism (Seibold et al. 2011), mucin-1 (KL-6), intracellular adhesion molecule 
1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1), surfactant proteins SP-A 
and SP-D and periostin (Naik et al. 2012). Matrix metalloproteinases 1 and 7, 
chemokines CCL18 and CXCL8, calgranulin B (S100A12) are produced by 
macrophages and other immune cells (Rosas et al. 2008; Vij and Noth 2012). 
Of these potential biomarkers, only periostin is a matricellular protein and its 
production is predominantly linked to the epithelium (Sidhu et al. 2010).  However, as 
fibroblasts are the main producers of ECM (Kisseleva and Brenner 2008), more 
biomarkers related to activated resident lung fibroblasts are needed.  
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1.2.4 ECM proteins as biomarkers in IPF 
The development of fibrosis is by definition the dysregulation of ECM production 
resulting in net deposition by lung fibroblasts. The ECM is created by secretion of 
ECM components and their extracellular organization into a distinct structure by 
mechanisms that remain to be fully elucidated. Particular ECM components are also 
found as serum proteins that are released from the ECM by matrix metalloproteinases 
(MMPs) (Mott and Werb 2004) or other endogenous enzymes. 
Changes in the levels of serum ECM proteins have been used to identify states of 
disease in cancer (Liu et al. 2006), infertility (Liu et al. 2011), and diabetes (Cangemi 
et al. 2011) that reflect their respective changes in ECM.  In addition, the matrix is 
bioactive (Roman and Mcdonald 1993), influencing the behaviours of the cells that 
inhabit it (Perumpanani et al. 1998; Frantz et al. 2010). Therefore, it has been 
hypothesized that ECM proteins found in the blood, like periostin, have potential as 
biomarkers of activated fibroblasts and therefore disease progression in IPF (Vij and 
Noth 2012). 
1.3 The extracellular matrix 
1.3.1 Conservation throughout evolution  
The ECM is made up of hundreds of different proteins each with a different purpose 
(Hynes 2012). Many of these proteins are highly conserved throughout the animal 
kingdom (Hynes 2012). The reason the diversity of ECM molecules was able to 
evolve is due to the modular structure of their protein domains. This layout allows for 
extensive exon shuffling during the molecular course of evolution (Engel 1996). The 
EGF-like repeats that are found as a common feature of ECM proteins can mediate 
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protein-protein interactions (Kubota et al. 2004). The emergence of extracellular 
proteins allowed for the physical linking of individual cells, allowing for the basis of 
the development of multicellular organisms (Frantz et al. 2010). 
The general structure of the ECM is similar throughout the body (Figure 1.3) but 
organ specific changes in ECM composition result in different biochemical and 
biophysical profiles (Bosman and Stamenkovic 2003). The conceptual understanding 
of the function of the ECM started out as a simple physical barrier between different 
cell types (Vracko 1974) but knowledge of its influence on cellular behaviour is 
increasing (Pardo and Selman 2001; Marinkovic et al. 2012; Parker et al. 2014).  
Even though the ECM is fundamentally composed of water, proteins and 
polysaccharides, each tissue has a specific combination of these components in which 
a dynamic cross-talking relationship between cells and their extracellular environment 
is made possible.  Maintenance of the ECM is regulated through selective deposition 
and degradation of ECM proteins via MMPs and tissue inhibitors of 
metalloproteinases (TIMPs)(Nagase et al. 2006) and other endogenous enzymes such 
as cathepsins (Xie et al. 2008).   
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Figure 1.3 Diagrammatic representation of the general structure of the 
extracellular matrix (ECM) in the lung parenchyma 
The ECM supports many cells and is made of proteins that each have a role in the 
maintenance of the interstitial space of the parenchyma.  
The interstitum contains many cells and is made of ECM proteins and a diversity of 
cellular elements.  
 
 
Page 22 of 252 
 
 
The ECM is not simply an inert scaffold but also contributes to essential parts of 
homeostasis, including cell-to-cell signalling (Perumpanani et al. 1998) and cytokine 
regulation (Crosby and Waters 2010). The ECM interacts with many cell types and 
provides an essential chemical and physical framework for intrabody communication.   
1.3.2 A bioactive entity 
The control of cell proliferation (Krimmer et al. 2012), differentiation (Maxson et al. 
2012), migration (Kubota et al. 2006) and other biological processes is directly and 
indirectly driven by the ECM and it is particular constituent proteins that directly 
affect cell behaviour (Hynes 2009; Royce et al. 2009). ECM proteins do not only have 
biological functions in situ, as soluble fragments of ECM have been shown to induce 
biochemical effects in the circulation (Perumpanani et al. 1998).  
The physical properties of the ECM allows it to function as an important store of 
growth factors and also regulates growth factor activity (Araya and Nishimura 2010), 
as these cytokines are often stored in latent form within the ECM (Raghunath et al. 
1998). Fibrotic growth factors, like TGFβ1, in turn can alter the stiffness of the matrix 
by increasing production of ECM molecules like fibronectin and collagen.  
The importance of a tightly regulated matrix stiffness lies in the fact that cells respond 
to mechanical signals as well as chemical ones. The expression of the contractile 
protein α-smooth muscle actin (α-SMA) by pulmonary fibroblasts in vitro has been 
shown to be dependent on the stiffness of the surface they are seeded on while 
substrate stiffness can also alter the sensitivity of cells to cytokines (Chia et al. 2012). 
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Therefore, understanding the role of the ECM as a controller of tissue homeostasis is 
key in understanding fibrotic disease progression. 
1.3.3 Tissue homeostasis and ECM turnover 
The complexities of cell turnover are outside the scope of this thesis, but it is 
important to point out that as cells are being turned over, so too is the underlying 
structure that holds them all together (Pardo and Selman 2001).   
In the normal organ, there is continuous ECM deposition and degradation, known as 
tissue homeostasis. Tissue homeostasis is necessary to replace any dead or damaged 
cells in the body. The rate of cell turnover differs in each organ. For example, lung 
epithelium takes six months to regenerate whereas the lining of the gut is thought to 
turnover every five days (Blanpain et al. 2007) .  
Dysregulation of the MMPs and TIMPs is a shared mechanism of metastasis in 
multiple cancers (Ricciardelli and Rodgers 2006) and is also seen in pulmonary 
fibrosis (Corbel et al. 2002).  
1.3.4 Cells that produce ECM 
While all cells produce varying amounts of ECM, there are two categories of cells 
that are responsible for the majority of the structure known collectively as the ECM in 
the lung.  
1.3.4.1 Lung mesenchymal cells 
The type of mesenchymal cells that are the major contributor to the ECM are 
fibroblasts. Fibroblasts are difficult to define as they lack a unique and universal cell-
surface marker, despite being present in most tissues (Burstein et al. 2008).  
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Fibroblasts themselves are not a homogeneous population of cells. Fibroblast sub-
types are differentiated in the tissue they are found in. In the lung, the heterogeneity 
of fibroblasts from different areas of the lung is specifically dysregulated depending 
on the type of lung disease present (Kotaru et al. 2006). In IPF, fibroblasts from areas 
undergoing rapid fibrotic change show increased responsiveness to inflammatory 
cytokines compared to fibroblasts from areas of slower fibrotic change (Habiel and 
Hogaboam 2014). Fibroblasts are also potent sources of mediators that recruit other 
cells to the site of injury, such as eotaxin which attracts eosinophils (Kotaru et al. 
2006).  
Similarly, circulating fibroblast progenitor cells, known as fibrocytes, are thought to 
home in on areas requiring sudden ECM deposition (Andersson-Sjoland et al. 2008). 
The contribution of the fibrocyte has been identified in renal fibrosis, and airway 
remodelling in asthma and there is a positive correlation between the number of lung 
fibrocytes and the abundance of fibroblastic foci in patients with IPF (Hardie et al. 
2009), a potential marker of disease severity (Flaherty et al. 2003).  
1.3.4.2 Lung epithelial cells 
The main function of epithelial cells is maintenance of barrier function. The epithelial 
lining of the airway system is divided into 3 anatomically distinct regions, the 
trachea/bronchi, the bronchioles, and the alveoli. All three areas contain epithelial 
cells that appear typically cobblestone-shaped in monolayer cell culture (Rackley and 
Stripp 2012). Major cell types of the airways include ciliated, columnar, 
undifferentiated, secretory and basal cells (Hackett et al. 2008).   
In the alveolar region, type I and type II pneumocytes line branches 223 and greater. 
90% of the alveolar surface is covered in type I cells to provide a surface suitable for 
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gas exchange. In concert, type II cells are found closer in proximity to mesenchymal 
cells and serve as surfactant producers and type I progenitors (Selman and Pardo 
2006).   
1.3.5 Important ECM proteins 
Due to the incredible protein diversity that is exhibited by the ECM, we have chosen 
to investigate a few ECM proteins of note in this study that have previously been 
identified to play roles in fibrogenesis. Collagen and fibronectin make up the majority 
of the ECM as they provide the main structural components. Periostin and tenascin-C 
play important roles in the orientation of collagen and fibronectin respectively (Kii et 
al. 2010).  
1.3.5.1 Fibronectin 
Fibronectin is one of the most highly conserved ECM proteins in the animal kingdom 
and its assembly into the ECM is a cell-mediated, integrin-dependent process (Mao 
and Schwarzbauer 2005). During this assembly, fibronectin is required to undergo 
many conformational changes that allow for the exposure of the necessary binding 
sites for other proteins needed to assist in the process (Sottile and Hocking 2002).  
Aside from directly influencing cell behaviour such as proliferation, attachment, 
migration and survival, the formation of a scaffold of fibronectin guides the 
deposition of latent TGFβ binding proteins that regulate the storage of TGFβ and 
therefore influence its activity (Dallas et al. 2005).  Briefly, soluble fibronectin dimers 
are dispersed diffusely over the cell surface. Next these dimers are arranged into short 
fibrils and finally into a fibrillar network (Mao and Schwarzbauer 2005).  
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Fibronectin has been shown to be critical in development as mice lacking in the 
fibronectin gene die in early embryogenesis due to defects in cell migration (Muro et 
al. 2008). Furthermore, fibronectin is an essential part of the wound provisional 
matrix and is a major blood protein (Midwood et al. 2006). A functioning fibronectin 
scaffold is necessary for the deposition of collagen I (Sottile and Hocking 2002), one 
of the other main components of the ECM. 
1.3.5.2 Collagen 
Collagen is the most abundant protein in the ECM, accounting for about 30% of the 
total weight of the ECM. In addition, there are dozens of collagens that differ in 
function and ECM abundance (Prockop and Kivirikko 1995). It is type I collagen that 
is induced upon treatment with bleomycin (Reiser and Last 1983), a drug typically 
prescribed for cancer chemotherapy which has been shown to cause pulmonary 
fibrosis (Mouratis and Aidinis 2011). Collagen fibrils are most responsible for the 
strength of the tissue and define an organ’s shape. The generation of these fibrils is an 
important step to understand in the context of both development and disease and this 
process is still not fully elucidated. The induction of collagen by TGFβ1 is one of the 
most well-studied effects of pro-fibrotic cytokines (Kenyon et al. 2003). The exact 
mechanisms driving collagen deposition are outside the scope of this thesis, but 
collagen maturation is important to mention as all scar formation is made of immature 
collagen (Widgerow 2011).  
Pro-collagen fragments are translocated to the lumen of the endoplasmic reticulum 
(ER) where it co-localises with other molecular chaperones and enzymes necessary 
for correct folding and polymerization (Lamande and Bateman 1999), similar to 
fibronectin fibrillogenesis. Fibrillogenesis of the major structural components, both 
fibronectin and collagen, is a tightly organized process involving other ECM proteins 
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that act as molecular bridges. Previously identified molecular bridges of collagen 
include decorin (Culav et al. 1999) and periostin (Norris et al. 2007). 
1.3.5.3 Periostin 
Periostin is a secreted ECM protein that is associated with collagen-rich fibrous 
connective tissues and directly controls proper collagen I fibre formation (Norris et al. 
2007). Periostin was first described as a TGFβ-induced protein that was expressed 
following inflammation during tooth and bone remodelling (Kudo 2011). In addition 
to TGFβ, periostin is also upregulated by inflammatory cytokines such as interleukin 
(IL)-13 and contributes to the airway remodelling seen in asthma (Takayama et al. 
2006).  
During  remodelling, periostin  enhances the activity of lysyl oxidase (LOX), the 
enzyme responsible for collagen cross-linking,  through interactions with both 
fibronectin and bone morphogenic protein (BMP) -1 (Maruhashi et al. 2010). 
Furthermore, periostin also acts in concert with tenascin-C, possessing adjacent 
domains to those on tenascin-C that bind to fibronectin and type I collagen. 
Deposition of tenascin-C into the ECM was shown to be dependent on the presence of 
periostin (Kii et al. 2010).  
1.3.5.4 Tenascin C 
Tenascin-C is a member of the tenascin family which includes other tenascins such as 
tenascin-X and tenascin-H (Udalova et al. 2011). It is only expressed during periods 
of active tissue repair and is downregulated once repair is complete. As a hexametric 
molecule with multiple binding sites, tenascin-C exhibits the ability to bind to and 
regulate a variety of cell-cell and cell-matrix interactions (Midwood et al. 2011). In 
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this manner, tenascin-C can be thought of as a counter to the adhesive actions of 
fibronectin.  
Similar to fibronectin and other ECM protein binding partners, tenascin-C can also be 
induced by TGFβ1 (Hau et al. 2006). In addition, tenascin-C participates in the 
fibrinolytic system through its ability to inhibit plasminogen, the precursor to plasmin, 
the enzyme that degrades fibrin (Brellier et al. 2011). The fibrinolytic system plays an 
important role during normal wound healing and is vital in dampening fibrosis 
(Swaisgood et al. 2000). 
1.4 Fibrosis 
1.4.1 Regeneration vs Repair   
Damage as a consequence of mere existence is a problem shared by all living 
organisms. Tissue homeostasis is maintained through tightly regulated cell turnover 
during which older cells are replaced by newer ones. During this process of 
regeneration, normal tissue morphology and function are preserved. In a review of 
tissue homeostasis, authors Pellettieri and Alvarado state “it has been estimated that 
each of us eradicates and, in parallel, generates a mass of cells equal to almost our 
entire body weight each year” (Pellettieri and Sanchez Alvarado 2007). 
In contrast to this, reconstitution of an adult tissue that does not exactly replicate the 
original state is known as repair (Martin and Parkhurst 2004). Fibrosis can be thought 
of as pathological wound healing (Diegelmann and Evans 2004). The process of 
fibrosis is part of the natural wound healing process that is necessary for development 
and growth as well as repair. However, somewhere along this process, the regulation 
of ECM deposition goes awry. The end result is excessive ECM deposition that 
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changes the architecture of the organ that is affected. Similarities between fibrogenic 
lung diseases have been repeatedly reviewed throughout the literature (Araya and 
Nishimura 2010; Murray 2012).  
1.4.2 The stages of wound healing 
During wound repair, one of two things can occur. Either the wound can be mended 
with fibrotic scar tissue, or it can be replaced with normal, and ordinarily functioning, 
tissue. Some species are known to have great systems to keep that repair process in 
check. The scar-free repair process following tail loss in the gecko is a perfect 
example of this (Delorme et al. 2012)(Figure 1.4) .   
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Figure 1.4 Images of scar-free wound healing and regeneration following tail 
loss in the leopard gecko. 
The gross morphology of the tail following (A, C, E, G) autonomy, the self-
detaching of the tail, or (B, D, F, G) amputation is indistinguishable from one 
another.  
Reproduced with permission from (Delorme et al. 2012) 
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The gecko, and many other urodeles (tailed amphibians), can spontaneously 
regenerate a lost tail, without any scarring occurring during the repair process 
(Delorme et al. 2012). While the regenerative capabilities of these animals are outside 
the scope of this thesis, it would be also be interesting to study the processes active in 
those animals in contrast to the formation of scar tissue that is a possible, and 
unwanted, conclusion of wound repair (Yates et al. 2011).  
In humans, wound healing is a complicated process involving the initiation and 
resolution of a number of different stages. Each stage involves many different cell 
types, proteins and signalling pathways. Haemostasis is the first stage that involves 
the cooperation of the coagulation system as well as the fibrinolytic system. During 
haemostasis the formation of the fibronectin provisional matrix occurs and its 
development is controlled by members of the coagulation cascade (Mosher 1995). 
The ECM molecule fibrin is a fibrous protein formed from fibrinogen and is 
polymerized to form the mesh work that plugs the wound (Reinke and Sorg 2012). 
After haemostasis at the wound site is complete, the stages of wound healing are 
classically divided into three parts, (1) inflammation, (2) proliferation, (3) 
remodelling (Figure 1.5).  
During the inflammation stage, neutrophils are the cell type most abundant and they 
move from the circulation into the wound microenvironment as guided by 
chemokines and other chemotactic agents, like ECM proteins. Neutrophilic 
phagocytosis removes any foreign material, bacteria, dead cells and bits of damaged 
ECM. Also present in the wound microenviroment are mast cells, monocytes and 
Page 32 of 252 
 
macrophages. These cells provide the chemical mediators to activate the structural 
cells for the next stage of wound healing (Diegelmann and Evans 2004).  
 
Figure 1.5 The stages of wound healing 
Wound healing is a series of events that commence and conclude in series. The failure 
to resolve the final stage, remodelling, results in fibrosis.  
Adapted from www.worldwidewounds.com accessed September 2013. 
 
Following inflammation, proliferation is required to replace the cells that have been 
lost and to start knitting together the edges of the wound. TGFβ1 is a critical cytokine 
in this process and will be covered in greater detail later in this chapter. TGFβ1 
increases the deposition of many ECM molecules, in particular, but by no means 
limited to, collagen (Sidhu et al. 2010). At the same time, TGFβ1 can inhibit 
proteases involved in ECM turnover and increase inhibitors of those matrix proteases 
to further encourage ECM deposition (Sidhu et al. 2010).  
Epithelisation is driven by cytokines produced by platelets and macrophages (Reinke 
and Sorg 2012). New blood vessels begin to form at the wound site, stimulated by 
growth factors produced by vascular endothelial cells. Fibroblasts produce the 
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increased quantities of ECM proteins needed to create the supramolecular structures 
that stabilize the newly formed tissue for the next phase of the process.  
Resolution of wound healing involves the remodelling of the tissue architecture. 
Fibroblasts are the connective tissue cells that are responsible for the ECM deposition 
needed to repair the injury. Increased ECM deposition is necessary to replace 
structures that were lost. Before proliferation decreases, the edges of the wound need 
to be brought together in a process that is regulated through the fibroblasts’ contractile 
properties (Tomasek et al. 2002).  
The idea is that by the end of this process (1-2 years or longer) the acute inflammatory 
and proliferative environment at the wound site is no longer needed. As the wound 
heals, the number of fibroblasts and macrophages should decrease by apoptosis and 
the growth of blood capillaries stops (Bonner 2010). If there is too little deposited 
ECM at the wound site, the repair will be weak and may split apart. However, if too 
much ECM is deposited then the normal architecture of the site is compromised and 
anatomical function is lost. This is called fibrosis. 
1.4.3 The ECM in fibrosis 
Fibrosis in humans is thought to follow a similar pattern no matter which is the 
organ/tissue that is affected (Thannickal et al. 2004). When the fibrosis is in the lung, 
it is termed pulmonary fibrosis. This term is often confused with the named types of 
ILD, such as IPF, and should be thought of as a consequence of many different 
diseases, not a disease in and of itself.  
A common reoccurring theme of fibrosis, no matter the organ affected, is the 
disruption of one or more of the regulatory processes that control the ECM. Because 
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there is not a particular protein that is only found in areas of active fibrosis and ECM 
production and turnover of the ECM is a normal part of homeostasis, understanding 
the underlying mechanisms and key ECM components contributing to fibrosis is 
essential. However, little attention has been paid to the exact composition of the ECM 
as it changes throughout development and during stages of disease (Royce et al. 2009; 
Booth et al. 2012).  
1.4.4 Dysregulation of ECM in pulmonary fibrosis 
Change to ECM protein organization is an essential step in the development and 
restoration of organ function and similarities between these two processes have been 
recognized in the context of fibrotic disease (Martin and Parkhurst 2004; Redd et al. 
2004; Hardie et al. 2009; Imanaka-Yoshida 2012). In pulmonary fibrosis, 
dysregulation of particular ECM proteins can be linked to every stage of wound 
healing.  
As one of the initial stages following damage, the importance of the fibrinolytic 
system has been implicated in pulmonary fibrosis as mice that do not express either 
urokinase or plasminogen exhibited accelerated fibrosis in response to bleomycin 
treatment (Swaisgood et al. 2000). This pro-fibrinolytic system is diminished in the 
alveolar microenvironment of lung diseases (Sisson and Simon 2007) while tenascin-
C levels  are increased in the serum of patients with collagen diseases (Inoue et 
al. 2013). Plasmin is secreted from the liver as plasminogen, which is inactive in the 
circulation.  Tenascin-C was shown to inhibit the conversion of plasminogen to 
plasmin by downregulating tissue plasminogen activator (Brellier et al. 2011). 
Plasmin is responsible for the degradation of the fibrin that is present in the 
provisional wound matrix.  
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Although IPF is no longer thought to be driven by inflammation, abnormal wound 
repair in the alveolar microenvironment is thought to propagate pulmonary fibrosis 
from the epithelium to the interstitium (Selman and Pardo 2006). During the 
inflammatory phase, ECM proteins like periostin (Takayama et al. 2006) are released 
from damaged epithelial cells and contribute to subepithelial fibrosis found in the 
context of asthma.  
Release of pro-fibrotic mediators like TGFβ1 and platelet-derived growth factor 
(PDGF)  by both  immune cells, like mast cells (Thomas et al. 2010) and 
macrophages (Lacronique et al. 1984), as well as by epithelial cells becomes 
excessive in fibrosis (Leask and Abraham '2004). Cytokine production also induces 
the proliferation and activation of fibroblasts that drive fibrosis (Kramann et al. 2013) 
and results in ECMs with an altered protein profile (Booth et al. 2012). 
This altered ECM profile, the result of chronic injury, slowly disrupts the resolution 
of the wound (Yates et al. 2011). Furthermore, ECM deposition becomes unrestrained 
as the mechanisms regulating survival of mesenchymal cells are decreased (Bonner 
2010). The effect of the ECM on cell survival is well documented in the context of 
cancers (DeClerck 2010) however the contribution of small ECM proteins has not 
been fully examined. 
Composition of the ECM is important because the particular make-up of the ECM 
defines both its biomechanical and biochemical properties (Antunes et al. 2009). In 
the context of fibrotic lung disease, it has long been established that the lung becomes 
stiffer as the disease progresses (Gibson and Pride 1976). The result of increased 
stiffness may be important in the pathogenesis of fibrosis as fibroblasts from patients 
with scleroderma express increased levels of contractile ECM proteins and lower 
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levels of elastic fibre content (Reich et al. 2009).  However, there have been few 
studies relating the changes to matrix stiffness with alterations in the ECM profile in 
patients with IPF.  
1.4.5 Matrix Stiffness 
Physical effects of the ECM are of particular importance in the lung. The ECM is 
responsible for the compressive and tensile strength of the tissue or organ. Increases 
in ECM stiffness relate to the progression of fibrosis of the lung and increase the work 
of breathing (Faffe and Zin 2009).  The stiffening of lung tissue has previously been 
regarded as the passive end-point of the fibrotic process. In fact, more modern 
concepts describe how fibroblasts and other cells respond to increased matrix stiffness 
by selectively increasing expression of contractile proteins and decreasing production 
of fibrosis-inhibiting cytokines (Liu et al. 2010; Mih et al. 2012).  
1.4.6 Atomic Force Microscopy 
Matrix stiffness can be measured using a technique that has long been employed in 
research on inorganic surfaces. In 1988, atomic force microscopy (AFM) on an 
organic material showed that the forces used for imaging had no effect on a 
monolayer of polymer strands and could potentially be used to study biological 
systems (Marti et al. 1988). 
AFM can measure the amount of deflection that a cantilever experiences as it travels 
over the surface of the fibroblast (topography). In addition, it can also measure the 
amount of resistance to deflection, also known as stiffness, of each point on that 
surface. We can then overlay the two measurements and obtain both the surface 
morphology and underlying stiffness of fibroblasts grown in a monolayer. In addition 
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to the ability to measure basal differences between normal and fibrotic fibroblasts 
(Reich et al. 2009), it is also possible to measure the changes in matrix stiffness as a 
result of stimulation with growth factors such as TGFβ1(Chia et al. 2012).  
1.5 Transforming growth factor-β1 
1.5.1 Background 
TGFβ1 is a multifunctional cytokine that is one of the most effective at promoting the 
fibrotic microenvironment. Upon activation of TGFβ1, a complicated series of 
signalling events is set off, involving multiple pathways, within and external to  the 
cell. Because multiple cellular pathways are affected, TGFβ1 is able to influence 
many different phenotypes and biological processes including cancer and wound 
healing.  
In particular, TGFβ1 promotes the fibrotic phenotype by increasing the expression of 
many ECM proteins including but not limited to, collagen, fibronectin, tenascin C and 
periostin. Furthermore, TGFβ1 decreases the production of MMPs and increases 
TIMPs, resulting in greater ECM conservation (Nagase et al. 2006). Due to the 
accumulation of latent TGFβ1, within the ECM, a greater amount of ECM results in a 
greater store of potentially active TGFβ1 (Lepparanta et al. 2012).   
Because of the pro-fibrotic environment it generated, it was quickly demonstrated that 
TGFβ1 plays a critical role in the development of fibrotic lung disease (Hoyt and 
Lazo 1988). Dysregulation of fibroblasts and epithelial cells play a central role in the 
mechanisms that drive pulmonary fibrosis. Firstly, TGFβ1 can delay epithelial cell 
proliferation and migration while promoting apoptosis (Lee et al. 2004). Secondly, 
TGFβ1 is a major growth factor that regulates the conversion of a quiescent fibroblast 
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to the contractile alpha-smooth muscle actin (αSMA) expressing myofibroblast 
(Horowitz and Thannickal 2006). Finally, TGFβ1 signals the recruitment of 
inflammatory cells to the site of the insult (Diegelmann and Evans 2004). All these 
cells also produce cytokines that mediate TGFβ1 activity (Bonner 2010). 
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1.5.2 Cytokines, the ECM and TGFβ1 regulation 
TGFβ1 is secreted in an inactive complexed form and targeted to specific places in the 
ECM by the latent TGFβ1 binding protein (LTBP) (Hyytiainen et al. 2004) (Figure 
1.6).  
 
Figure 1.6  The formation of the small and large latent forms of transforming 
growth factor-beta 1 (TGFβ1). 
 TGFβ1 is secreted and stored in the lung extracellular matrix (ECM) in an inactive 
form through the direction of the latent TGFβ1 binding protein (LTBP). Activation of 
TGFβ1 requires removal of the latency binding peptide (LAP). 
Adapted from (Hyytiainen et al. 2004) 
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The large latent complex is bound to the ECM through ECM binding regions at the 
amino and carboxyl terminals of the LTBP. The small latent complex is released from 
the ECM through protease cleavage sites but activation of TGFβ1 requires the 
additional removal of the non-covalently bound latency binding peptide (LAP) from 
the TGFβ1 dimer (Dubois et al. 1995).  
The activity of TGFβ1 is both pro-inflammatory and anti-inflammatory and is 
mediated through several mechanisms. Due to the exceedingly complex array of 
pathways affected by TGFβ1, only those mechanisms known to be pertinent to the 
role of TGFβ1 in the lung will be mentioned. It is not surprising that in the human 
lung, the means by which regulation and storage of TGFβ1 is accomplished have not 
been fully elucidated (Lepparanta et al. 2012). 
TGFβ1 signals by initially binding to the TGFβ type II receptor which then recruits 
TGFβ type I receptor on the cell membrane. The receptor complex activates the 
Smad2/3/4 complex, causing it to be transported to the nucleus and combine with 
transcriptional coactivators CREB-binding protein (CBP) and p300. In addition, the 
TGFβ1 receptor complex can also activate Smad-independent pathways such as 
through c-Jun N-terminal kinase (JNK).  
TGFβ induces many ECM proteins such as perlecan (Ichimaru et al. 2012) and 
collagen (Kenyon et al. 2003), as well as growth factors such as connective tissue 
growth factor (CTGF) (Kono et al. 2011), vascular endothelial growth factor (VEGF) 
(Lee 2012) and fibroblast growth factors (FGF) (Srisuma et al. 2010). TGFβ1 can also 
increase ECM proteases such as matrix metalloproteinases MMP2 and MMP9 (Dallas 
et al. 2002). All of these factors are likely to be important in the development of 
fibrosis. 
Page 41 of 252 
 
1.5.3 TGFβ1, EMT and pulmonary fibrosis 
TGFβ1 is overexpressed in many pathological conditions that have a fibrotic 
component such as pulmonary fibrosis (Lepparanta et al. 2012), kidney disease 
(Lopez-Hernandez and Lopez-Novoa 2012), Crohn’s disease and cancer (Prud'homme 
2007). LTBP-1 expression was found to be increased in the lungs of patients with IPF 
(Lepparanta et al. 2012).  In addition, increased active TGFβ1 is found in the 
bronchoalveolar lavage (BAL) of patients with IPF compared to normal controls 
(Khalil et al. 2001).  
Pulmonary fibrosis is the consequence of a range of acute and chronic lung injuries 
that eventually culminate in the destruction of the normal lung architecture and death 
(Araya and Nishimura 2010). It has been shown through tissue specimens of patients 
with pulmonary fibrosis that it is an abnormal wound response driving excessive 
ECM deposition (Thannickal et al. 2004; Araya and Nishimura 2010). As a 
pleiotropic cytokine, TGFβ1 can tip the cellular phenotype of epithelial cells towards 
a pro-fibrotic phenotype (Doerner and Zuraw 2009) making it a critical contributor to 
the pulmonary fibrosis in interstitial lung disease (Strieter 2008).  
Previous work in our laboratory has shown that TGFβ1 increases the production of 
the ECM protein fibulin-1 and which plays a role in the pathophysiology of airway 
fibrosis in asthma (Lau et al. 2010). Fibulin-1 may play an important role in the 
pathophysiology of diseases such as IPF, which are predominately characterized by 
diffuse pulmonary fibrosis.  
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1.6 Fibulin-1  
1.6.1 Background 
Fibulin-1 is an ECM glycoprotein that was first discovered as an unknown binding 
partner of fibronectin (Argraves et al. 1989). Further study into the characterization of 
fibulin-1 showed that it was a calcium-binding protein with a repeated structure and 
was expressed in cultured gingival fibroblasts (Tanaka et al. 1994). One of the first 
described roles of fibulin-1 was its association with elastic fibres (Roark et al. 1995).  
Fibulin-1 was found in the unstructured core of elastic fibres but not in the fibrillin-
containing, elastin-associated microfibrils, suggesting that fibulin-1 was a structural 
protein with a role in the elastic properties of connective tissue fibres (Roark et al. 
1995).  Secreted fibulin-1 becomes incorporated into a fibrillar ECM when added 
exogenously to cultured fibroblast monolayers (Argraves et al. 1990), and recent 
studies have shown that fibulin-1 ECM production is in part driven by TGFβ1 (Chen 
et al. 2013). In the blood, fibulin-1 is the predominant fibulin, with a reported plasma 
concentration range of 30-40µg/mL (Tran et al. 1995). In addition, fibulin-1 mRNA is 
found in most tissues and in some cultured cells (Roark et al. 1995).   
Previous studies have identified the role of fibulin-1 in asthma (Lau et al. 2010). In 
asthma, the generation of airway fibrosis is among a variety of structural changes 
known collectively as airway remodelling (Elias et al. 1999). The degree of airway 
remodelling, similar to the degree of parenchymal remodelling, has been linked to 
increased disease severity (Shifren et al. 2012). The extent of fibrosis, or the degree of 
parenchymal consolidation, has been used as a measure of disease severity in IPF 
(Wells et al. 2003). 
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Similarities between fibrotic lung diseases outline the potential for common 
mechanisms of fibrogenesis in the lung (Araya and Nishimura 2010). Fibulin-1 may 
be involved in the general mechanism that is essential for normal wound healing and 
dysregulation of fibulin-1 may have a role in the pathogenic changes that occur during 
lung fibrosis.  
1.6.2 The fibulin family 
The fibulin family of ECM proteins currently sits at eight identified members which 
all share a similar elongated structure with overlapping binding sites for several 
basement-membrane proteins. Fibulin-1 was the first to be identified (Argraves et al. 
1989) and was followed by discoveries of fibulin-2 (Pan et al. 1993), fibulin-3 and 
fibulin-4 (Giltay et al. 1999), and fibulin-5 (Kowal et al. 1999), also known as 
DANCE (Nakamura et al. 2002). Fibulin-6 (Katoh and Katoh 2004), also known as 
HMCN1, and fibulin-7 are recently added members of the fibulin family. Fibulin-7 is 
also a binding partner of fibulin-1 (de Vega et al. 2007).  
Orthologs of fibulins are seen in all animals (Segade 2010) with seven of the fibulins 
found in mammals (Vogel et al. 2006). Fibulin-8 is the last of the fibulins that have 
been described and is not found in any mammals, except the platypus (Segade 2010) 
(Figure 1.7). 
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Figure 1.7 The molecular evolution of the fibulins (FBLN). 
The FBLN genes are highly conserved throughout the animal kingdom. There are eight 
FBLNs known to date.  
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1.6.3 The structure of fibulin-1 
Fibulin-1 and its family members share a similar repeated domain structure.  Named 
after the latin fibula, meaning clasp or buckle, members of the fibulin family are 
widespread components of the ECM whose protein structures are all arranged in a 
distinct form. These repetitive domains are necessary for the protein interactions 
involved in ECM assembly (Hynes 2009). 
Their amino acid sequences are grouped into modules named domain I, II and III 
(Figure 1.8).  Domain I is the amino-terminal sequence that varies among fibulin 
members. Domain II contains a variable number of repeated epidermal growth factor 
like modules. The specific part of the sequence is domain III, also known as the 
fibulin C-terminal globular (FC) domain which is shared between 7 of the fibulin 
members (Fibulin-1 to 7) (de Vega et al. 2009).  
 
Figure 1.8 The structure of fibulin-1 
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This repetitive domain structure is a reflection of the ancient origins of the fibulin 
family. The highly conserved structure can be seen in the multiple orthologs that are 
shared by all vertebrates (Vogel et al. 2006) and in fact, the origin of the fibulin gene 
family has been traced to the base of the metazoans, or animal kingdom (Segade 
2010). The simplest of the metazoans are nematodes (flat worms) and mammals share 
both fibulin-1 (Hesselson et al. 2004; Kubota et al. 2004) and fibulin-6 (Vogel and 
Hedgecock 2001) with them. As a result of this interspecies homology, a lot of the 
study into the function of fibulin-1 has been carried out in “simpler” model systems.   
Evolutionarily speaking, the fibulin family can be described as basement membrane 
proteins (Argraves et al. 2003), and some, like fibulin-1, have involvement in elastic 
fibre assembly (Roark et al. 1995).  Fibulin-1 is 90-100kDa and gene splicing results 
in 4 isoforms of varying C-terminal domains (A-D) (Figure 1.8). 
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1.6.4 Fibulin-1 has 4 isoforms 
The functions of the four fibulin-1 isoforms have not been fully elucidated. The 
natural expression of fibulin-1A and fibulin-1B is in the human placenta, and at low 
abundance.  Fibulin-1A and B have also been shown to be expressed in ovarian 
tissues and cancer cell lines at trace amounts (Moll et al. 2002).  Alternative splicing 
of the gene gives rise to proteins of varying lengths (Table 1.1).  For proper 
processing through the golgi apparatus, each fibulin-1 isoform undergoes post-
translational modification where an identical 29-amino acid signal peptide is added to 
Domain I.  
 
Table 1.1 The size and sequence of the fibulin-1 isoforms in humans 
 
Isoform # Amino acid residues GenBank Accession 
number 
A 537 NM_006487 
B 572 NM_006485 
C 654 NM_001996 
D 656 NM_006486 
 
 
All four isoforms of fibulin-1 share the first 537 amino acid residues with fibulin-1A 
completely missing the C-terminal domain III (Tran et al. 1997). Only the two longer 
fibulin-1 isoforms, C and D, contain the fibulin-type carboxy-terminal module 
(Fujimoto et al. 2005). The predominant fibulin-1 forms in humans are isoforms C 
and D (Roark et al. 1995) and these are proteins of similar molecular weight (100kDa) 
but whose functions are thought to be distinct (Moll et al. 2002). However, functional 
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redundancy between fibulin-1C and D and fibulin-6 has been shown, albeit in 
zebrafish (Feitosa et al. 2012).  
In Caenorhabditis elegans (C. elegans), the flatworm model organism which was the 
first to get its genome sequenced (Sulston and Brenner 1974), the function of fibulin-
1C was shown to be involved in the control of developmental growth through the 
epidermal growth factor (EGF)-like repeats (Hesselson and Kimble 2006). C. elegans 
fibulin-1C had specific roles in the development of the pharynx, intestine, gonad and 
muscle. Conversely, fibulin-1D was shown to assemble in the flexible polymers that 
connected the pharynx and basement membranes of the body wall (Muriel et al. 
2005).  However, in humans, the EGF domain of fibulin-1 is the same for all fibulin-1 
isoforms (Argraves et al. 1990). The nucleotide length difference between fibulin-1C 
and fibulin-1D is a mere 0.6kb but they share only approximately 28% identity with 
each other’s C-terminal domain (Tran et al. 1997). The isoform specific functions of 
human fibulin-1 have not been fully examined.   
Dysregulation of the isoform balance has been reported in some cancers (Moll et al. 
2002) but not others (Wlazlinski et al. 2007). Fibulin-1C has been linked to tumour 
progression (Moll et al. 2002) whilst haplo-insufficiency of the fibulin-1D gene 
results in limb malformations seen in synpolydactyly (Debeer et al. 2002).  In mice, 
isoforms C and D were found to differ in their affinity for nidogen, another important 
ECM protein (Sasaki et al. 1995). Furthermore, the assembly of fibulin-1C into the 
ECM was shown to be dependent on the basement membrane protein laminin in C. 
elegans, but the inclusion of fibulin-1D was linked to perlecan, another component of 
the basement membrane (Muriel et al. 2006). This indicates that it is likely that there 
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are site-specific functions to fibulin-1 isoforms that have been conserved over a long 
period of time.  
However, investigations of fibulin-1 often do not specify which isoform is being 
studied. Despite this limitation in the literature, the common modules of fibulin-1 
confer properties of interest as the vast majority (~80%) of each isoform is of 
identical sequence.  
1.6.5 Fibulin-1 protein-protein interactions  
The ability of fibulin-1 to participate in supramolecular structures stems from the 
presence of overlapping binding sites with several other basement-membrane proteins 
such as tropoelastin, fibrillin, and fibronectin (Timpl et al. 2003) in addition to the 
aforementioned nidogen (Sasaki et al. 1995), laminin and perlecan (Muriel et al. 
2006). Fibulin-1 is also known to bind to aggrecan and versican (Aspberg et al. 1999) 
as well as nidogen (Sasaki et al. 1995). Nidogen is part of the CCN family of growth 
factors of which connective-tissue growth factor (CTGF) is also a member (Perbal 
2001).  
Fibulin-1 can also enhance the properties of other ECM proteins such as the 
metalloproteinase A Distintegrin And Metalloprotease with Thrombospondin repeats 
(ADAMTS)-1 (Lee et al. 2005). Fibulin-1C was shown to bind to the C-terminal 
domain of NOVH protein, which is a negative regulator of cell growth and member of 
the CCN family (Perbal et al. 1999).  One way that fibulin-1 exerts influence is by 
modulating the bioactive effects of fibronectin, one of the main ECM proteins. 
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1.6.6 Fibulin-1 and fibronectin 
As the molecule responsible for the discovery of fibulin-1, fibronectin-fibulin-1 
interactions may be a confounding factor in this study.  As previously mentioned in 
this Chapter, fibronectin is an essential ECM player that influences proliferation, 
attachment, migration and growth factor storage. Fibronectin is also a highly 
expressed protein found in the blood, having been reported at concentrations of 300-
350µg/mL.  Serum fibronectin levels are also elevated in, and were able to 
discriminate between those with liver fibrosis and those with non-fibrotic livers 
(Attallah et al. 2013). As fibronectin is required for collagen deposition, it is possible 
that increased fibronectin levels contribute to increased pulmonary fibrosis.  
In ILD, fibronectin levels are elevated in the BALF but not in the plasma of patients 
with IPF, sarcoidosis and “other” ILDs compared to healthy controls and patients with 
non-interstitial lung diseases (Rennard and Crystal 1982). Surprisingly, the most 
recent study on the levels of fibronectin in patients with ILD was published in 1994 
(Zhao et al. 1994). However, plasma levels of fibronectin were found to be elevated in 
asthmatics compared to healthy controls (Ohke et al. 2001) and studies undertaken by 
a previous PhD student in this laboratory have shown that fibulin-1 is increased in the 
serum and BALF of asthmatics (Lau et al. 2010).  It is possible that with advances in 
methodologiess with which to distinguish the different forms of fibronectin, that an 
increase in the levels one form of fibronectin in the serum of patients with IPF may be 
identified. As fibronectin and fibulin-1 bind together, this could therefore influence 
the levels of fibulin-1 in patients with IPF. 
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1.6.7 Fibulin-1 and collagen 
Collagen is the main component in fibrosis and but its relationship to fibulin-1 has not 
been studied in great detail. Collagen fibrillogenesis is a complex cell-mediated 
process that involves helper molecules like periostin (Kudo 2011) and possibly 
fibulin-1. Decades old analysis on fibulin-1 binding activity demonstrated that fibulin-
1 binds to collagen IV but not to collagen I, II, III, V and VI (Sasaki et al. 1995).  
During gonadogenesis in the C. elegans, the orthologs to mammalian fibulin-1 and  
ADAMTS act antagonistically against each other to control tissue architecture 
involving collagen IV (Kubota et al. 2012). In a model of IPF, alveolar epithelial cells 
produced biologically active TGFβ1 and increased deposition of collagens I, III, V 
and in particular IV (Xu et al. 2003), highlighting another potential mechanism by 
which fibulin-1 may play a role in pulmonary fibrosis. 
Fragments of collagens (type I, III, V, and VI) have been reported as increased in the 
serum of patients with IPF, stressing the potential of ECM molecules as biomarkers 
(Leeming et al. 2012).  
1.6.8 Fibulin-1 and periostin 
Both fibulin-1 and periostin function as regulators of collagen fibre formation (Norris 
et al. 2007) and periostin is the only ECM molecule that has been identified as a 
biomarker of disease progression in IPF (Naik et al. 2012). Like fibulin-1, periostin 
acts as a bridging molecule which alludes to an overarching mechanism by which 
dysregulated large fibre formation is a driver of fibrosis. Orientation of the large 
fibres collagen and fibronectin are both regulated by periostin, which works in concert 
with tenascin-C (Kii et al. 2010). There is nothing known about the direct interaction 
between fibulin-1 and periostin. 
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1.6.9 Fibulin-1 and tenascin-C 
Tenascin-C functions by altering the binding of cells on a fibronectin matrix and 
shares a binding site on the amino-terminal end of fibronectin with fibulin-1, the 
HepII region of fibronectin. (Williams and Schwarzbauer 2009). Cell signalling and 
matrix contraction are induced though this site and require binding of the heparin 
sulphate proteoglycan syndecan-4 (Midwood et al. 2006).  
Syndecan-4 is an important mediator of fibroblast-matrix interactions. In syndecan-4 
null mice, treatment with bleomycin resulted in a marked increase in myofibroblast 
recruitment and interstitial fibrosis compared to wild type controls (Jiang et al. 2010).  
Therefore, by competing for this binding site, both tenascin-C and fibulin-1 can 
influence fibrogenic cell adhesion and behaviour as both tenascin-C and fibulin-1 
inhibit fibroblast spreading and cell-mediated contraction of a matrix (Williams and 
Schwarzbauer 2009) . 
1.6.10 Fibulin-1 in embryonic morphogenesis and elastic fibre assembly 
As previously discussed, fibulin-1 is a highly conserved ECM molecule that is 
essential during normal development (Singh et al. 2006). It is thought to play a role in 
stabilizing the ECM, as it colocalizes with elastin fibres during the first stages of 
embryogenesis (Visconti et al. 2003), the deposition of which occurs as one of the 
initial stages of development. Because elastic fibres are one of the two main 
determinants responsible for biomechanical properties of the lung (Faffe and Zin 
2009), alterations in elastic fibre assembly affect lung function. Increased fibulin-1 
deposition may alter elastic fibre assembly and hinder proper lung function. 
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1.6.11 The role of fibulin-1 in other diseases 
Ultimately, as an ECM protein, and one that is essential to normal ECM formation, 
fibulin-1 plays an important role in diseases which involve ECM dysregulation. 
Fibulin-1 dysregulation in both the blood form and tissue form has been seen in a 
variety of diseases such as diabetes (Cangemi et al. 2011), preeclampsia (Liu et al. 
2011), and synpolydactyly (Debeer et al. 2002). One common factor between these 
diseases is the disruption of the tissue architecture.  
In the context of IPF, progressive disruption of the tissue architecture results in 
eventual lung failure and fibulin-1 may play a similar role in IPF pathogenesis. 
1.6.12 Hypothesis  
Fibulin-1 may be a biomarker of disease progression in patients with IPF as it is: 
• Increased in fibrotic lung fibroblasts 
• Increased in fibrotic tissue 
• Induced by TGFβ1 in lung fibroblasts 
• Increased in patients with fibrotic lung disease 
Therefore, we hypothesize that fibulin-1 may play a role in disease progression by 
altering the 3D structure of the lung ECM as a consequence of its dysregulated 
deposition in the lung tissue. Elevated and progressive fibulin-1 deposition may result 
in gradual lung function impairment  in patients with IPF (Figure 1.9).  
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Figure 1.9 The potential role of fibulin-1 in idiopathic pulmonary fibrosis 
 
Fibrotic lung tissue is different to normal lung tissue. (1) During fibrosis, lung 
fibroblasts are thought to take on a myofibroblast phenotype. (2) Part of this 
phenotype involves the increased deposition of extracellular matrix (ECM) molecules 
such as collagen and fibronectin. Other ECM proteins like fibulin-1 may also be 
increased. (3) Myofibroblasts also produce increased amounts of growth factors such 
as transforming growth factor-beta 1 (TGFβ1). (4) TGFβ1 is known to induce 
production of collagen and fibronectin by fibroblasts and it is possible that fibulin-1 is 
similarly upregulated.   
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1.7 Summary and Aims 
IPF is a pulmonary disease that proceeds relentlessly with loss of the normal lung 
architecture and eventual respiratory failure, leading to death. Characterized by 
excessive ECM deposition, IPF is thought to be driven by a dysregulated wound 
repair process that involves activated fibroblasts. The pathogenesis of this disease 
remains unknown and there is a lack of mechanism-targeted treatments. Progression 
in IPF is also varied and more biomarkers of disease progression are needed.  
Fibulin-1 is involved in matrix and elastic fibre formation and may be a biomarker of 
activated fibroblasts in the context of IPF. Mechanisms of fibrogenesis are known to 
be shared between pulmonary diseases and fibulin-1 may play a role in the 
pathogenesis of IPF. Fibulin-1 is produced by normal lung fibroblasts, but its 
expression in diseased fibroblasts has not been examined. In IPF, TGFβ1 induces 
excessive ECM production and TGFβ1 has been shown to induce fibulin-1 in the 
context of asthma, a disease which exhibits airway fibrosis, however, the effect of 
TGFβ1 on fibulin-1 in IPF has not been investigated. 
The specific aims of this thesis are: 
1. To examine the expression of fibulin-1 in patients with interstitial pulmonary 
fibrosis and to determine if fibulin-1 is a biomarker of disease progression in 
patients with IPF. 
2. To compare the expression of fibulin-1 to other ECM proteins, that have been 
identified as dysregulated in the context of fibrotic interstitial lung disease, as 
biomarkers of disease progression in IPF. 
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3. To investigate the effect of TGFβ on fibulin-1 expression and production in 
fibroblasts derived from patients with IPF. The effect of TGFβ1 on the 
expression and production of other ECM proteins will also be investigated. In 
addition, the effect of TGFβ1 on fibroblast morphology will be examined. 
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Chapter 2. Fibulin-1 in Pulmonary Fibrosis 
2.1 Introduction 
The heterogeneous group of more than 200 parenchymal diseases that comprise the 
interstitial lung disease (ILD) spectrum differ in their presentation, histopathology, 
clinical course and aetiology. ILDs are difficult for the non-specialist to diagnose, 
treat and monitor. For example, the ability to discriminate between chronic 
hypersensitivity pneumonitis (HP), an allergic lung disease also known as extrinsic 
allergic alveolitis, and idiopathic pulmonary fibrosis (IPF) is of particular concern due 
to their similarities in clinical presentation and stark difference in prognosis (Thomeer 
et al. 2004).  
IPF is the most common of the idiopathic interstitial lung diseases and has the highest 
mortality (Demedts et al. 2001). Forty four percent of all IPF patients are expected to 
die within 5 years, compared with 33% of patients with connective tissue disease and 
2% of patients with sarcoidosis, two other interstitial lung diseases (Demedts et al. 
2001). 
Treatment for ILDs are limited, differ widely between ILDs, and may be delayed as 
patients need to be referred to regional tertiary centres for the multidisciplinary 
diagnostic approach recommended by the guidelines (Raghu et al. 2011). In IPF, 
treatments have been largely unsuccessful (Raghu et al. 2013; Shulgina et al. 2013), 
mainly due to the fact that the underlying mechanisms of IPF are unresolved and there 
is no biomarker available to pinpoint individuals at risk of accelerated disease 
progression.  Therefore, biomarkers in IPF that reflect states of active fibrogenesis in 
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the lung are needed to indicate those patients that will rapidly decline, in order to 
prioritize them for intensive management care and lung transplantation. 
The large, fibrous extracellular matrix (ECM) proteins like collagen and fibronectin, 
are well-known to be increased in fibrotic conditions (Reiser and Last 1983; Muro et 
al. 2008; Araya and Nishimura 2010), but smaller, interlacing, ECM proteins can also 
play a key role. In their soluble form, altered ECM protein levels have been 
implicated in a variety of diseases such as cancer (Hellstrom et al. 2006) and 
mesothelioma (Robinson et al. 2003).  
The ECM glycoprotein fibulin-1 binds to several key ligands involved in the fibrotic 
process, including fibronectin (Mattei et al. 1994; Tanaka et al. 1994; Godyna et al. 
1995). Fibulin-1 is necessary during embryonic morphogenesis of several organs 
(Miosge et al. 1996; Cooley et al. 2008), and is essential for alveolar septa formation 
in the lung (Kostka et al. 2001). It is likely that there are common pathways between 
normal embryogenesis and fibrogenesis in many diseases with a fibrotic component 
(Araya and Nishimura 2010). The composition of the ECM is a known important and 
unifying factor in the pathophysiology of fibrosis, including lung fibrosis 
(Tschumperlin et al. 2012). 
A number of ECM proteins also circulate in the blood.  However, the utility of blood 
borne ECM proteins as serum biomarkers in IPF has not been well investigated 
(Richards et al. 2012; Vij and Noth 2012). In a recent review of peripheral blood 
biomarkers of importance in IPF, only one of the 13 described was an ECM protein, 
periostin (Vij and Noth 2012). This reflects our lack of knowledge of the contribution 
of particular components of the ECM to the disease pathology of pulmonary fibrosis.   
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Fibulin-1 is produced by lung fibroblasts (Roark et al. 1995) and has been shown to 
play a role in the pathophysiology of patients with asthma (Lau et al. 2010), a disease 
characterized in part by airway fibrosis (Royce et al. 2012). Therefore, it was 
reasoned that dysregulated fibulin-1 expression may be involved in lung diseases with 
more extensive fibrosis as mechanisms of fibrogenesis are likely to be shared 
(Kisseleva and Brenner 2008).  
This study explored the role of fibulin-1 in disease pathogenesis and progression of 
IPF. Intitially serum and tissue fibulin-1 levels in patients with IPF and other ILDs 
were examined and related to lung function. Fibulin-1 production by lung fibroblasts 
derived from patients with IPF and from subjects without lung fibrosis were then 
measured. Lastly, whether serum fibulin-1 could serve as a biomarker was 
investigated and its prognostic utility assessed in several cohorts of IPF patients. 
2.2 Methods 
2.2.1 Patient Data  
Due to the relatively low prevalence of ILDs within the local populations, this study 
involved collaborations with researchers in tertiary referral centres in Modena, Italy 
and San Francisco, USA. In addition, a researcher in Perth, Australia provided more 
samples of lung tissue from patients with IPF. The materials for this study were 
obtained from patients recruited from tertiary referral centres located in three different 
countries. Serum and tissue from Italy and San Francisco was obtained through 
collaboration with Professor Luca Richeldi and Dr. Stefania Cerri (University of 
Modena, Italy) and Professor Paul Wolters (University of California, San Francisco). 
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Tissue from Perth was obtained from Assoc. Prof. Cecilia Prele (University of 
Western Australia).  
2.2.1.1 Ethical Approval 
Ethical approval for this study was obtained from each of the institutions involved, as 
detailed in Table 2.1. All participants provided informed patient consent. 
Table 2.1 Detailed ethical approval for the materials studied in this thesis 
 
Institution Location # Ethics Board Sample 
collected 
University of 
Sydney 
Sydney, 
Australia 
2012/946 University of 
Sydney Human 
Research Ethics 
Committee 
Serum, tissue 
Royal Prince 
Alfred Hospital 
Sydney, 
Australia 
HREC/10/RPAH/613 Ethics Review 
Committee  
Serum 
Lung Institute 
of Western 
Australia 
Perth, 
Australia 
2011-10-497 Bellberry 
Human 
Research Ethics 
Committee 
Serum, tissue 
University of 
Modena 
Modena, Italy #74-08 and 31/12 Comitato Etico 
Provinciale di 
Modena 
Serum, tissue 
University of 
California, San 
Francisco 
San Francisco, 
USA 
IRB#10-00198 Laurel Heights 
Panel 
Serum, lung 
lysates 
 
Australia:  Consecutive patients referred to the Interstitial Lung Disease Clinic at the 
Royal Prince Alfred Hospital, Sydney were recruited and written informed consent 
attained. Diagnoses as determined by multidisciplinary review of patients included 
definite IPF (n=14), probable IPF (n=13), HP (n=11), and sarcoidosis (n=7). Other 
ILDs included non-specific interstitial pneumonia (NSIP) (n=3), connective tissue 
ILD (n=22), drug-induced ILD (n=1) and lymphangioleiomyomatosis (LAM) (n=2). 
Healthy volunteers with no history of lung disease were also recruited (n=17). 
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Italy: Consecutive IPF patients referred to the Centre for Rare Lung Diseases at the 
University of Modena and Reggio Emilia were recruited and written informed consent 
attained. Diagnoses as determined by multidisciplinary review of patients included 
definite IPF (n=28) and other ILDs included lymphangioleiomyomatosis (n=2). 
USA: Consecutive ILD patients recruited through the Nina Ireland Lung Disease 
program were recruited and written informed consent attained. Diagnoses as 
determined by multidisciplinary review of patients included definite IPF (n=17), HP 
(n=21), and sarcoidosis (n=5). Other ILDs included NSIP (n=1), and connective tissue 
ILD (n=4). 
The total numbers of participants in each disease category are summarized in Table 
2.2. 
Table 2.2 Numbers of participants in each of the diagnostic categories studied 
Disease Category Number of patients 
No lung disease 17 
Sarcoidosis 12 
HP 32 
“Other ILDs”  35 total 
• Connective tissue ILD (26) 
• NSIP (4) 
• LAM (4) 
• Drug induced ILD (1) 
IPF 72 
 
Lung Function Measurements: Demographic information including age, gender, body 
mass index (BMI) and smoking history were collected. Baseline lung function 
measurements taken included pre-bronchodilator percent predicted forced vital 
capacity (FVC%), percent predicted forced expiratory volume in 1 second (FEV1%), 
percent predicted diffusing capacity of carbon monoxide (DLCO%) and percent 
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predicted total lung capacity (TLC%) (Miller et al. 2005).The Composite Physiologic 
Index (CPI) was calculated as previously published (Wells et al. 2003). Follow up 
FVC% and DLCO% were collected at 365 days (±1) when available. 
2.2.2 Definition of progression 
Patients with IPF were followed up for a minimum of one year (365 ± 1 day) after 
blood draw.  A progression event was defined as any of the following occurring 
within the first one-year follow up period, ≥10% relative fall in FVC%, ≥15% relative 
fall in DLCO%, or death, as previously published (Ryerson et al. 2013).   
2.2.3 Serum collection 
Whole blood from patients and healthy volunteers in Sydney was collected, processed 
and stored by Jade Jaffar. Methods for whole blood processing from all centres were 
as follows: 
Whole blood was isolated from patients using sterile venepuncture technique by a 
qualified phlebotomist into serum Vacutainer (Becton Dickinson, USA cat #367958). 
The containers were inverted five times and left upright to clot for a minimum of 30 
minutes at room temperature (approximately 22-25°C). Samples were then 
centrifuged at 14,000 x g for 10 minutes and the serum fraction was aspirated with a 
sterile pipette. Aliquots of 200 – 500µL of serum was stored at -80°C until testing.  
2.2.4 Tissue collection 
Australia: Lung tissues from patients with IPF, who had provided written informed 
consent, were obtained from explanted lung following lung transplantation at St. 
Vincent’s Public Hospital, Sydney (n=5; 2 samples per patient) or from diagnostic 
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biopsies from Perth (n=7; 2-6 samples per patient). Where permission had been 
provided by the next of kin for the lungs to be used for research purposes,  normal 
human lung tissue was obtained from healthy transplant donors’ lungs that were 
deemed not suitable for transplantation (n=5) . 
Italy: Excess tissue following diagnostic surgical lung biopsies were obtained from 
patients with IPF who had given permission for their tissues to be used for research 
(n=6; 2-6 samples per patient). 
USA: Whole lung lysates extracted from explanted lung following transplantation. 
Where permission had been provided for the tissue to be used for research were stored 
at -80°C until testing (n=8). The method for preparation of lung lysates is found 
below. 
2.2.4.1 Tissue processing  
Tissue samples used for immunohistochemistry were processed as follows. Following 
removal from the patient, the tissues were submerged in 10% neutral buffered 
formalin solution (Sigma Aldrich, Sydney, Australia) to prevent post mortem 
decomposition. Tissues were then submerged in graded alcohol baths (from 70% 
alcohol to 100% alcohol) until all water had been removed. Finally, the samples were 
submerged in xylene and embedded in paraffin wax for sectioning. 
Whole lung lysates were a gift from Dr. Paul Wolters (University of California, San 
Francisco) and were prepared as follows: Lung tissue was directly snap-frozen in 
liquid nitrogen immediately after harvest. Samples were stored at –80°C until used for 
experiments. For immunoblot experiments, frozen lung tissue was pulverized using a 
stainless steel tissue pulveriser (Fisher Scientific, USA) pre-cooled in liquid nitrogen 
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and was immediately lysed in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Sigma-Aldrich, USA) running buffer and analysed as described below.  
2.2.5 Cell isolation 
Primary parenchymal fibroblasts were isolated from 7 patients diagnosed with non-
small cell carcinoma and 8 patients with IPF. Human distal parenchymal fibroblasts 
were isolated from lung tissue obtained from donors undergoing resection for either 
thoracotomy or transplantation. For all experiments in this thesis, cell cultures at less 
than 6 passages are used. Demographic information for donors of tissue is found in 
Table 2.8. 
Tissue from distal parenchyma was minced into 1-2mm3 pieces and placed into sterile 
Hanks Buffered Saline Solution (Hanks) (Sigma Aldrich, Sydney Australia) and 
centrifuged for 5 minutes at 1000rpm. After aspiration of the supernatant, the tissue 
pellet was resuspended in media containing 10% (vol/vol) foetal bovine serum (FBS) 
with 2% Penicillin-Streptomycin (Invitrogen)  in Dulbecco's Modified Eagle Medium 
(DMEM) (Invitrogen) and plated into tissue culture grade plastic flasks (BD 
Biosciences, North Ryde, Australia).  
2.2.6 Cell culturing 
Cells were passaged using 0.4% trypsin-EDTA (Thermo Scientific, Melbourne, 
Australia): a confluent monolayer of cells from a single flask was washed with Hanks 
and then incubated with 5 ml 0.4% trypsin-EDTA (Thermo Scientific, Melbourne 
Australia) for up to 5 minutes at 37oC, 5% CO2. The trypsin was then inactivated 
with double its volume of 5%FBS/DMEM. The cells were then centrifuged for 5 mins 
at 1000 x g and resuspended in 6mL 5% FBS/DMEM supplemented with 1% 
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Pencillin-Streptomycin (anti-mycotic) (growth media) and divided into three new 175 
cm2 sterile culture flasks each containing 8mL growth media.  
Passages of cells between 3 and 5 were used in all experiments. All cultures tested 
negative for the presence of mycoplasma before use in experiments. 
2.2.7 Cell experimentation 
Primary fibroblasts were seeded in 6-well plates at 1 x 104cells/cm2 in 5%FBS/1% 
antibiotics/DMEM for 72 hours and then quiesced in 0.1% FBS/1% Pencillin-
Streptomycin /DMEM (quiescing media) for 24 hours. Fresh quiescing media is then 
added for a further 72 hours.  
2.2.7.1 RNA collection 
Total RNA was collected using the BIOLINE mRNA Isolate Miniprep kit (Bioline, 
London, UK). Cells were seeded in 6-well plates as previously described and the 
supernatant was removed and discarded. Cells were lysed with 450µL of Lysis Buffer 
and incubated for 3 minutes at room temperature. Cell lysates were collected and 
placed into the 1.5mL spin column R1 placed inside a collection tube. After spinning 
at 10,000 x g for 2 minutes at room temperature, the filtrate was saved and transferred 
to a new spin column R1. 450µL of 70% ethanol was added to the filtrate and spun 
again at 10,000 x g for 2 minutes at room temperature. The filtrate was then discarded 
and 500µL of wash buffer AR was added. The column was spun again at 10,000 x g 
at room temperature for 1 minute and the filtrate was discarded. 700µL of wash buffer 
BR was added and the column was spun for 1 minute at 10,000 x g at room 
temperature, the filtrate was discarded and then the column was spun again at 10,000 
x g for 2 minutes. Finally, the column was placed in a fresh RNA-free microtube and 
30µL of RNase-free water was added. Following 1 minute incubation at room 
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temperature the RNA was collected by spinning the tube at 6,000 x g for 1 minute at 
room temperature. The concentration of the RNA was measured using a Nanodrop 
2000 (Thermo Scientific, Melbourne, Australia).  
The Nanodrop 2000 is a spectrophotometer that measures the light diffraction in a 
1µL sample of RNA isolate using a narrow beam of light. The amount of light that 
travels through the sample corresponds to the amount of RNA present.  
RNA was stored at -80°C until conversion to cDNA. 
2.2.7.2 Cell supernatant and cell lysate collection 
Cells were seeded in 6-well plates as previously described. Cell culture supernatants 
were collected into microtubes and the remaining cells are immediately washed twice 
in cold sterile phosphate buffered saline (PBS, pH 7.2).  
On wet ice, total cellular protein extracting buffer was added. Extraction buffer 
contains 20mM Tris, pH 7.4, 150mM NaCl, 1mM Na2EDTA, 1% Triton X-100, 10% 
glycerol, 0.1% SDS, 0.5% sodium deoxycholate, 1% protease inhibitor cocktail set III 
(Millipore, USA) and 1mM phenylmethylsulfonyl fluoride (PMSF) (Amresco, Solon, 
OH, USA).   
Lysates are then collected and centrifuged at 4°C/14,000g for 5 mins to pellet debris. 
The cell debris-free fraction was then aspirated and aliquoted into a fresh microtube. 
Cell supernatants and lysates were stored at -20°C until analysis. This extraction 
buffer is also used as a diluent in immunoblot experiments. 
2.2.8 Real-time reverse transcription polymerase chain reaction (QPCR) 
2.2.8.1 mRNA to cDNA conversion 
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PhD candidate Alen Faiz isolated and converted the mRNA to cDNA specific to this 
chapter. All further experiments were performed and analysed by Jade Jaffar. 
500 ng of mRNA was converted to cDNA using the M-MLV reverse transcriptase 
(Invitrogen, USA cat# 28025-013). On ice, 500 ng of the mRNA isolate was added to 
1 µL of random primer (Biolabs cat#S1230S). The random primer was a mixture of 
hexamers (a 6 nucleotides fragment of cDNA) that was used to start the cDNA 
conversion. To this, 1 µL of 10mM dNTPs (Invitrogen) was added and DNA-free 
water was added to make the final volume 12 µL.  This mixture was heated for 5 
minutes at 65°C and then immediately chilled on ice.  
Next, 4 µL of 1st strand buffer (Invitrogen,  cat#Y002321), 2µL of 0.1M dithiothreitol 
(DTT)(Invitrogen, cat#Y00147), and 1µL of ribonuclease inhibitor (Invitrogen, 
cat#10777-019) was added to the mixture and incubated for 2 minutes at 37°C. 
Finally, 200 units (1 µL) of M-MLV reverse transcriptase was added. The mixture 
was incubated at 25°C for 10 mins, then at 37°C for 50 minutes and finished with a 15 
minute incubation at 70°C to stop the reaction. cDNA was then stored at -20°C until 
use in QPCR. 
2.2.8.2 Measurement of fibulin-1 mRNA levels  
A commercially available QPCR primer pair specific for human fibulin-1 was 
obtained from Invitrogen (Hs_00243545_m1). Quantitative analysis of fibulin-1 
expression was performed using human 18S rRNA (Invitrogen) as the endogenous 
control. All samples were kept on ice during experiment set up and every sample was 
tested in triplicate. To each 3.3µL sample of cDNA, 33µL of TaqMan Universal 
Master Mix (Invitrogen), 3.3µL of fibulin-1 primer, 3.3µL of 18S primer and 23.1µL 
of DNA-free water was added. In a 96-well PCR plate (Invitrogen) 20µL of this 
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solution was added in sequential wells.  As a negative control, three wells that 
contained the master mix, primers, and water, but without cDNA was included.  
Thermal cycle conditions  were 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute (Johnson et al. 2006). QPCR was performed using the StepOne Plus detection 
system and the data were collected and analyzed using StepOne software (Applied 
Biosystems, Melbourne, Aus). The relative abundance of mRNA was calculated by 
using the ∆∆Ct method and the results were normalized against the 18S rRNA levels.  
2.2.9 Immunoblotting 
Placental fibulin-1 was donated by Dr. Scott Argraves (Medical University of South 
Carolina) and was purified as published (Twal et al. 2001). Placental fibulin-1 was 
reconstituted in sterile PBS (Invitrogen)  and was used as a positive control in 
immunoblot experiments.  
Cell-derived fibulin-1 was also donated by Dr. Scott Argraves. The fibrosarcoma cell 
line HT-1080 (Rasheed et al. 1974)  was transfected with the fibulin-1 gene in their 
lab. This cell line was chosen as it does not normally produce the fibulin-1 protein 
(Godyna et al. 1995; Xie et al. 2008).  
Fibulin-1 transfected HT-1080 cells were grown in growth media supplemented with 
300µg/mL G418 antibiotic (Invitrogen) as a selection agent. This maintained the 
selection pressure an ensured that all the cells present contain the plasmid with the 
fibulin-1 gene. HT-1080 cell supernatants and cell lysates were collected from tissue 
culture flasks as previously described (2.2.6) and used as positive controls in 
immunoblot experiments.  
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Whole lung lysates, fibroblast cell lysates, fibroblast supernatants and sera were 
separated by SDS-PAGE. For whole lung and cell lysates, total protein was measured 
by Bicinchoninic Acid (BCA) assay (Sigma Aldrich, Melbourne, Australia cat 
#BCA1). The separating gel was made of 25% Tris-SDS buffer (pH 8.8),  0.1% w/v 
N,N,N‟,N‟-Tetramethylethylenediamine (TEMED) (Sigma) , 1% w/v ammonium 
persulfate (APS) (Sigma), and 25% v/v Acrylamide:Bis solution (40% 37:1 
Acrylamide:Bis-acrylamide) (Bio-Rad) in distilled water. The stacking gel consisted 
of 25% Tris-SDS buffer (pH 6.8), 0.1% w/v TEMED, 1% w/v APS, and 10% v/v 
Acrylamide:Bis solution in distilled water.  
Using the mini-PROTEAN gel casting equipment (Bio-Rad), the separating gel was 
poured and flattened using 500µL of 100% butanol to ensure an even polymerisation 
across the gel. After letting the gel set for at least 2 hours at room temperature, the 
butanol was decanted and the gel was washed twice with distilled water and the 
stacking gel was added along with 15-well combs (Bio-Rad) and allowed to set for a 
further 30 minutes. 
A 5X loading dye was made consisting of 0.312M Tris-HCl, 5% SDS, 0.5M DTT, 
and 50% glycerol in distilled water and then diluted with sample/lysis buffer at 1:5 
dilution for use. The pre-stained molecular weight marker (ranging between 10 – 
250kDa) was sourced from Bio-Rad (USA). 
 
 
Page 70 of 252 
 
The samples were diluted as follows: 
Sample  Quantity of sample Volume of extraction 
buffer 
Volume of 5X 
loading dye 
Serum (pre-diluted 
1:10 with sterile 
PBS) 
8µL  72µL 20µL 
Whole lung lysates 0.15µg/µL As needed* As needed* 
Fibroblast cell 
lysates 
0.15µg/µL As needed* As needed* 
Fibroblast cell 
supernatants 
6µL none 24µL 
Placental fibulin-1 0.5ng/µL As needed* As needed* 
HT-1080 cell lysate 0.15µg/µL As needed* As needed* 
HT-1080 supernatant 3µL 3µL 24µL 
*As needed, the volumes of lysis buffer and dye were adjusted to provide a final 
concentration of the sample as listed. 
 
Samples diluted in lysis buffer and/or extraction buffer (10µL/well) was added to 
each well and run in SDS electrophoresis tank buffer which consisted of 0.3% w/v 
Tris-Base, 1.44% w/v glycine and 0.1% w/v SDS in distilled water (pH 8.5). A Bio-
Rad power pack 300 was set at 125 V and the gel was run for approximately 90 
minutes.    
Proteins were transferred to a 0.45µm pore size polyvinylidenedifluoride (PVDF) 
membrane using a Bio-Rad trans-blot tank filled with 10% methanol in SDS 
electrophoresis buffer. Bio-Rad power pack was set at 25 V for 1.5 hours. Membranes 
were blocked with 5% skim milk/2% BSA/TBS-Tw for 1 hour at room temperature, 
and rinsed quickly with TBS/Tw before being probed with  primary antibody to 
fibulin-1 (#SC25281, Santa Cruz Biotechnologies, USA) diluted to a concentration of 
0.2 µg/mL in 2% BSA/TBS-Tw for two hours at room temperature or overnight at 
4°C. 
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Membranes were washed in three changes of TBS-Tw for 5 minutes each at room 
temperature before being incubated with horseradish peroxidase-conjugated 
secondary anti-mouse antibodies (Dako, USA) diluted to 0.1µg/mL in 2% BSA/TBS-
Tw for one hour at room temperature. Membranes were again washed in three 
changes of TBS-Tw for 5 minutes at room temperature before visualization was 
carried out by incubating the membranes in enhanced chemiluminescence (ECL) 
western blot detection reagent (Millipore, USA) for one minute. A Kodak Image 
Station 4000MM camera was used to capture images and analysis was performed 
using Carestream Molecular Imaging software (v. 5.3.3.17476 Carestream Health Inc. 
1994-2011). 
Membranes loaded with whole lung or cell lysates were then stripped by incubating 
the membranes in 2% SDS/Tris-HCl (pH 6.8) supplemented with freshly added 0.8% 
β-mercaptoethanol (Sigma) for 15 minutes at 50°C. Membranes were washed in 3 
changes of TBS-Tw as before and then blocked again using 5% skim milk/ 2% BSA/ 
TBS-Tw for another hour at room temperature.  
Membranes were incubated at room temperature for 45 minutes with anti-human 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (Millipore) diluted 
to 0.04µg/mL in 2% BSA/TBS-Tw. Membranes were washed in three changes of 
TBS-Tw for 5 minutes each before being incubated with horseradish peroxidise-
conjugated secondary anti-mouse antibodies (Dako, USA) diluted to 0.02µg/mL in 
2% BSA/TBS-Tw for 30 minutes at room temperature. Membranes were again 
washed in three changes of TBS-Tw for 5 minutes before visualization was carried 
out as before. Image capture and analysis were carried out as described above. 
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2.2.10 Specificity of fibulin-1 antibody 
There were no previous reports in the literature of publications involving the use of 
the SC25281 monoclonal antibody and western blotting as a method for the 
quantification of fibulin-1. Therefore, initial experiments were carried out to ensure 
specificity and sensitivity of the antibody for use in this study (Figure 2.1). Fibulin-1 
was discovered as a binding partner for fibronectin (Argraves et al. 1989) and 
therefore it was important to ensure that the fibulin-1 specific antibody did not cross 
react with fibronectin. Fibronectin is also present in high concentrations in the blood 
(Lafuma et al. 1987) and could affect the measurements. Anti-fibronectin antibody 
(#MAB1935, Chemicon, USA) and plasma purified fibronectin protein (#FC010, 
Millipore, USA) were used as negative controls. By assaying the samples at 3-5 
concentrations, a standard curve was drawn indicating that there was a linear 
relationship between the concentration of fibulin-1 and the resulting band intensity 
and that this method could be used to quantify the level of fibulin-1 in samples 
(Figure 2.1).  
Importantly, Figure 2.2 shows that there was no fibronectin contamination in either of 
the positive fibulin-1 control materials used in this study. Finally, all quantification of 
fibulin-1 (whether in serum or tissue) was done without knowledge of the patient’s 
corresponding lung function measurements in order to ensure the data were analysed 
in a blinded manner. 
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Figure 2.1 The sensitivity and specificity of the fibulin-1 antibody  
A representative immunoblot showing fibulin-1 (FBLN1) protein 
purified from human placenta (lanes 1-3), recombinant fibulin-1(C-
isoform) isolated from transfected human fibrosarcoma cell line (HT-
1080) (lanes 4-8), and purified human plasma fibronectin 
(hFibronectin, #FC010, Millipore, USA)(lane 9) as probed by anti-
fibulin-1 antibody (#SC25281, Santa Cruz Biotechnologies, USA). 
Protein size ladder is shown on the left.  
Cell-secreted FBLN1 is the cell-free culture supernatant from HT-
1080 cells that have been transfected with the FBLN1(C-isoform) 
gene.(A) Densitometric analysis was performed on the immunoblot shown.  A dilution of 1 indicates an undiluted sample. Fibulin-1 
concentration (FBLN1 conc) was measured by BCA assay. Net, Sum, and Mean Intensity of each band was analysed by Kodak Image Station 
4000MM (Carestream Molecular Imaging Software v. 5.3.3.17476). The Interior Area indicates the number of pixels that is analysed for each 
sample. The Sum Intensity indicates the total intensity of each pixel in the interior area. The Mean Intensity is the average intensity of the 
interior area. The Net Intensity is the sum intensity minus the intensity of the background of the blot.  
(B) Net intensity of each band is then plotted against the FBLN1 concentration and a linear regression is performed.   
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Figure 2.2 Purity of fibulin-1 positive controls were investigated by probing with 
an antibody to human fibronectin 
A representative immunoblot showing fibulin-1 (FBLN1) protein from placenta (lanes 
1-3), from a fibulin-1(C-isoform) transfected human fibrosarcoma cell line (HT-1080) 
(lanes 4-8), and purified human plasma fibronectin (hFibronectin, #FC010, Millipore, 
USA)(lane 9) as probed by anti-fibronectin antibody (#MAB1935, Chemicon, USA). 
Protein size ladder is shown on the left. Net, Sum, and Mean Intensity of each band 
was analysed by Kodak Image Station 4000MM (Carestream Molecular Imaging 
Software v. 5.3.3.17476). 
Concentration of the proteins loaded were as follows: 
Lane 1 8ng/mL, Lane 2 4ng/mL, Lane 3 2ng/mL, Lane 4 6ug/mL, Lane 5 3ug/mL, 
Lane 6 1.5ug/mL, Lane 7 0.75ug/mL, Lane 8 0.38ug/mL, Lane 9 100ng/mL 
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Lastly, the level of fibulin-1 in serum samples at the same concentration were 
compared (Figure 2.3). Serum fibulin-1 contained 4 bands. Fibulin-1 was considered 
to be 100kDa as this is the size of the protein that was first identified as a binding 
partner of fibronectin (Argraves et al. 1989). The other bands may be fragments of 
fibulin-1 or non-specific binding of the antibody to other proteins which have not 
been identified in this thesis. To our knowledge, this is the first time that serum 
fibulin-1 has been quantified in this manner and there is no evidence in the literature 
of other sizes of fibulin-1 in the serum.  
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Figure 2.3 Serum levels of fibulin-1 quantified by western blot.  
 (A) A representative immunoblot of fibulin-1 in serum samples. In lane 1, placental 
fibulin-1 (5ug/mL) loaded as a positive control. Lane 2 contained the serum sample 
used for relative quantification of fibulin-1 and is diluted 1:500. Lane 3 contained 
100ng/mL human plasma fibronectin as a negative control. Serum from ten 
independent patients was diluted 1:500 and loaded in lanes 4-10.  Densitometric 
analysis was performed using Kodak Image Station 4000MM (Carestream Molecular 
Imaging Software v. 5.3.3.17476). Fibulin-1 is 100kDa. 
 
(B) The net intensity of the 100kDa band of lane 2 was set to 1. The net intensities of 
each of the patient samples were then calculated relative to the net intensity of lane 2. 
Fibulin-1 level was reported in relative units.  
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2.2.11 Optimization of normalization protocol for cell supernatants 
There is evidence in both the literature (Ramos et al. 2001) and from work previous 
completed in our laboratory (Havryk, PhD thesis 2005) that fibroblasts from patients 
with IPF have lower levels of proliferation compared to fibroblasts from subjects 
without lung disease. Therefore it was important to take cell number into account 
(which has been referred to as normalisation) when comparing the level of fibulin-1 in 
cell culture supernatants.  
This experiment was designed to investigate the effect of different methods of cell 
number normalisation and 4 cell lines were determined to be enough to address this 
question. Fibroblasts from patients with IPF (n=2) and subjects without IPF (n=2) 
were grown in 5% FBS/ DMEM/1% Penicillin-Streptomycin for 72 hours described 
in Chapter 2.2.6 and supernatants were harvested as described in Chapter 2.2.7.2. 
Duplicate wells were harvested for estimations of cell numbers by (A) manual cell 
counting, (B) commercially available DNA-binding assay CyQuant (#C7026, 
Invitrogen, USA) (Marinkovic et al. 2012), and by (C) measurement of the total 
protein concentration of the cell monolayer as described in the Methods 2.2.9. Briefly, 
plates used for manual cell counting were washed and cells were detached using 
trypsin as described in Chapter 2.2.6. Total cells were stained with haematoxylin 
(Sigma Aldrich, Melbourne Australia) and the ones dye excluded were counted using 
a haemocytometer. The average of 10 large squares was calculated.  
The fibulin-1 level in the cell supernatant as measured by immunoblot was then 
normalized to each of the three cell number estimations (Figure 2.4). There was no 
difference between the level of fibulin-1 when normalized to either manual cell 
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number (Figure 2.4A), Cyquant estimation (Figure 2.4B), or to the concentration of 
the cell monolayer (Figure 2.4C).  
 
Figure 2.4 The effect of normalization to different cell number estimations on 
fibulin-1 level. 
Fibroblasts from four patients were grown in 5% FBS/DMEM for 72 hours and 
supernatants were harvested. Fibulin-1 level was measured by immunoblot. 
Total cell numbers were estimated using (A) manual cell counts as performed by 
haemocytometer, (B) commercially available CyQuant assay (#C7026, Invitrogen, 
USA), and (C) the total protein concentration as measured by BCA assay. 
BCA bicinchroninic acid, IPF idiopathic pulmonary fibrosis 
Subsequently, for measurements of fibulin-1 level in fibroblast supernatants, equal 
volumes of supernatant were loaded and final fibulin-1 levels are adjusted for the total 
protein concentration of the respective confluent cell monolayer lysate as measured 
by BCA and described in the literature ((Quesnel et al. 2008; Quesnel et al. 2010)). 
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2.2.12 Immunohistochemistry 
Five micrometre thick paraffin sections from formalin-fixed tissue were directly 
stainedfor fibulin-1 and in parallel with the matching isotype control, mouse IgG2a 
(Dako, Sydney, Australia).  The concentration of the primary antibodies that were 
used are found in Table 2.3. 
Table 2.3 Concentrations of the primary antibodies used for 
immunohistochemistry 
 Source Final concentration 
Fibulin-1 antibody Santa Cruz (cat# 25281) 0.01µg/mL 
Mouse IgG2a 
antibody 
Dako 0.01µg/mL 
 
Slides were deparaffinised by incubating in 2 baths of xylene for 5 minutes at room 
temperature. This was followed by 2 minute incubations each in 2 baths of 100% 
ethanol, 95% ethanol, 70% ethanol and 50% ethanol before being left standing in 
distilled water for the final 2 minutes or up to overnight. 
No antigen retrieval was used. Antigen retrieval is a technique employed to “unmask” 
sites for antigen binding that may be blocked by the fixation process. Slides were then 
blocked for one hour at 37°C in 10% normal goat serum diluted in pH 7.4 Tris 
buffered saline (0.3% Tris, 0.8% NaCl, 0.02% KCl) supplemented with 0.05% tween-
20 (Sigma) and 1% BSA (1% BSA/ TBS-Tw). The blocking solution prevents non-
specific binding of the primary antibody and was removed by tapping the slide once 
on paper towels. The fibulin-1 antibody was diluted in 1% BSA/TBS-Tw and 50 – 
200 µL of the solution was loaded onto each slide. Slides were incubated at 37°C for 
another 2 hours.  
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Slides were then washed twice in TBS-Tw for 5 minutes each and oxidised in 3% 
hydrogen peroxide for 5 minutes at room temperature. This prevents the endogenous 
peroxidise activity in the tissue from affecting the secondary reagent. Slides were 
again washed twice in TBS-Tw for 5 minutes each and 50 to 200 µL of the secondary 
reagent (Dako cat#K4006) was added for 30 minutes at room temperature.  
After incubation with DakoEnVision secondary reagent, areas that were positive for 
the antibody were visualized by incubating in diaminobenzidine (DAB) (Dako 
cat#K3467) for 2 minutes. This dye was diluted 1 drop per mL of substrate for use 
and turned brown when in contact with the horseradish peroxidase (HRP) enzyme that 
was conjugated to the anti-mouse secondary antibody. The reaction was stopped once 
the slides were dipped in distilled water. Sections were counterstained by incubating 
in Mayer’s haematoxylin (Sigma cat#MHS1) for 3 minutes. Slides were then washed 
briefly in tap water, taken backwards through the graded alcohols to finish in xylene 
and coverslipped with the xylene-based mounting medium DPX (Sigma cat# 44581). 
Serial sections were also stained using standard Masson’s Trichrome in order to 
quantify total collagen levels. Masson’s Trichrome staining was performed by Dr. 
Rema Oliver, University of New South Wales. Following deparaffinisation as 
described above, slides are incubated in Weight’s haematoxylin for 20 minutes at 
room temperature. Slides were washed in running tap water for 5 minutes before 
incubation with 0.5% acid fuchsin solution and then again washed briefly in tap 
water. Slides were then incubated for 25 minutes in 1% phosphomolybdic acid and 
rinsed in tap water before incubating for 3 minutes in 2% Light Green Counterstain 
solution. Slides were washed with tap water and incubated for 1 minute in 1% acetic 
acid before being dehydrated in the graded alcohols and mounted in DPX as before. 
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Collagen stained green while cell nuclei were a blue/black. Cytoplasm, muscle or 
erythrocytes were red. 
2.2.13 Image Capture 
A majority (75%) of the image capture of stained tissue sections was performed by 
undergraduate student Sofia Unger as part of a student research project, under the 
tutelage of Jade Jaffar. All further experimentation and analysis was performed by 
Jade Jaffar.    
Western blot images were captured using a Kodak Image Station 4000mm camera and 
analysed using Carestream Molecular Imaging software (v. 5.3.3.17476 Carestream 
Health Inc. 1994-2011). Immunohistochemisty images were taken at 20X 
magnification using an Olympus BX60 microscope (North Ryde, Australia). 20 
consecutive (minimally overlapping) images of each section were randomly (not 
focused on any particular structure) taken using a DP71 camera with Kohler 
illumination and it was ensured that the entire surface of the section was included in 
the final analysis. Pictures of all sections that were stained in the same manner were 
taken on the same day to maintain identical light settings. Two to six sections from 
each patient were imaged. 
2.2.14 Densitometric analysis 
The images of sections stained for fibulin-1 were analysed by the open source 
software ImageJ (http://rsb.info.nih.gov/ij/ accessed June 2011) (Busquets et al. 
2010). First, each image was colour deconvoluted (Ruifrok and Johnston 2001; 
Lesack and Naugler 2012) using an algorithm and the plugin vector H&E DAB 
(http://www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.html, accessed 
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July 2013). The resulting brown stain was further investigated and a threshold of 
positive staining was set manually by examining 5 random images of sections from 5 
independent non-diseased control patients. This threshold was then applied to every 
image. The algorithm then calculated the positively stained area as a numerical value 
and adjusted for the total positively stained area in the image. The resultant mean 
value took into account any compression of the tissue during processing as well as the 
increased tissue mass in fibrotic lesions (Haafiz et al. 2011). 
Similarly, images of sections stained with Masson’s trichrome were colour 
deconvoluted using an algorithm and the plugin vector Masson trichrome 
(http://www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.html, accessed 
July 2013). The resulting green stain was quantified and reported as the percentage 
area of collagen. 
Each of the 20 image values in each analysis set were then averaged to obtain the 
average staining density for each tissue section. 
Finally, the multiple samples from each patient were averaged together to give the 
final fibulin-1 level or percentage area of collagen per patient. A sample of an image 
used for analysis is seen in Figure 2.5. 
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Figure 2.5 Quantification of fibulin-1 level by computer-based image analysis 
(A) A single image of a tissue section stained for fibulin-1 (brown) and counterstained 
with haematoxylin (blue). (B) A computer algorithm separates the brown stain from 
the blue stain. The level of brown staining can then be quantified and in this case 
measures 131 units. (C) A sequential tissue section is stained with the isotype control 
for fibulin-1 and is used for quality control purposes. The level of brown staining in 
the isotype control should not be greater than that of the fibulin-1 stained section. 
Details regarding methods can be found in 2.2.14 
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2.2.15 Statistical analysis 
To determine the repeatability and the reliability of the measurements, the coefficient 
of repeatability and intraclass correlation coefficient were calculated (Bland and 
Altman 1996). 
Duplicate serum samples from 17 subjects were tested on two separate occasions and 
the coefficient of repeatability was 1.48 units of fold difference. This indicates that 
the same serum tested the first time would be expected to differ by more than 1.48 
fold on the second test only 5% of the time. The intraclass correlation coefficient was 
0.91 (95% CI 0.77 to 0.97) indicating that there was a high degree (>0.6) of 
reproducibility of the serum measurements.  
Graphs were made using GraphPad Prism 6 Software for Windows (Version 6 
GraphPad Software Inc. 1992-2007, Redmond, USA). Statistical analysis was done 
using Statistical Package for the Social Sciences (SPSS) (Version 21 IBM 
Corporation 1989-2012, Armonk, USA). 
Characteristics of the subjects and spirometric results were summarized with the use 
of descriptive statistics.  
Distributions of serum, parenchyma and fibroblast levels of fibulin-1, and lung 
function parameters were tested for normality using the Kolmogorov-Smirnov test, 
Shapiro-Wilk test, and skewness and kurtosis were calculated. 
Serum fibulin-1 levels were not normally distributed (n=168; p<0.0001). For 
multivariate linear analyses, serum fibulin-1 levels were transformed to the natural log 
value to obtain a normal distribution. Between-group differences were assessed by 
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means of one-way analysis of covariance (ANCOVA) with adjustments for 
confounders with post-hoc analysis by Tukey’s test.  
Receiver-operator curves (ROC) were used to model the utility of serum fibulin-1 as a 
marker of progression.  Cox regression, with and without baseline parameters, were 
used to model the impact of serum fibulin-1 levels on predicting progression. Kaplan-
Meier survival curves were used to model the progression-free survival rate of serum 
fibulin-1 and between group rates were compared using the Mantel-Cox log rank test. 
Parenchyma fibulin-1 levels were normally distributed (n=25; p=0.504). Between-
group differences were assessed by Student’s unpaired t-test. 
To study the relationship between serum fibulin-1 levels and lung function 
parameters, correlations between serum fibulin-1 and lung function variables were 
analysed using Spearman’s rank correlation co-efficient. To study the relationship 
between parenchyma fibulin-1 levels and lung function parameters, correlations 
between tissue fibulin-1 and lung function were analysed using Pearson’s product-
moment tests.  
The sample size for analysis of fibroblast fibulin-1 levels was too small to determine 
normality (n=15). Between-group differences were assessed by means of Student’s 
unpaired t-test.  

2.3 Results 
Baseline demographics for our study population are summarized in Table 2.4. 
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Table 2.4 Baseline demographics for the study population 
 
 
Serum was collected from 151 patients with interstitial lung disease (ILD) and 17 subjects without lung disease.  
 
*”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-specific interstitial pneumonia (n=4), lymphangioleiomyomatosis (n=4), 
and drug-induced ILD (n=1). 
** P value for  unpaired t-test, non-diseased control vs. all ILDs  
***P value for Chi-squared test, non-diseased control vs. all ILDs  
 
BMI body mass index, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, DLCO diffusing capacity of carbon monoxide, CPI composite 
physiologic index, TLC total lung capacity, Yr year, n/a Not available, ns Not significant 
 
  
Non-diseased 
control 
Sarcoidosis Hypersensitivity 
Pneumonitis 
“Other” ILD* Idiopathic 
pulmonary fibrosis 
P value ** 
  n=17 n=12 n=32 n=35 n=72 
  Mean SD Mean SD Mean SD Mean SD Mean SD 
Age, yr 34 12 48 11 61 11 59 14 68 9 <0.0001 
BMI, kg/m2 n/a n/a 31 5 31 5 26 5 30 6 ns 
Baseline FEV1, % predicted n/a n/a 79 23 70 19 74 22 79 20 ns 
Baseline FVC, % predicted n/a n/a 91 22 68 22 78 24 74 20 ns 
Baseline DLCO, % predicted n/a n/a 70 23 49 15 48 20 41 16 ns 
Baseline CPI, units n/a n/a 22 19 46 14 44 18 52 13 ns 
Baseline TLC, % predicted n/a n/a 88 20 73 20 76 22 67 13 ns 
                        
  Count % Count % Count % Count % Count % P value *** 
Male 5 29 7 58 10 31 10 29 41 57 <0.0001 
History of smoking 1 6 2 17 16 50 14 40 45 63 <0.0001 
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2.3.1 Serum fibulin-1 is increased in patients with IPF compared to other ILDs 
and subjects without lung disease 
The level of serum fibulin-1 was greatest in IPF compared to the other ILDs after 
adjustments for potential confounding variables – age, gender and smoking history  
(Figure 2.6). Levels of serum fibulin-1 were greater in patients with IPF compared to 
subjects without lung disease. 
 
 
Figure 2.6  Serum fibulin-1 levels are increased in patients with IPF compared to 
non-diseased controls.  
The fibulin-1 level of each serum sample was determined by immunoblotting and 
reported as relative to a standard serum sample. Densitometric analysis was 
performed using a Kodak Image Station 4000MM (Carestream Molecular Imaging 
Software v. 5.3.3.17476). Serum fibulin-1 levels were adjusted for age, gender and 
smoking history. (Analysis of covariance, n=168, post-test Tukey’s *p<0.05. 
***p=0.006, median ± 25th & 75th percentiles). 
”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-
specific interstitial pneumonia (n=4), lymphangioleiomyomatosis (n=4), and drug-
induced ILD (n=1). 
HP hypersensitivity pneumonitis, ILD interstitial lung disease, IPF idiopathic 
pulmonary fibrosis 
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2.3.2 Serum fibulin-1 correlates with disease severity in patients with ILDs 
Serum fibulin-1 correlates with CPI in patients with ILDs. The CPI is a representation 
of the morphological extent of fibrosis as seen on high resolution computed 
tomography (Wells et al. 2003). Spearman’s rank correlation analysis was used to 
model the relationship between serum fibulin-1 and CPI in patients with ILDs. 
(rho=0.34, p=0.01, n=73) (Figure 2.7). 
 
Figure 2.7 Serum fibulin-1 levels correlate with disease severity in patients with 
fibrotic ILD 
The composite physiologic index (CPI) was calculated in 73 patients with interstitial 
lung disease (ILD). CPI was derived from lung function measurements and provided a 
representative measurement of disease severity. 
The fibulin-1 level of each serum sample was determined by immunoblotting and 
reported as relative to a standard serum sample. Densitometric analysis was 
performed using Kodak Image Station 4000MM (Carestream Molecular Imaging 
Software v. 5.3.3.17476). The linear regression line was calculated by least squares 
methodology and the significance of the relationship was determined using 
Spearman’s rank correlation analysis (rho=0.34, p=0.01). 
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Lung function measurements were used to assess disease severity in patients with 
ILDs. Serum fibulin-1 correlated with FVC% (rho =-0.3, p=0.01), DLCO% (rho=-0.25, 
p=0.04), CPI (rho =0.34, p=0.01) (Figure 2.7) and TLC% (rho =-0.34, p=0.01) but not 
with FEV1% (Spearman’s rho correlation, Table 2.5). 
Neither age, BMI, nor smoking status correlated with serum fibulin-1 levels. 
Table 2.5 Serum fibulin-1 correlates with lung function parameters in patients 
with ILDs 
Variable 
Spearman’s  
correlation 
coefficient 
p value 
Age, yr 0.17 0.20 
BMI, kg/m2 0.10 0.49 
Baseline FEV1, % predicted -0.14 0.23 
Baseline FVC, % predicted -0.30 0.01 
Baseline DLCO, % predicted -0.25 0.04 
Baseline CPI, units 0.34 0.01 
Baseline TLC, % predicted -0.34 0.01 
 Pearson chi-square p value 
Male 0.001 0.98 
History of smoking 0.40 0.82 
 
Lung function parameters and demographic information was obtained for 73 patients 
with interstitial lung disease (ILD). The time between serum collection and lung 
function measurements was no more than 15 days (±5). Continuous variables were 
analysed with spearman’s rank correlation analysis and categorical variables were 
analysed by Pearson chi-square test. Serum fibulin-1 was measured by immunoblot. 
BMI body mass index, FEV1 forced expiratory volume in 1 second, FVC forced vital 
capacity, DLCO diffusing capacity of carbon monoxide, CPI composite physiologic 
index, TLC total lung capacity, Yr year 
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2.3.3 The level of fibulin-1 in whole lung lysates was increased in patients with 
IPF compared to subjects without lung disease 
The presence of fibulin-1 in the tissue of patients with IPF was then examined 
specifically. The level of tissue fibulin-1 in whole lung lysates from patients with IPF 
(n=4, mean 3.43 units, SD 0.91) was 2.6 fold higher than in non-diseased controls 
(n=4, mean 1.34, SD 0.2; p=0.02) (Figure 2.8).  
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Figure 2.8 Tissue fibulin-1 is increased in the whole lung lysate derived from 
patients with IPF compared to subjects without lung disease 
(A) The level of fibulin-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
in whole lung lysates derived from patients with and without IPF was determined by 
immunoblot. The cell lysate of the fibulin-1 transfected cell line (HT-1080) was used 
as a positive control. Densitometric analysis was performed using Kodak Image 
Station 4000MM (Carestream Molecular Imaging Software v. 5.3.3.17476). The 
intensity of the fibulin-1 band was normalised to the intensity of the GAPDH band 
and reported in arbitrary units. 
(B) The relative levels of fibulin-1 of subjects without disease and patients with IPF 
were compared using unpaired t-test. Values are expressed as means ± SD, *p=0.02.
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2.3.4 Tissues from patients with IPF show greater levels of fibrosis. 
As a positive control ensuring the presence of fibrosis in our samples, we measured 
the levels of total collagen in tissues from patients with IPF. Patient information is 
found in Table 2.6. 
More total collagen (percentage area stained with Masson’s trichrome) was measured 
in tissue from IPF patients (n=12, mean 25.0% area, SD 10.5) than in tissue from 
subjects without lung disease (n=5, mean 12.1, SD 6.4; p=0.02) (Figure 2.9). 
 
Table 2.6 Characteristics of subjects used for lung tissue analysis 
 
 
Non-Diseased 
Control (n=5) 
Idiopathic pulmonary 
fibrosis (n=20)  
p value* 
 Mean SD Mean SD 
Age, yr 38 14 59 8 0.03 
FEV1, % predicted n/a n/a 77 21 n/a 
FVC, % predicted n/a n/a 74 20 n/a 
DLco, % predicted n/a n/a 42 20 n/a 
CPI, units n/a n/a 52 16 n/a 
TLC, % predicted n/a n/a 81 18 n/a 
    
 Number % Number % p value** 
Male 4 80 14 70 0.24 
*P value for unpaired t-test 
**P value for Fisher’s exact test 
Continuous data were compared by use of unpaired t-tests, and categorical data by 
Fisher’s exact tests 
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, DLCO 
diffusing capacity of carbon monoxide, CPI composite physiologic index, TLC total 
lung capacity, Yr year 
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Figure 2.9 Tissues from patients with IPF are more fibrotic compared to tissues 
from subjects without lung disease. 
Paraffin-embedded formalin fixed tissue sections from subjects without lung disease 
(n=5) and patients with IPF (n=12) were stained by Masson’s trichrome. Levels of 
total collagen were quantified by computer aided image analysis using ImageJ and 
reported as the percentage area of tissue components stained green. Twenty images 
from each tissue section were analysed and 2-6 tissue sections were measured for 
each subject.  Averaged staining levels of collagen between the groups were 
compared using unpaired t-test. (*p<0.05). Values are expressed as mean ± SD. 
IPF idiopathic pulmonary fibrosis, SD standard deviation 
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2.3.5 The level of fibulin-1 in paraffin embedded formalin fixed tissue was 
increased in patients with IPF compared to subjects without lung disease 
In patients with IPF, the level of tissue fibulin-1 detected in paraffin embedded 
formalin fixed tissue sections was significantly higher (n=20, mean 129.2 units, SD 
4.32) compared to non-diseased controls (n=5, mean 118.6, SD 3.73) (p<0.001). Age 
was not a confounding factor. There was no significant difference in the level of 
tissue fibulin-1 between samples taken from patients with IPF whether the tissue 
originated from a diagnostic surgical lung biopsy or from explanted lung post-
transplant (p=0.24)(Figure 2.10).  
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Figure 2.10 Tissue sections derived from patients with IPF have greater fibulin-1 
levels compared to sections derived from subjects without lung disease. 
 
Paraffin-embedded formalin fixed tissue sections were stained for fibulin-1 and 
counterstained for all other tissue components. Levels of fibulin-1 were quantified by 
computer aided image analysis using ImageJ and reported as the area positively 
stained for fibulin-1 as a percentage of the total area stained. Twenty images of each 
tissue section were analysed, 2-6 tissue sections were measured for each subject. 
Subsequently, measurements of each image were averaged together to obtain a single 
value per subject/patient.   
Levels of fibulin-1 compared using one-way analysis of variance and Tukey’s 
multiple comparison post-test (**p<0.005). 
Values are expressed as mean ± SD. 
IPF idiopathic pulmonary fibrosis, SD standard deviation 
Details on staining quantification can be found in 2.2.14 and seen in Figure 2.5 
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2.3.6 Tissue fibulin-1 levels correlate with disease severity in patients with IPF 
Higher tissue fibulin-1 levels correlated significantly with lower FEV1% and FVC% 
measurements (FEV%1 r=-0.86, p=0.014, FVC% r=-0.92, p=0.004) (Figure 2.11). 
Tissue fibulin-1 levels did not significantly correlate with age, DLCO%, CPI, or TLC% 
(Table 2.7).  All samples for correlation analysis were from Modena and the time 
between lung function test and biopsy was not more than 30 (±5) days. 
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Figure 2.11 . Lung tissue fibulin-1 levels in patients with IPF inversely correlate 
with lung function measurements.  
Paraffin-embedded formalin fixed tissue sections were stained for fibulin-1 and 
counterstained for all other tissue components. Levels of fibulin-1 were quantified by 
computer aided image analysis using ImageJ and reported as the area positively 
stained for fibulin-1 as a percentage of the total area stained. Twenty images of each 
tissue section were analysed and 2-6 tissue sections were measured for each subject. 
Subsequently, measurements of each image were averaged to obtain a single value per 
patient. Averaged tissue fibulin-1 levels for each patient (n=7) was compared to their 
(A) FEV1 and (B) FVC percentage predicted measurements. The linear regression line 
represents Pearson product-moment coefficients (FEV1 r=-0.86, p=0.014, FVC 
r=0.92, p=0.004). The time between biopsy and lung function measurements was 30 
days (±5). 
 
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, IPF idiopathic 
pulmonary fibrosis  
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Table 2.7 Tissue fibulin-1 correlates with percentage predicted FEV1 and FVC 
measurements in patients with idiopathic pulmonary fibrosis 
 
Variable 
Pearson 
Correlation 
Coefficient 
P-value 
FEV1, % predicted -0.855 0.014 
FVC, % predicted -0.916 0.004 
DLCO, % predicted -0.589 0.164 
TLC, % predicted -0.786 0.064 
CPI 0.665 0.103 
Age, yr -0.624 0.135 
Levels of fibulin-1 were quantified by computer aided image analysis using ImageJ 
and reported as the area positively stained for fibulin-1 as a percentage of the total 
area stained. Twenty images of each tissue section were analysed, 2-6 tissue sections 
were measured for each subject. Subsequently, measurements of each image were 
averaged to obtain a single value per patient. Two to six surgical lung biopsies and 
lung function parameters were obtained from each of 7 patients with idiopathic 
pulmonary fibrosis. The relationship between tissue fibulin-1 level and lung function 
variables were examined by Pearson correlation analysis. The time between biopsy 
and lung function measurements was 30 days (±5). 
 
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, DLCO 
diffusing capacity of carbon monoxide, CPI composite physiologic index, TLC total 
lung capacity, Yr year 
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2.3.7 Fibroblasts from IPF patients produce more fibulin-1 mRNA under basal 
conditions than fibroblasts from subjects without lung disease 
To investigate the role of the fibroblast in the production of fibulin-1, fibroblasts 
derived from the distal parenchyma of patients with and without IPF were compared. 
Initially, the levels of fibulin-1 at the transcription level were examined.  
Fibroblasts isolated from patients with IPF and from age and gender matched subjects 
without IPF were cultured under non-stimulatory conditions. Patient information from 
whom the fibroblasts were isolated are found in Table 2.8. 
Equal amounts of mRNA from each fibroblast line were converted into cDNA and 
levels of mRNA were quantified by QPCR.  The comparative (or ∆∆Ct) method was 
used to calculate the relative abundance of mRNA compared to the housekeeping 
gene 18S. Samples with a high amount of a particular mRNA transcript have a 
smaller delta Ct value because fewer cycles of PCR are required to amplify the target 
gene to a pre-determined threshold value. Fibroblasts from patients with IPF (n=5, 
mean 9.05 cycles, SD 0.70) produced more fibulin-1 mRNA under basal conditions 
compared to fibroblasts from subjects without IPF (n=4, mean 11.17, SD 0.40, 
p=0.03) (Figure 2.12). 
Therefore, for ease of reference, mRNA levels are displayed as 1/delta Ct.  
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Table 2.8 Patient information from whom fibroblasts were derived 
 
 
Parenchymal fibroblasts were isolated from lung tissue obtained from donors 
undergoing thoracotomy for either resection or transplantation. Non-IPF fibroblasts 
were derived from the macroscopically normal tissue isolated from the tumour-free 
margin of resections from patients with non-small cell carcinoma (NSCLC). 
Pulmonary function and smoking data were not available for these patients. 
IPF idiopathic pulmonary fibrosis, Yrs years 
 
Donor # Gender Age (Yrs) Diagnosis Surgery 
Non-IPF 1 Male 55 NSCLC Resection 
Non-IPF  2 Male 66 NSCLC Resection 
Non-IPF  3 Female 54 NSCLC Resection 
Non-IPF  4 Male 60 NSCLC Resection 
Non-IPF 5 Male 57 NSCLC Resection 
Non-IPF 6 Male 59 NSCLC Resection 
Non-IPF 7 Male 61 NSCLC Resection 
IPF 1 Male 53 Idiopathic pulmonary fibrosis Transplant 
IPF 2 Male 62 Idiopathic pulmonary fibrosis Transplant 
IPF 3 Male 57 Idiopathic pulmonary fibrosis Transplant 
IPF 4 Male 55 Idiopathic pulmonary fibrosis Transplant 
IPF 5 Male 58 Idiopathic pulmonary fibrosis Transplant 
IPF 6 Male 58 Idiopathic pulmonary fibrosis Transplant 
IPF 7 Male 54 Idiopathic pulmonary fibrosis Transplant 
IPF 8 Male 63 Idiopathic pulmonary fibrosis Transplant 
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Figure 2.12 Fibroblasts derived from patients with IPF produce more fibulin-1 
mRNA under basal conditions than fibroblasts from patients without IPF. 
 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender 
matched patients without IPF (n=7) were grown for 72 hours in 5% FBS/ DMEM/ 1% 
Pen-Strep, quiesced in 0.1% FBS/ DMEM/ 1% pen-strep for 24hours and maintained 
in fresh 0.1% FBS/ DMEM / 1% pen-strep for a further 72 hours. Non-IPF fibroblasts 
are derived from the macroscopically normal tissue isolated from the tumour-free 
margin of resections from patients with non-small cell carcinoma. 500ng of mRNA 
was converted to cDNA for this comparison. **p=0.003 unpaired t-test Values are 
expressed as median and interquartile range. 
Data are expressed as 1/delta cycle threshold to 18S (∆Ct) to enable a greater number 
to reflect more mRNA.  
IPF idiopathic pulmonary fibrosis, FBS foetal bovine serum, DMEM Dulbecco's 
Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
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2.3.8 Fibroblasts from IPF patients produce more fibulin-1 than fibroblasts 
from non-IPF fibroblasts 
The production of the two forms of fibulin-1 protein, secreted and cell-associated 
were examined. The secreted and cell-associated levels of fibulin-1 were compared 
between primary parenchymal fibroblasts from patients with IPF and with age and 
gender matched subjects without IPF under non-stimulated cell culture conditions and 
in fibroblasts at low passage number (≤ 5 passages). Cell-associated levels include 
intracellular, extracellular, and cell surface-bound proteins.  
Fibroblasts derived from patients with IPF produced significantly more secreted 
(measured by cell culture supernatant) fibulin-1 than fibroblasts derived from subjects 
without lung disease (p=0.003) (Figure 2.13A). In addition, fibroblasts from patients 
with IPF produced more cell-associated (measured by both intra- and extra-cellular 
protein)  fibulin-1 than fibroblasts derived from subjects without lung disease 
(p=0.007) (Figure 2.13B).   
The stability of the level of fibulin-1 between cell passages is not known and could be 
investigated in future studies. In these studies, cell cultures at less than 6 passages 
were used. 
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Figure 2.13 Parenchymal fibroblasts from patients with IPF produce more 
fibulin-1 than fibroblasts from patients without IPF. 
 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender 
matched patients without IPF (n=7) were grown for 72hours in 5% FBS/DMEM/1% 
pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep for 24hours and maintained in 
fresh 0.1% FBS/DMEM/1% pen-strep for a further 72hours. Supernatants and cell 
lysates were collected and analysed by western blot.  Densitometric values were 
normalised to total protein of the cell monolayer (supernatants, A) or GAPDH 
detected on the same blots (cell lysates, B).  Unpaired t-test **p<0.01. Values are 
expressed as median and interquartile range. 
Non-IPF fibroblasts are derived from the macroscopically normal tissue isolated from 
the tumour-free margin of resections from patients with non-small cell carcinoma.  
IPF idiopathic pulmonary fibrosis, GAPDH Glyceraldehyde 3-phosphate 
dehydrogenase, FBS foetal bovine serum, DMEM Dulbecco's Modified Eagle 
Medium, Pen-Strep penicillin-streptomycin 
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2.3.9 Serum levels of fibulin-1 between patients with IPF were similar across 
patient cohorts 
There were no significant differences in fibulin-1 levels between patients with IPF 
from the 3 cohorts used in this study. Patients with IPF from San Francisco had the 
poorest lung function of the groups (Table 2.9). 
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Table 2.9 Patient characteristics of the patients with IPF from 3 independent populations. 
 
 
Cohort 1 Cohort 2 Cohort 3 
  
Variable Sydney IPF (n=27) Modena IPF (n=28) 
San Francisco IPF 
(n=17) *ANOVA **Tukey's post-hoc (between group, p value) 
 
Mean SD Mean SD Mean SD p value 
Age, yr 67.7 7.7 65.9 10.1 71.6 9.7 0.225 n/a 
BMI, kg/m2 30.5 6.4 n/a n/a n/a n/a n/a n/a 
Baseline FEV1%, % predicted 82.7 20.5 80.6 22.0 72.3 14.0 0.248 n/a 
Baseline FVC%, % predicted 78.2 19.9 77.7 21.6 62.4 14.3 0.021 (1 vs 3, 0.03) (2 vs 3, 0.04) 
Baseline DLCO%, % predicted 41.0 16.2 42.3 18.0 38.9 15.6 0.838 n/a 
Baseline CPI, units 51.0 12.2 49.0 14.5 57.8 10.0 0.129 n/a 
Baseline TLC%, % predicted 66.8 11.2 75.6 12.1 62.0 13.0 0.039 (2 vs 3, 0.03) 
First blood draw serum fibulin-1, units 2.0 0.7 2.0 1.1 2.2 1.4 0.800 n/a 
    
 
Number % Number % Number % 
  
Male 21 77.80 10 35.70 10 83.30 0.00 (1 vs 2, 0.002) (2 vs 3, 0.008) 
History of smoking 17 63.00 17 60.70 11 70.60 0.21 n/a 
*One way analysis of variance (ANOVA) 
**Significant ANOVA comparisons were then analysed post-hoc for between group differences using Tukey’s 
IPF idiopathic pulmonary fibrosis, SD standard deviation, n/a not applicable, yr years, FEV1 forced expiratory volume in 1 second, FVC forced 
vital capacity, DLCO diffusing capacity of carbon monoxide, CPI composite physiologic index, TLC total lung capacity
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Patients with IPF, combined from the 3 independent populations, had significantly 
higher serum fibulin-1 levels than subjects without lung disease (Figure 2.14).  
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Figure 2.14 Patients with IPF had significantly higher levels of serum fibulin-1 
compared to subjects without lung disease. 
Serum fibulin-1 levels in patients with IPF, measured by western blot analysis of 
equal volumes of serum, were normalised against a standard serum sample loaded 
onto every gel.  Densitometric values were transformed to natural log values before 
analysis.  Data were adjusted for age, gender and smoking history. (ANCOVA, 
Sydney cohort n=27, black circle, San Francisco cohort n=17, black square, Modena 
cohort n=28, grey diamond, post-test Tukey’s ***p=0.006, median ± 25th & 75th 
percentiles).  
IPF idiopathic pulmonary fibrosis, ANCOVA analysis of covariance
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2.3.10 Serum fibulin-1 was increased in patients with IPF who progressed 
compared to those who remained stable 
The utility of serum fibulin-1 as a biomarker of disease progression in patients with 
IPF was then investigated. There were a total of 72 patients with IPF and of those 48 
had follow up information available. Patient characteristics of the patients with IPF 
used in the progression analysis are found in Table 2.10. 
Table 2.10 Characteristics of patients with IPF used in progression analysis 
 
  All IPF Stable Progressed p 
value
* 
  n=72 n=21 n=27 
  Mean SD Mean SD Mean SD 
Age, yr 68 9 65 11 70 9 ns 
FEV1, % predicted 79 20 79 19 76 20 ns 
FVC, % predicted 74 20 78 18 68 21 ns 
DLco, % predicted 41 16 48 18 33 14 0.012 
CPI, units 52 13 44 14 58 10 0.002 
TLC, % predicted 67 13 75 12 63 12 0.027 
Serum fibulin-1, 
units 
2.04 1.05 1.59 0.83 2.34 1.18 0.013 
              p 
value
** 
  Number % Number % Number % 
Male 41 57 10 48 15 56 ns 
History of smoking 45 63 14 74 19 70 ns 
*P value for Kruskal-Wallis test 
**P value for Pearson Chi-squared test 
 
Of the total of 72 patients with IPF, 48 had follow up information available. 
Continuous data of patients with IPF that either remained stable or progressed in the 
year following blood draw were compared by the Kruskal-Wallis test, and categorical 
data were compared with Pearson’s chi-squared test. 
IPF idiopathic pulmonary fibrosis, SD standard deviation, yr years, FEV1 forced 
expiratory volume in 1 second, FVC forced vital capacity, DLco diffusing capacity of 
carbon monoxide, CPI composite physiologic index, TLC total lung capacity, ns non 
significant 
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Patients with IPF who later experienced a progression event had a higher level of 
serum fibulin-1 at the time of blood draw compared to patients with IPF who 
remained stable (Table 2.10). As expected, and as supported by evidence in the 
literature, those who progressed also had a poorer DLCO%, CPI and TLC% than those 
that remained stable (Best et al. 2008).   
2.3.11 Serum fibulin-1 predicts disease progression in patients with IPF 
To investigate the ability of serum fibulin-1 levels to discriminate between patients 
who progressed and those who remained stable, receiver-operating characteristic 
(ROC) curves were constructed. 
The area under the ROC curve was 0.71 (95%CI 0.57-0.86, p=0.012) (Figure 2.15A). 
Kaplan-Meier curves showed that IPF patients with a serum fibulin-1 level > 1.6 units 
had a shorter progression-free survival time than those with ≤ 1.6 units (p=0.003) 
(Figure 2.15B) 
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Figure 2.15 Serum fibulin-1 level predicts disease progression patients with IPF. 
Patients with IPF were followed up for at least one year (365 ± 1 day) following blood 
draw. (A) Fibulin-1 levels in patients who progressed (n=27) were compared to the 
levels in patients who did not progress (n=21) and a receiver operating characteristic 
(ROC) curve was generated. (B) Kaplan-Meier survival curves showing time to 
progression event were generated. Patients who had a serum fibulin-1 of less than 1.6 
units (n=23, dashed line) were compared to patients who had a level of more than 1.6 
units (n=25, solid line). Circles on each line represent time censoring. Mantel-Cox log 
rank **p=0.003.  
AUC area under the curve, CI confidence interval, IPF idiopathic pulmonary fibrosis 
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From the ROC, thresholds of serum fibulin-1 were used to estimate the ability of 
serum fibulin-1 to predict disease progression. The sensitivities and specificities of the 
test are found in Table 2.9. 
Three threshold values differing in their respective sensitivities and specificities were 
chosen for further analysis. The three thresholds are ≤ 1.1 units, ≤1.6 units and ≤2.9 
units.  
At a threshold of 1.6 units, serum fibulin-1 identified patients with IPF who 
progressed with 70% sensitivity and 71% specificity. At thresholds of 1.1 and 2.9 
units, the sensitivities and specificities were 93% and 33%, and 30% and 90% 
respectively (Table 2.11).   
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Table 2.11 Validity of serum fibulin-1 thresholds in patients with IPF to predict 
disease progression 
 
Representative 
threshold value 
Sensitivity Specificity Used for 
further 
analysis 
0.697 100% 5%  
0.815 100% 14%  
1.085 93% 33% * 
1.309 89% 38%  
1.355 85% 48%  
1.417 74% 48%  
1.535 70% 62%  
1.592 70% 71% * 
1.810 52% 71%  
1.857 48% 76%  
2.076 41% 81%  
2.500 37% 86%  
2.888 30% 90% * 
3.088 26% 90%  
3.497 15% 90%  
Selected threshold values from the ROC curve (Area under the curve = 0.71, 95% 
confidence interval 0.57 – 0.86, p=0.012, n=48). Values with * were used for further 
analysis 
IPF, idiopathic pulmonary fibrosis
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2.3.12 Patients with IPF and a high level of serum fibulin-1 had a shorter 
progression-free survival time than those with a low level of serum 
fibulin-1 
Additional threshold levels were also analysed for their ability to predict disease 
progression in patients with IPF. At three thresholds of serum fibulin-1, those that had 
a higher level of serum fibulin-1 had a shorter progression-free survival time 
compared to those that had a lower level of serum fibulin-1 at the time of blood draw. 
The case processing summary for these comparisons is found in Table 2.12. 
The progression-free survival rates of patients with IPF with high or low serum 
fibulin-1 levels at the time of blood draw were also significantly different if 
thresholds of 1.1 units or 2.9 units were used to stratify the groups (1.1 units p=0.016, 
2.9 units p=0.019) (Table 2.12). 
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Table 2.12 Patients with IPF who presented with a high level of serum fibulin-1 
had a shorter progression free survival time compared to those who had a low 
level of serum fibulin-1 
 
   Average time to progression event (days) 
Threshold 1.1 
units 
Total N N of 
Progressed 
Estimate Std. 
Error 
95% CI p value 
Lower Upper 
Low fibulin-1 10 2 1772 360 1066 2478 0.016 
High fibulin-1 38 25 704 167 377 1031 
Threshold 1.6 
units 
Total N N of 
Progressed 
Estimate Std. 
Error 
95% CI p value 
Lower Upper 
Low fibulin-1 23 8 1509 241 1036 1982 0.003 
High fibulin-1 25 19 433 156 128 738 
Threshold 2.9 
units 
Total N N of 
Progressed 
Estimate Std. 
Error 
95% CI p value 
Lower Upper 
Low fibulin-1 39 20 1056 197 670 1441 0.019 
High fibulin-1 9 7 215 35 146 283 
The progression-free survival time of patients who presented with a high level of 
fibulin-1 (greater than the threshold of 1.1, 1.6 or 2.9) and low level of fibulin-1 (less 
than the threshold of 1.1, 1.6 or 2.9) were compared using the Mantel-Cox log rank 
test.  N= number, IPF= idiopathic pulmonary fibrosis, CI confidence interval 
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2.3.13 Measurement of serum fibulin-1 predicts progression in patients with IPF 
independent of other predictors.  
Due to the small number of patients with IPF available for follow up analysis, only a 
few traditional predictors of disease progression were included in the cox regression 
models. The predictors of disease progression in IPF included in the models were 
baseline age, history of smoking, FVC%, and DLCO%.  
An increase in one unit of serum fibulin-1 level in patients with IPF carried a 
significant hazard ratio for the likelihood of disease progression of 1.69 (95%CI 1.2 – 
2.3, p=0.001).   
Univariate logistic regression showed that age, history of smoking, or FVC% did not 
predict disease progression in our study population.  When the variables serum 
fibulin-1, age, history of smoking, FVC%, and DLCO% were analysed simultaneously 
in the multivariate model, the independent contribution of serum fibulin-1 increased 
to 2.11 (95%CI 1.3 – 3.5, p=0.004) (Table 2.13). DLCO% did not predict disease 
progression in the multivariate model. 
Finally, an IPF patient with a level of serum fibulin-1 > 1.6 units was 5 times more 
likely to progress compared to a patient with a level of serum fibulin-1 ≤ 1.6 units 
(HR 5.2, 95% CI 2.0 – 13.3, p=0.001). 
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Table 2.13  Measurement of serum fibulin-1 predicts progression in patients with 
IPF 
 
*Significant p value of <0.05 
FVC forced vital capacity, DLCO diffusing capacity of carbon monoxide, HR hazard 
ratio, CI confidence interval, Yr years 
 
 
 
Fibulin-1 was increased in all the tested materials from patients with IPF compared to 
subjects without lung disease or without IPF. Importantly, a potential source for the 
increased serum fibulin-1 was the mesenchymal fibroblast. Furthermore, levels of 
serum fibulin-1 were able to discriminate between IPF patients who later experienced 
a decline in lung function and those who did not.  
Fibulin-1 may play an important role in the pathogenesis of pulmonary fibrosis and 
may be useful to identify patients with IPF who are at a greater risk of disease 
progression. 
 
 
 
  Univariate Multivariate 
Variable HR 95% CI  P value HR 95% CI P value 
Serum fibulin-1, 
units 
1.691 1.225 2.335 0.001* 2.109 1.271 3.500 0.004* 
Age, yr 1.019 0.981 1.058 0.332 0.965 0.913 1.019 0.200 
History of smoking 0.939 0.411 2.149 0.882 0.879 0.291 2.649 0.818 
FVC, % predicted 0.989 0.970 1.009 0.280 0.990 0.965 1.015 0.428 
DLco, % predicted 0.971 0.942 1.000 0.050* 0.997 0.960 1.035 0.875 
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2.3.14 Summary of findings 
Fibulin-1 is increased in materials from patients with IPF compared to individuals 
without IPF (Table 2.14) 
 
Table 2.14 Fibulin-1 is increased in patients with IPF compared to subjects 
without IPF 
Sample material Without IPF* IPF 
Serum  ↑ 
Whole lung lysate  ↑ 
Parenchymal tissue  ↑ 
Primary fibroblasts 
• mRNA 
• Cell- secreted protein 
• Cell-associated 
protein 
 
 
 
 
↑ 
↑ 
 
↑ 
 = present/detected 
↑ = increased compared to without IPF 
 
*Primary fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from patients with non-small cell 
carcinoma. All other material was obtained from subjects without lung disease  
 mRNA messenger ribonucleic acid, IPF idiopathic pulmonary fibrosis 
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2.4 Discussion 
In this chapter, the importance of fibulin-1 as a biomarker in IPF was examined. This 
chapter contained four subsections. Firstly the presence of fibulin-1 in the serum of 
patients with various ILDs was characterised and the level was related to that patient’s 
lung function measurements. Secondly the presence of fibulin-1 in the tissue of 
patients with IPF specifically was identified and measured, and the levels were also 
related to the lung function measurements. Parenchymal fibroblasts from patients with 
IPF and age and gender matched patients without IPF were then examined as a 
potential source of fibulin-1. Finally, the prognostic utility of serum fibulin-1 in 
patients with IPF was explored. 
This is the first study linking the levels of fibulin-1 with the severity and disease 
progression of IPF, a relentlessly progressive disease with high mortality rates. 
Increased levels of fibulin-1 were found in the serum, lung tissue, and primary 
fibroblast cultures of patients with IPF  
and importantly, a high serum fibulin-1 level may serve as a biomarker for future 
disease progression.  Moreover, the findings were derived from four separate patient 
cohorts from three different countries, which is important, as IPF is a variable and 
global disease.  
Raised fibulin-1 levels in the serum and bronchoalveolar lavage fluid of patients with 
asthma have been previously observed by our research group (Lau et al. 2010), a 
disease in which fibrosis of the airways is associated with disease progression (Royce 
et al. 2012).  Across diseases in which fibrosis occurs there may be similar 
mechanisms contributing to fibrogenesis (Kisseleva and Brenner 2008).  Hence, it 
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was logical to explore whether fibulin-1 would also be important in a disease 
predominantly characterised by fibrosis, ie IPF.  This was the case, as serum, tissue 
and fibroblast-produced fibulin-1 were increased in patients with IPF compared to 
subjects without IPF. Interestingly, while the full length of fibulin-1 was considered to 
be 100kDa, as this is the size of fibulin-1 isolated from placenta and used as the 
positive control in the western blots, serum appears to contain at least four sizes of 
proteins that were detected with the fibulin-1 antibody used in these studies. Within 
the constraints of this study, it was not possible to sequence the remaining bands to 
investigate whether these additional bands represented smaller fragments of fibulin-1 
or other proteins.    
Alterations in fibulin-1 levels have been observed in a number of diseases.  Plasma 
levels of fibulin-1 were identified as a potential marker for kidney malfunction 
(Neiman et al. 2011), and increased levels of fibulin-1 were detected in sera from 
patients with preeclampsia (Liu et al. 2011). It is likely that the feature common to 
these diseases and the lung disease that was the focus of this study is active fibrosis.   
Serum fibulin-1 levels were elevated across patients with various ILDs and were not 
specifically increased in patients with IPF. The average level of serum fibulin-1 
increased as the likelihood of lung fibrosis increased within the ILDs. However, when 
age, gender and smoking history were taken into account, only patients with IPF have 
levels of serum fibulin-1 significantly greater than subjects without lung disease. 
Further investigation into the levels of fibulin-1 in other ILDs is warranted.   
Sarcoidosis is an ILD which rarely progresses to fibrosis while IPF is invariably 
fibrotic. This relationship between increasing levels of serum fibulin-1 and extent of 
fibrosis was supported by the inverse correlations between serum fibulin-1 and lung 
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function among patients with ILD, although serum fibulin-1 did not correlate with 
lung function among patients with IPF alone. However, this could be because the 
study population was recruited from tertiary referral centres and there were limited 
numbers of IPF patients with lung function at the higher end of the scale (>70 % 
predicted). 
In addition, in this study progression was defined as a decline in lung function. So if a 
patient had stable but poor lung function at presentation, then unless the patient died, 
the patient would not have been considered to have "progressed". Progression was a 
yes/no (discrete) event in this study. Correlation is a continuous relationship. Serum 
fibulin-1 doesn't perfectly identify which patients will progress (70% specificity at 1.6 
units cutoff). It may be possible to overcome the limit of random chance (p<0.05) 
with a greater study population.  
In correlation analysis, the strength of the relationship determines the minimum 
number of samples that are needed in order to correctly reject the null hypothesis 
(which is that there is no relationship between the two variables in question). The 
relationship between serum fibulin-1 at blood draw in patients with ILD and their 
corresponding DLCO% value was rho=-0.25 and the number of samples tested was 73 
in this study. If it is assumed that this sample relationship was true in only patients 
with IPF then more than 45 samples would be needed to test in order to be able to 
correctly reject the null hypothesis. Although our study consisted of 72 patients with 
IPF, only 36 of these patients had a lung function test within 15 (±5) days of blood 
draw and therefore could be included in the correlation analysis. Measurements of 
serum fibulin-1 and lung function would be needed from nine more patients with IPF 
in order to be able to correctly reject the null hypothesis. 
Page 120 of 252 
 
If fibulin-1 were to be biologically important during active fibrosis, then levels of 
fibulin-1in the serum could stem from  increased secretion of fibulin-1 by lung 
fibroblasts. The excess fibulin-1 may also be deposited into the ECM and therefore 
promote to disease progression by modulating cell behaviour such as increasing 
platelet adhesion (Godyna et al. 1995). Fibulin-1 is a provisional matrix protein 
(Williams and Schwarzbauer 2009) and as such is one of the first proteins to be 
deposited during the wound healing cascade (Midwood et al. 2004). While much of 
the focus in the literature has centred on the importance of collagen to fibrosis 
(Calabresi et al. 2007), it is possible that smaller ECM connecting proteins 
(Bensadoun et al. 1996), like fibulin-1 which binds to elastic fibres (Roark et al. 
1995), can also act to alter the mechanical properties of the lung (Le Saux et al. 2008). 
In this study, as the levels of tissue fibulin-1 increased, the lung function of the 
patients decreased.   
Fibulin-1 is a known modulator of the ECM during the progression of some diseases 
(Argraves et al. 2009) and therefore may be a protein to target during fibrogenesis. 
There is emerging evidence that the changes in ECM composition are relevant for 
understanding pulmonary fibrosis, as a “fibrotic” matrix induces myofibroblast 
differentiation (du Bois 2010). The “activated” fibroblast is central to the 
development of fibrogenesis (Liu et al. 2010) and our cellular studies on fibroblasts 
have reinforced the importance of fibulin-1 in IPF.  
The primary parenchymal fibroblasts derived from patients with IPF produced more 
secreted and cell-associated fibulin-1 than fibroblasts derived from patients without 
lung disease. This dysregulation was seen at the transcriptional level as fibroblasts 
from patients with IPF also produced more mRNA under basal conditions than 
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fibroblasts from subjects without lung disease. The contribution of particular ECM 
molecules to the development of fibrogenesis has not been extensively investigated in 
IPF, as research has largely focused on either chemokines or circulating progenitors 
of myofibroblasts as targets to dampen the “pro-fibrotic environment” that drives 
fibrosis (Naik et al. 2012).  Although it is possible that excessive production of 
secreted fibulin-1 by the resident fibroblasts of IPF patients contributes to the 
increased fibulin-1 level found in the blood, a second hypothesis could be that damage 
to alveolar epithelial cells also causes increased fibulin-1 secretion.  
As shown in the ROC curve analysis, serum fibulin-1 has predictive value for acute 
disease progression in patients with IPF which is an important finding for the future 
management of IPF. The AUC analysis showed that there was a 71% chance that 
there was a higher serum fibulin-1 level in a patient with IPF who experienced a 
progression event within 1 year compared to a patient who remained stable. In 
addition, patients with a high level of serum fibulin-1 had a higher likelihood of 
progression and a shorter progression-free survival time compared to their low 
fibulin-1 counterparts.  
A number of serum biomarkers of disease severity and progression in IPF have been 
identified and reviewed (Richards et al. 2012; Vij and Noth 2012).  These include 
mucin-1 (KL-6), surfactant proteins SP-A and SP-D, matrix metalloproteinases 1 and 
7, chemokines CCL18 and CXCL8, calgranulin B (S100A12), intracellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1) as well as 
periostin (Naik et al. 2012). Other biomarkers include the gene polymorphism,  mucin 
5B (MUC5B)(Seibold et al. 2011).   
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This shows that it is likely that numerous factors contribute to fibrogenesis. The value 
of our focus on fibulin-1 lies in the fact that we have been able to study it in multiple 
patient cohorts and multiple forms - soluble and tissue incorporated - and have been 
able to relate these to physiological measurements of lung function. In addition, while 
all lung fibroblasts are capable of producing fibulin-1, an increased production of 
fibulin-1 likely reflects the activated fibrogenic state of fibroblasts derived from 
patients with IPF.    
It is crucial to identify factors which are able to categorise which IPF patients will 
rapidly decline compared to those patients with a more stable form of the disease. 
Further follow up studies to confirm the potential of fibulin-1 levels for the 
stratification of patients with IPF are urgently needed. This information will enable 
clinicians to optimise early referral to transplantation programs and palliative care. 
Additionally, fibulin-1 may be a useful tool to stratify patients for inclusion in future 
therapeutic trials, and to guide future management decisions. 
In the future, it would be worthwhile to measure fibulin-1 levels in fibroblasts and 
tissues isolated from patients with the other ILDs, in particular sarcoidosis, due to its 
rare fibrotic component. Differences in levels of certain biomarkers between ILDs 
would help in identify which proteins are surrogate markers of fibrogenesis, not just 
interstitial lung disease.  
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Chapter 3. Other matrix proteins and fibulin-1 
3.1 Introduction 
It is the extracellular matrix (ECM) that allows tissue to withstand tensile forces and 
collagen is the main source of this strength (Canty and Kadler 2005). Fibroblasts are 
the main source of ECM in the lung (Hutchison et al. 2013) and changes in the ECM 
can influence the behaviours of the cells that populate it (Klingberg et al. 2013). The 
role of fibroblasts in pulmonary fibrosis will be investigated in greater detail in 
Chapter 4. Fibroblasts routinely deposit collagen and other ECM molecules during 
normal tissue homeostasis but this process becomes uncontrolled during pathological 
wound healing such as fibrosis (Phan 2002).  
The process of collagen and elastin fibril formation from their insoluble components 
is a complicated process that is outside the scope of this thesis however, the general 
overview is that the matrix is a collagen scaffold from which a network of interlacing 
proteins is formed (Bosman and Stamenkovic 2003).  
Collagen is the most abundant protein in the ECM, accounting for about 40% of the 
total protein mass of the ECM, and densely fibrotic tissue display increased type I 
(Raghow et al. 1985) and type IV collagens (Specks et al. 1995). Collagen has long 
been the hallmark protein of pulmonary fibrosis (Reiser and Last 1983). Collagen IV 
was first reported to be increased in the serum of patients with idiopathic pulmonary 
fibrosis (IPF) in 1996 (Kasuga et al. 1996). It was shown that measurement of serum 
concentrations would be reflective of fibrotic changes occurring in the lung.  
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Because the ECM is a complicated and diverse structure, it is likely that there are 
numerous ECM proteins that are dysregulated in the context of pulmonary fibrosis. In 
support of this, there are many differences in the composition of decellularized ECM 
from normal and fibrotic lungs that have recently been described (Booth et al. 2012). 
The bioactive nature of the ECM, the majority of which is deposited by pathogenic 
fibroblasts,  is increasingly being recognized as a key factor of the fibrogenic process 
(Klingberg et al. 2013).  
Because of this, three other ECM proteins related to fibulin-1 that are also produced 
by lung fibroblasts were selected for investigation in this study (Figure 3.1). 
Fibronectin,  periostin, and tenascin-C are members of the matricellular class of 
proteins so named because of their ability to modulate cell-matrix interactions (Frantz 
et al. 2010). Like other matricellular proteins including fibulin-1, these proteins are 
typically expressed at high levels during periods of development, but only appear in 
adult tissue during repair or disease (Strieter 2008; Kaarteenaho et al. 2010; Midwood 
et al. 2011).    
Collagen IV interacts directly with fibulin-1 during development (Kubota et al. 2012) 
and with plasma fibronectin during infection (Hauk et al. 2008). Collagen I interacts 
directly with periostin during collagen I fibre formation (Kii et al. 2010), and collagen 
I increases tenascin C expression in smooth muscle cells (Jones et al. 1999). 
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Figure 3.1 Extracellular matrix molecules produced by lung fibroblasts that 
were investigated in this thesis 
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Fibronectin was the first discovered binding partner of fibulin-1 (Argraves et al. 1989) 
and is essential in normal tissue maintenance (Tran et al. 1995). It is a large 220-250 
kDa molecule that plays a key role in cell migration and adhesion in addition to being 
the initial scaffold for the ECM. Fibronectin provides the initial “wound plug” during 
haemostasis, the first stage of wound healing. In association with fibrin, the 
fibronectin/fibrin clot seals the wound before collagen is deposited by contractile 
mesenchymal cells (Stenman et al. 1980).   
Fibulin-1, which also binds fibrinogen (Tran et al. 1995), is found alongside 
fibronectin and can inhibit the effect of fibronectin on cell attachment and spreading 
(Twal et al. 2001). Fibronectin increases cell attachment and spreading through 
activation of its integrins, which are the main class of matrix receptors that allow 
cross-talk between cells and the matrix (Bosman and Stamenkovic 2003). Binding 
sites on fibronectin for other ECM proteins, such as periostin (Kudo 2011) and 
tenascin-C (Kudo 2011), further demonstrate how complex the relationship between 
ECM proteins is.   
Periostin is a secreted, 90kDa, cell adhesion protein that plays an important role 
during connective tissue development (Hamilton 2008). Fibroblasts produce 
significant amounts of periostin (Hamilton 2008), as well as fibulin-1, and 
immunohistochemical staining shows increased deposition of periostin in fibrotic 
tissue (Naik et al. 2012). Periostin has been implicated in the sub-epithelial fibrosis of 
asthma (Takayama et al. 2006) and serum levels of periostin have been shown to 
predict disease progression in patients with IPF (Naik et al. 2012). 
The binding sites for fibronectin, tenascin-C and collagen I are located adjacent to 
each other on periostin (Norris et al. 2007). This allows periostin to acts as a structural 
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bridge between the larger fibres and to support the deposition of tenascin-C into the 
matrix (Kii et al. 2010).  
Tenascin-C is member of the tenascin family, which are known to be overexpressed in 
diseases like asthma and certain cancers (Kaarteenaho-Wiik et al. 2000), although 
tenascin-C is the only member of the family which forms hexamers. Interestingly, like 
fibulin-1 and fibronectin before it, tenascin-C is associated with fibrin expression in 
tissue (Brellier et al. 2011) and it is thought that its hexameric structure allows it to 
support the larger fibres in the ECM (Kii et al. 2010).  
In a role that can be thought of as opposing the actions of fibronectin, tenascin-C is an 
anti-adhesive molecule (Midwood et al. 2011) which also increases the expression 
and activity of matrix metalloproteinases (Imanaka-Yoshida 2012). One mechanism 
driving these processes is shared with fibulin-1. Both tenascin-C and fibulin-1 bind to 
the HepII domain on fibronectin (Balbona et al. 1992; Williams and Schwarzbauer 
2009) and block syndecan-4 (cell surface receptor also implicated in pulmonary 
fibrosis (Jiang et al. 2010) binding.  
Serum tenascin-C (Inoue et al. 2013), serum periostin (Yamaguchi et al. 2013) and 
serum fibronectin (Lafuma et al. 1987) have been reported to be increased in fibrotic 
lung conditions, thus supporting the hypothesis that serum ECM molecules can be 
used as biomarkers of disease progression in pulmonary fibrosis. Although there have 
been several blood-based biomarkers of disease progression in patients with 
pulmonary fibrosis reported (Richards et al. 2012) the utility of the aforementioned 
ECM molecules as biomarkers, as well as their inter-relationships (Table 3.1),  has not 
been fully explored.  
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Table 3.1 ECM proteins interact with each other as well as with collagen 
 
 Fibronectin Periostin Tenascin-C Collagen 
Fibulin-1 Fibulin-1 binds 
to fibronectin 
(Argraves et al. 
1989) 
Fibulin-1 and 
periostin are 
both increased 
in Hodgkin’s 
lymphoma 
(Kischel et al. 
2011)  
Fibulin-1 shares 
adhesion 
mechanism with 
tenascin-C 
(Williams and 
Schwarzbauer 
2009) 
Fibulin-1 
interacts directly 
with Col IV 
(Kobayashi et 
al. 2007) 
Fibronectin  Periostin binds 
to fibronectin 
(Takayama et al. 
2006) 
Tenascin-C 
binds to 
fibronectin 
(Midwood et al. 
2011) 
Collagen 
interacts via 
membrane 
protein with 
fibronectin 
(Stenman et al. 
1980) 
Periostin   Tenascin-C 
structurally 
supported by 
periostin (Kii et 
al. 2010) 
Collagen I fibre 
formation 
regulated by 
periostin 
(Hamilton 2008) 
Tenascin-C    Collagen I 
induces  
tenascin-C 
(Jones et al. 
1999) 
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The physical properties of connective tissues are determined by the amount, type and 
composition of the ECM (Culav et al. 1999). Importantly, it has been shown that the 
interconnecting ECM proteins such as periostin can act on the biomechanical 
properties of the tissue they populate (Norris et al. 2007). It is known that the 
mechanical properties of the lung, similar to any organ, are dependent on the physical 
formation of the collagen and elastic fibres and that these differences may be due to 
differences in ECM composition (Antunes et al. 2009). 
As shown in Chapter 2, increased levels of fibulin-1 were an accurate indication of 
disease progression of patients with IPF. It is the aim of this chapter to establish the 
strength and specificity of that relationship by comparing the performance of fibulin-1 
as a biomarker in IPF against the performance of three other ECM proteins known to 
be implicated in pulmonary fibrogenesis.  
This chapter aimed to establish if the relationship between fibulin-1 and pulmonary 
fibrosis was unique, or if similar pathological associations (such as the ability to 
predict disease progression in patients with IPF) could be seen in other ECM proteins 
also thought to be involved in fibrogenesis. In addition, a group of patients with 
chronic obstructive pulmonary disease (COPD) was included to investigate if ECM 
dysregulation was a function of any diffuse parenchymal disease.  
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3.2 Methods 
3.2.1 Patient data  
The patients with and without IPF from whom the fibroblasts were derived were 
previously described in Chapter 2 (Table 2.8). The patients with COPD from whom 
the fibroblasts were derived are described in Table 3.10. 
3.2.2 Fibroblast isolation, cell culture and sample collection 
Primary parenchymal fibroblasts were cultured and set up for experiment as 
previously described in Chapter 2 (Methods 2.2.5, 2.2.6, 2.2.7). 
3.2.3 RNA isolation and QPCR 
Primers from Invitrogen were obtained for periostin (Hs01566734_m1), tenascin-C 
(Hs01115665_m1), and fibronectin (Hs00365052_m1). RNA isolation and QPCR 
were performed as described in Chapter 2 (Methods 2.2.8). 
3.2.4 Sandwich ELISA 
Cell-secreted periostin, tenascin-C and fibronectin were measured by enzyme-linked 
immunosorbent assay (ELISA) antibody sets (for periostin and tenascin-C) or 
complete kits (for fibronectin). The specifics of each assay are summarised in Table 
3.2. For fibronectin, all reagents were provided as part of the kit (Life Science cat# 
L00170025). 
The ELISA assay was similar for each of the ECM proteins. For periostin and 
tenascin-C, polystyrene 96-well Corning COSTAR flat-bottom plates (Fisher 
Scientific, Sydney) were coated with 100µL/well of the primary antibody of interest 
Page 131 of 252 
 
diluted in phosphate buffered saline (PBS pH7.2, 137mM NaCl, 2.7mM KCl, 100mM 
Na2HPO4, 2mM KH2PO4) as summarised in Table 3.2. The plates were sealed with 
Parrafilm (Holgate Scientific, NSW) and incubated overnight at 4°C. The primary 
antibody was then decanted on clean paper towels and each well was washed three 
times with wash buffer (0.05%v/v Tween-20 in PBS). After washing, 300µL of 
1%BSA/PBS (blocking solution) was added to each well and the plates were sealed 
and incubated for one hour at room temperature on a shaker. For fibronectin, the 
plates provided as part of the kit were pre-coated with the primary antibody and 
samples were assayed immediately.  
Plates coated with anti-periostin and anti-tenascin-C antibodies were decanted and 
washed three times as before and 100µL of cell-free supernatant (containing only 
secreted extracellular proteins) was added to each well in duplicate. Standards for all 
three ECM proteins were diluted in a serial two-fold manner with the top standard 
concentrations for each assay listed in Table 3.2. Wells with standards also contained 
100µL. The final standard concentration was the respective antibody diluents without 
any standard protein present. In all plates, a sample of cell-free culture media was also 
added as a baseline control for the endogenous level of ECM protein.  
After incubation for two hours at room temperature on a shaker (periostin, tenascin-C) 
or 90 minutes at 37°C (fibronectin), the plates were again decanted and washed as 
before and 100µL/well of the secondary antibody was added and plates were 
incubated at room temperature as described in Table 3.2. Plates were again decanted 
and washed as before and incubated with 100µL/well streptavidin-horseradish 
peroxidase (HRP) diluted in 1% BSA/PBS and incubated as described in Table 3.2.  
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Lastly, plates were decanted and washed and 50µL of the substrate solution 3,3’,5,5’-
Tetramethylbenzidine (TMB) (Zymed, CA, USA) was added to each well. Plates were 
incubated in the dark for 5-15 minutes (dependent on colour development) and the 
reaction was stopped with the addition of 50µL/well of stop solution (0.1M H3PO4) 
per well. Plates assayed for fibronectin used TMB and stop solution provided as part 
of the kit. The optical density (OD) was read at 450nm using a microplate reader and 
the amount of each ECM protein was determined from the OD of the corresponding 
standard curves.  
Table 3.2 Concentrations of the materials used in secreted ECM measurements 
 Periostin kit 
(R&D cat#DY2955) 
Tenascin-C  
(R&D cat# 
MAB3358, BAF3358) 
Fibronectin kit  
(Life Science cat# 
L00170025) 
Primary antibody 4µg/mL in PBS 1µg/mL in PBS Pre-coated plates 
Blocking media 1%BSA/PBS 1%BSA/PBS Not applicable 
Standard 6000pg/mL  
0pg/mL 
30ng/mL  0ng/mL 
(R&D cat#3358-TC) 
100ng/mL  0ng/mL 
Samples Diluted as necessary 
in PBS 
Diluted as necessary 
in PBS 
Diluted as necessary 
in PBS 
Secondary antibody 0.4µg/mL in PBS 0.5µg/mL in PBS Kit reagents 
Detection antibody 1:200 (R&D 
cat#DY998) 
1:200 (R&D 
cat#DY998) 
Kit reagents 
Substrate TMB (Zymed cat#00-
2023) 
TMB (Zymed cat#00-
2023) 
Kit reagents 
Stop solution 1M H3PO4 1M H3PO4 Kit reagents 
Lower limit of 
detection 
93.8pg/mL 0.47ng/mL 0.72ng/mL 
 
3.2.5 Immunohistochemistry, image capture and analysis  
Immunohistochemistry was performed in the same fashion as for fibulin-1 and 
described in Chapter 2 (Methods 2.2.12). Like fibulin-1, sections that were 
investigated for the levels of periostin and fibronectin did not require antigen 
retrieval. Antibodies directed against both periostin and fibronectin were produced 
from rabbit and therefore used the same isotype control (Table 3.3).  
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In addition, because the same DAB system was used for visualisation (2.2.12) the 
same image capture and deconvolution techniques were employed for both periostin 
and fibronectin quantification (2.2.13, 2.2.14).  
Table 3.3. Concentrations of the primary antibodies used for immunohistochemistry 
 Source Final concentration 
Periostin antibody ABCAM (cat# 
ab14041) 
0.5µg/mL 
Fibronectin antibody Sigma (cat# F3648) 0.5µg/mL 
Rabbit IgG isotype 
control 
Dako  0.5µg/mL 
 
3.2.6 Statistical Analysis 
Graphs were made using GraphPad Prism 6 Software for Windows (Version 6 
GraphPad Software Inc. 1992-2007). Statistical analysis was done using SPSS 
(Version 21 IBM Corporation 1989-2012). 
Distributions of serum, parenchyma and fibroblast levels of periostin, tenascin-C and 
fibronectin, and lung function parameters were carried out in the same fashion as 
described in Chapter 2 (Methods 2.2.15). 
It was not necessary to determine the repeatability and reliability of the periostin, 
tenascin-C or fibronectin measurements as these investigations were carried out by 
sandwich ELISA and a standard curve was used in every experiment for 
quantification.   
Between-group differences, receiver-operating characteristic (ROC) curves, and 
correlations between serum and tissue ECM proteins and lung function parameters 
were performed as described in Chapter 2 (Methods 2.2.15). 
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Because the same patients were investigated for the levels of fibulin-1 and collagen 
(Chapter 2), as well as for periostin, tenascin-C and fibronectin (Chapter 3), 
correlation analysis investigating the relationship between ECM proteins was 
possible. Correlations between fibulin-1, periostin, tenascin-C and fibronectin in the 
serum of patients with interstitial lung disease (ILD) were performed with Spearman’s 
rank correlation co-efficients. 
Serial sections were used to investigate the levels of fibulin-1, collagen, periostin and 
fibronectin in patients with IPF. This allowed for additional correlation analysis 
between the ECM proteins in parenchyma tissue to be performed.  
Statistical analysis was performed as described in Chapter 2 (Methods 2.2.15). 
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3.3 Results 
3.3.1 Serum periostin is increased in patients with IPF 
Serum periostin was increased in patients with IPF compared to subjects without lung 
disease and patients with other ILDs after adjustments for potential confounding 
variables – age, gender and smoking history. Unlike serum fibulin-1, serum periostin 
was not increased in patients with IPF compared to patients with sarcoidosis (Figure 
3.2).  
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Figure 3.2 Serum periostin is increased in patients with IPF compared to 
subjects without lung disease. 
Serum periostin levels were measured by ELISA. Values were adjusted for age, 
gender and smoking history. (ANCOVA, n=168, post-test Tukey’s *p<0.05. 
***p=0.006, median ± 25th & 75th percentiles). 
”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-
specific interstitial pneumonia (n=4), lymphangioleiomyomatosis (n=4), and drug-
induced ILD (n=1). 
HP hypersensitivity pneumonitis, ILD interstitial lung disease, IPF idiopathic 
pulmonary fibrosis, ANCOVA analysis of covariance 
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3.3.2 Serum tenascin-C is decreased in patients with IPF compared to patients 
with HP 
Interestingly, the level of tenascin-C was decreased in the patients with IPF compared 
to patients with HP (Figure 3.3).   
 
Non-Diseased ControlSarcoidosis HP Other ILD IPF
0
100
200
300
(n=17) (n=12) (n=32) (n=35) (n=72)
**
 
Figure 3.3 Serum tenascin-C is decreased in patients with IPF compared to 
patients with HP 
Serum tenascin-C levels were measured by ELISA. Values were adjusted for age, 
gender and smoking history. (ANCOVA, n=168, post-test Tukey’s **p<0.01, median 
± 25th & 75th percentiles). 
”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-
specific interstitial pneumonia (n=4), lymphangioleiomyomatosis (n=4), and drug-
induced ILD (n=1). 
HP hypersensitivity pneumonitis, ILD interstitial lung disease, IPF idiopathic 
pulmonary fibrosis, ANCOVA analysis of covariance 
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3.3.3 Serum fibronectin is not increased in patients with ILD 
There was no difference in serum fibronectin level between the 5 groups (Figure 3.4). 
Non-Diseased ControlSarcoidosis HP Other ILD IPF
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0
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Figure 3.4 Serum fibronectin is not increased in patients with ILD 
Serum fibronectin levels (ELISA) were adjusted for age, gender and smoking history. 
(ANCOVA, n=168, median ± 25th & 75th percentiles). 
”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-
specific interstitial pneumonia (n=4), lymphangioleiomyomatosis (n=4), and drug-
induced ILD (n=1). 
HP hypersensitivity pneumonitis, ILD interstitial lung disease, IPF idiopathic 
pulmonary fibrosis, ANCOVA analysis of covariance 
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3.3.4 Serum periostin and tenascin-C correlate with lung function in patients 
with ILD 
Next the relationship between the serum level of the three ECM proteins and lung 
function in patients with ILD was examined. Serum draw and lung function 
measurements were taken no more than 15 (±5) days apart.  
Both fibulin-1 (Table 2.5) and periostin correlated significantly with poorer percent 
predicted FVC (FVC%), percent predicted DLCO (DLCO%), composite physiologic 
index (CPI) and percent predicted TLC (TLC%)  measurements(Table 3.4) in patients 
with ILD. Tenascin-C only correlated with FVC% while fibronectin did not correlate 
with any measurement (Table 3.4).  
None of the four ECM proteins examined correlated with age, gender or smoking 
history.  
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Table 3.4 Serum ECM proteins correlate with lung function in patients with ILD 
 
  Periostin Tenascin-C Fibronectin 
FEV1, % predicted -0.091 -0.236 0.039 
FVC, % predicted -0.265* -0.287* -0.006 
DLco, % predicted -0.308* -0.178 0.189 
CPI, units 0.377** 0.213 -0.091 
TLC, % predicted -0.312* -0.225 -0.083 
Age, yr 0.131 0.172 0.132 
Gender 0.031 0.043 0.103 
Smoking History 0.124 -0.104 0.140 
Lung function parameters and demographic information was obtained for 73 patients 
with interstitial lung disease (ILD). The time between serum collection and lung 
function measurements was no more than 15 days (±5). Serum periostin, tenascin-C 
and fibronectin levels were measured by ELISA. Continuous variables were analysed 
with spearman’s rank correlation analysis and categorical variables were analysed by 
Pearson chi-square test.  
*p<0.05 ,**p<0.01  
 
3.3.5 Serum ECM proteins correlate with each other in patients with IPF 
Serum fibulin-1 and periostin both correlated strongly with tenascin-C in patients 
with IPF (Table 3.5). In correlation analysis, a coefficient of more than 0.3 is 
considered a “large” effect and is therefore more likely to be biologically meaningful 
(Hayek and Heyer 2005).
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Table 3.5 The correlation between the four serum ECM proteins is disease group 
specific 
 
Serum fibulin-1 was measured by western blot and quantified using densitometric 
analysis. Serum periostin, tenascin-C and fibronectin levels were measured by 
ELISA.  
Spearman’s rank correlation analysis (*p<0.05, **p<0.01) 
”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-
specific interstitial pneumonia (n=4), lymphangioleiomyomatosis (n=4), and drug-
induced ILD (n=1). 
ECM extracellular matrix, HP hypersensitivity pneumonitis, ILD interstitial lung 
disease, IPF idiopathic pulmonary fibrosis 
 
 
 
Sarcoidosis 
(n=12) Fibulin-1 Periostin Tenascin-C Fibronectin 
Fibulin-1  .126 -.119 .000 
Periostin .126  .329 -.679 
Tenascin-C -.119 .329  -.536 
Fibronectin 0.000 -.679 -.536  
 
HP 
(n=32) Fibulin-1 Periostin  Tenascin-C Fibronectin 
Fibulin-1  .188 .285 .020 
Periostin .188  .017 -.468* 
Tenascin-C .285 .017  .355 
Fibronectin .020 -.468* .355  
“Other “ 
ILD (n=35) 
 Fibulin-1 Periostin Tenascin-C Fibronectin 
Fibulin-1  .078 .163 -.001 
Periostin .078  .341 .312 
Tenascin-C .163 .341  .019 
Fibronectin -.001 .312 .019  
IPF 
(n=72) Fibulin-1 Periostin Tenascin-C Fibronectin 
Fibulin-1  .212 .416** .126 
Periostin .212  .406** -.189 
Tenascin-C .416** .406**  -.232 
Fibronectin .126 -.189 -.232  
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3.3.6  No difference in serum periostin, tenascin-C or fibronectin between 
patients with IPF who progressed and those patients who remained stable 
There was no difference in serum ECM level between those patients with IPF who 
experienced significant lung function decline  (≥ 10% fall in FVC%, ≥ 15% fall in 
DLCO%, or death)  during the year following blood draw and those patients who 
remained stable in the same time period (Table 3.6). 
Table 3.6 Serum periostin, tenascin-C or fibronectin levels in patients with IPF 
who progressed or who remain stable  
 
 Stable (n=21) Progressed (n=27) 
 
(ng/mL) Mean SD Mean SD P Value 
Periostin 54.26 39.03 48.46 27.39 .549 
Tenascin-C 46.20 18.05 60.66 43.95 .173 
Fibronectin 14916.43 18669.12 23920.83 46436.72 .481 
Patients with IPF were followed up for at least one year (365 ± 1 day) following blood 
draw. 
Serum periostin, tenascin-C and fibronectin levels were measured by ELISA.  
Between group differences were assessed by unpaired t-tests. All p values were > 0.05 
and therefore not considered significant. 
IPF idiopathic pulmonary fibrosis, SD standard deviation 
 
 
 
3.3.7 Periostin, tenascin-C, fibronectin do not predict disease progression in 
patients with IPF 
In order to investigate the utility of each ECM protein as a biomarker of disease 
progression, ROC curves were constructed (Figure 3.5).  
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Figure 3.5 ROC analysis shows that neither periostin, tenascin-C or fibronectin 
are able to discriminate disease progression in patients with IPF. 
The utility of periostin (A), tenascin-C (B) and fibronectin (C) as biomarkers of 
disease progression were modelled using receiver-operating characteristic curve 
analysis in patients with idiopathic pulmonary fibrosis (IPF) (n=48).
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The area under the curve for each of the three potential biomarkers is shown in Table 
3.7. Serum periostin, tenascin-C and fibronectin levels were unable to accurately 
identify patients with IPF who progressed. 
 
Table 3.7 ROC curve analysis of periostin, tenascin-C and fibronectin  
ROC Analysis Area under the curve 
95% Confidence 
Interval P value 
Periostin .487 .319  to .655 .876 
Tenascin-C .613 .450  to .776 .189 
Fibronectin .591 .389  to .794 .347 
Patients with IPF were followed up for at least one year (365 ± 1 day) following blood 
draw. Serum periostin, tenascin-C and fibronectin levels were measured by ELISA. 
Serum levels in patients who progressed (n=27) were compared to the levels in 
patients who did not progress (n=21). A receiver operating characteristic (ROC) curve 
was generated and the area under the curve was calculated. 
 
 
3.3.8 Tissue periostin and fibronectin levels in patients with IPF 
Periostin and fibronectin have been reported to be increased in lung tissue of patients 
with IPF. As shown in Chapter 2, tissues from patients with IPF showed increased 
levels of fibrosis as measured by total collagen deposition (Figure 2.9). In addition to 
having higher levels of fibulin-1 (Figure 2.10), tissue from patients with IPF also had 
increased levels of periostin compared to tissue from subjects without lung disease 
(Figure 3.6A).  Levels of fibronectin were not different between tissue from patients 
with IPF and subjects without lung disease (Figure 3.6B).  
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Figure 3.6 Levels of tissue periostin and fibronectin in patients with IPF and 
subjects without lung disease 
Levels of (A) tissue periostin and (B) tissue fibronectin were measured by 
immunohistochemistry. Paraffin-embedded formalin fixed tissue sections from 5 
subjects without lung disease and 17 patients with IPF were stained for the proteins 
individually and each was counterstained for all other tissue components.  
Levels of each protein were quantified separately by computer aided image analysis 
using ImageJ and reported as the area positively stained for each protein as a 
percentage of the total area stained. Twenty images of each tissue section were 
analysed, 2-6 tissue sections were measured for each subject. Subsequently, 
measurements of each image were averaged together to obtain a single value per 
patient.  
Between group differences were compared using the unpaired t-test (****p<0.0001, 
**p<0.01). 
IPF = idiopathic pulmonary fibrosis  
 
 
 
Representative images of tissue from a subject without lung disease (A-D) and from a 
patient with IPF (E-H) are found in Figure 3.7. 
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Figure 3.7 Immunohistochemical stains of total collagen, fibulin-1, periostin, and 
fibronectin. 
Representative paraffin-embedded formalin fixed parenchymal tissue sections from a 
subject without lung disease or a patient with IPF were stained for total collagen 
(green, with cell cytoplasm in red), fibulin-1 periostin or fibronectin (brown). Cell 
nuclei are blue in fibulin-1, periostin and fibronectin stains.  
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3.3.9 Tissue levels of total collagen, periostin, or fibronectin do not correlate 
with lung function in patients with IPF 
The relationship between the level of tissue ECM proteins and lung function in 
patients with IPF who had undergone a diagnostic biopsy within 30 (±5) days of a 
lung function test was then investigated. Unlike tissue fibulin-1, tissue periostin did 
not correlate with either FEV%1 or FVC% (Figure 3.8). In addition, the relationship 
between the ECM proteins and other lung function variables was also examined in 
Table 3.8. Age did not correlate with any ECM protein level. 
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Figure 3.8 Tissue periostin does not correlate with percentage predicted FEV1 or 
FVC in patients with IPF 
 
Paraffin-embedded formalin fixed tissue sections were stained for periostin and 
counterstained for all other tissue components. Levels of periostin were quantified by 
computer aided image analysis using ImageJ and reported as the area positively 
stained for periostin as a percentage of the total area stained. Twenty images from 
each tissue section were analysed and 2-6 tissue sections were measured for each 
subject.  Averaged tissue level of periostin for each patient (n=5) was compared to 
their (A) FEV1 and (B) FVC percentage predicted measurements using Pearson 
product-moment coefficients.  
Time between biopsy and lung function measurements were within 30 days (±5). 
 
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, IPF idiopathic 
pulmonary fibrosis  
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Table 3.8 Tissue ECM protein levels do not correlate with lung function 
measurements or age in patients with IPF 
 FEV1% FVC% DLco% CPI TLC% Age, Yrs 
Total 
Collagen -.169 -.178 -.215 .226 .208 .003 
Periostin -.253 -.249 -.225 .245 -.034 .045 
Fibronectin -.564 -.491 -.518 .522 -.447 -.067 
Two to six surgical lung biopsies and lung function parameters were obtained from 
each patient with idiopathic pulmonary fibrosis (n=5-7). Tissue ECM protein level 
was measured by immunohistochemistry. Twenty images of each tissue section were 
analysed and 2-6 tissue sections were measured for each subject. The relationship 
between tissue ECM level and lung function variables were examined by Pearson 
correlation analysis and P>0.05 all cases. The time between biopsy and lung function 
measurements were within 30 days (±5).  
FEV1% percentage predicted forced expiratory volume in 1 second, FVC% 
percentage predicted forced vital capacity, DLCO% percentage predicted diffusing 
capacity of carbon monoxide, TLC% percentage predicted total lung capacity, CPI 
composite physiologic index, IPF idiopathic pulmonary fibrosis, Yrs years, ECM 
extracellular matrix  
 
Finally, the relationships between ECM proteins continued into the tissue. Fibulin-1 
correlated strongly with periostin with 26.4% (Pearson r2 = 0.264, p<0.05) with one 
protein (eg. Fibulin-1) able to predict the other (eg. Periostin). Tissue periostin 
correlated even more strongly with fibronectin and collagen as it was able to predict 
52.9% of the level of tissue fibronectin (Pearson r2 = 0.529, p<0.01) and 66.6% of 
total collagen (Pearson r2 = 0.666, p<0.01) (Figure 3.9, Table 3.9). 
Table 3.9 Tissue ECM proteins correlate with each other in patients with IPF 
 Fibulin-1 Periostin Fibronectin Total Collagen 
Fibulin-1  0.514* 0.479 0.286 
Periostin   0.727*** 0.816*** 
Fibronectin    0.251 
Total collagen     
Two to six surgical lung biopsies and lung function parameters were obtained from 
each patient with idiopathic pulmonary fibrosis (IPF) (n=17). Tissue ECM protein 
levels was measured by immunohistochemistry. Twenty images of each tissue section 
were analysed and 2-6 tissue sections were measured for each subject. The 
relationships between tissue ECM levels were examined by Pearson correlation 
analysis. (*p<0.05, ***p<0.001) 
ECM extracellular matrix  
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Figure 3.9 Tissue ECM proteins correlate with each other in patients with IPF 
Paraffin-embedded formalin fixed tissue sections from 17 patients with IPF were stained for 
each ECM protein and counterstained for all other tissue components. Levels of ECM 
proteins were quantified by computer aided image analysis using ImageJ and reported as the 
area positively stained for ECM protein as a percentage of the total area stained. Twenty 
images of each tissue section were analysed, 2-6 tissue sections were measured for each 
subject. Subsequently, measurements of each image were averaged together to obtain a single 
value per patient and shown by a single solid dot. Significant (p<0.05) Pearson’s product 
moment correlations are shown with the linear regression line. 
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For ease of comparison, the fibulin-1 levels in fibroblasts derived from patients with 
and without IPF have been repeated from Chapter 2 in the following sections.  
3.3.10 Fibroblasts from patients with IPF do not produce more periostin or 
fibronectin mRNA 
Information of the patients from whom the non-IPF and IPF fibroblasts were derived 
are found in Table 2.8. Information of the patients from whom the COPD fibroblasts 
were derived are found in Table 3.10. 
Table 3.10 Patient information from whom COPD fibroblasts were derived 
Donor # Gender Age Diagnosis Reason for Surgery 
COPD 1 Male 62 COPD Transplant 
COPD 2 Male 54 COPD Transplant 
COPD 3 Male 63 COPD Transplant 
COPD 4 Male 58 COPD Transplant 
Parenchymal fibroblasts were isolated from lung tissue obtained from donors 
undergoing transplantation. Pulmonary function and smoking data were not available. 
COPD chronic obstructive pulmonary disease 
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Figure 3.10 shows the mRNA levels of the four ECM proteins of interest in this 
thesis. For ease of reference, results of fibulin-1 mRNA in non-IPF and IPF 
fibroblasts are repeated from Figure 2.12. 
Tenascin-C mRNA production was significantly lower in fibroblasts from IPF 
patients compared to those from patients with COPD and subjects without lung 
disease. Fibulin-1 mRNA was the only one of the ECM proteins to be increased in 
fibroblasts from patients with IPF compared to patients without IPF  
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Figure 3.10 Basal mRNA levels of ECM proteins in fibroblasts. 
Primary parenchymal fibroblasts from patients with IPF (n=5) and age and gender 
matched patients without IPF (n=4) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep, 
for 24 hours and maintained in fresh 0.1% FBS/DMEM/1% pen-strep for a further 72 
hours. Non-IPF fibroblasts are derived from the macroscopically normal tissue 
isolated from the tumour-free margin of resections from patients with non-small cell 
carcinoma. 500 ng of mRNA was converted to cDNA for this comparison. *p<0.05 
one way ANOVA with Tukey’s post-test for between group comparisons.  
Data are expressed as 1/delta cycle threshold to 18S (∆Ct) to enable a greater number 
to reflect more mRNA. 
FBLN1 fibulin-1, COPD chronic obstructive pulmonary disease, IPF idiopathic 
pulmonary fibrosis, FBS foetal bovine serum, DMEM Dulbecco’s Modified Eagle 
Medium, Pen-Strep penicillin-streptomycin 
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3.3.11 Basal production of fibulin-1, periostin and tenascin-C by fibroblasts 
To investigate a possible source of serum periostin and tenascin-C the basal levels of 
the two additional proteins secreted by the same fibroblasts used in Chapter 2 (Figure 
2.13) were measured. In addition, the levels of cell-secreted fibulin-1, periostin, and 
tenascin-C from fibroblasts derived from patients with COPD was also measured. 
Only fibulin-1 was increased in fibroblasts from patients with IPF compared to 
subjects without lung disease and patients with COPD (Figure 3.11).  
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Figure 3.11 Basal production of secreted ECM proteins by primary fibroblasts 
 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender matched 
patients without IPF (n=7) and patients with COPD (n=4) were grown for 72 hours in 5% 
FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep for 24 hours and 
maintained in fresh 0.1% FBS/DMEM/1% pen-strep for a further 72 hours. Supernatants were 
collected and analysed by western blot (fibulin-1) and ELISA (periostin, tenascin-C).  All 
values were normalised to total protein of the cell monolayer as measured by BCA assay. 
Between group differences were assessed by ANOVA with Tukey’s post-test analysis 
*p<0.05. Values are expressed as median and interquartile range. 
Non-IPF fibroblasts are derived from the macroscopically normal tissue isolated from the 
tumour-free margin of resections from patients with non-small cell carcinoma.  
COPD chronic obstructive pulmonary disease, ECM extracellular matrix, BCA 
Bicinchroninic Acid, IPF idiopathic pulmonary fibrosis, FBS foetal bovine serum, DMEM 
Dulbecco's Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
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3.3.12  Summary of results from biomarker investigation 
The aim of this chapter was to compare the utility of three other ECM proteins that 
have been implicated in disease progression of patients with pulmonary fibrosis and 
are also ECM proteins that relate (eg. bind same proteins) to fibulin-1. Fibulin-1 stood 
out as a better biomarker of disease progression in patients with IPF compared to 
periostin, tenascin-C and fibronectin. Fibulin-1 was increased in all the patient 
materials that were examined in this study and successfully predicted disease 
progression in patients with IPF, independent of baseline lung function measurements. 
A summary of the findings covered so far in this thesis is found in Table 3.11. 
Table 3.11 Summary of the biomarker investigation  
 
Research Question Fibulin-1 Periostin Fibronectin  Tenascin-C 
1  Is the biomarker 
increased in the serum 
of patients with IPF 
compared to controls?  
Yes  Yes No  No  
2  Does the biomarker 
predict progression in 
patients with IPF?  
Yes No  No  No  
3  Is the biomarker 
increased in the tissue 
of patients with IPF 
compared to controls?  
Yes Yes No   
4  Do fibroblasts from 
patients with IPF 
produce increased 
mRNA of the 
biomarker?  
Yes No  No  No 
5  In patients with IPF, 
do fibroblasts produce 
increased levels of the 
soluble biomarker 
protein?  
Yes No  No 
6 In patients with IPF, 
do fibroblasts produce 
increased levels of the 
cellular biomarker 
protein? 
Yes    
Grey boxes indicate research questions outside the scope of this thesis. 
mRNA messenger ribonucleic acid, IPF idiopathic pulmonary fibrosis 
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3.4 Discussion 
Because there are likely to be many ECM proteins that are dysregulated during 
pathogenic fibrogenesis, three additional ECM proteins were investigated in this 
Chapter to elucidate if they also were biomarkers of disease progression in patients 
with IPF. This chapter demonstrates that the ECM proteins, periostin, tenascin-C and 
fibronectin were not biomarkers of disease progression in patients with IPF. None of 
these additional ECM proteins were able to successfully predict which patients with 
IPF were at greatest risk of lung function decline within one year of blood draw.  
Published evidence suggests that serum levels of ECM proteins (like collagen) can be 
reflective of fibrotic changes in the lung (Kasuga et al. 1996), and in this study, the 
ECM protein periostin, which binds collagen, was increased in the serum of patients 
with IPF compared to subjects without lung disease. However, prior findings in the 
literature that reported an increased serum periostin level in patients with IPF who 
progressed compared to those who remained stable (Naik et al. 2012) were not 
replicated in this study. One explanation of this discrepancy may be the difference in 
the blood fraction that was studied.  
In this study serum periostin was examined whereas Naik and colleagues investigated 
plasma periostin levels in patients with IPF. The average plasma periostin level in 
patients with IPF in the Naik study was approximately 21 µg/mL but the average 
serum periostin level in patients with IPF in the current study was only 2.9 ng/mL. 
The main difference between plasma and serum is the lack of clotting factors and cells 
in the serum (Burnouf et al. 2013) and therefore it is possible that the level of 
periostin in the serum would be less than in the plasma.  
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Further support of our initial hypothesis that fibulin-1 is a unique ECM protein 
biomarker of disease progression in IPF, was drawn from ROC curve analysis, which 
showed that of the four serum ECM biomarkers tested, only fibulin-1 was able to 
accurately discriminate between patients with IPF who progressed or those who 
remained stable. While the 95% confidence intervals for the area under the curve of 
serum fibulin-1 were wide, they did not cross 0.5. This is an indication that serum 
fibulin-1 is worthy of further study as a biomarker. If the 95% confidence intervals 
cross 0.5, then the biomarker has no better than a 50% chance of discriminating 
between the two cases being compared (in our case whether a patient was likely to 
progress or remain stable), which was the case for the other three ECM proteins.  
The three ECM proteins periostin, tenascin-C and fibronectin have roles in the 
progression of fibrosis in patients with IPF (Carey et al. 2010; Lepparanta et al. 2012; 
Naik et al. 2012). Furthermore, increased periostin mRNA has been implicated as a 
characteristic of myofibroblasts in fibroblastic foci. Although accuracy of disease 
progression prediction was the characteristic most important in this biomarker study, 
alterations in ECM levels may still reflect changes in lung function.  
When the relationship between lung function and serum ECM proteins in patients 
across all ILDs was examined, three of the four (all except fibronectin) ECM 
molecules were increased as FVC% decreased. In addition, both serum fibulin-1 and 
periostin were increased as DLCO% and TLC% decreased, and as CPI increased. 
Taken together, we begin to illustrate an environment of elevated serum ECM 
proteins that is reflective of an overall poorer state of lung function and increased 
disease severity in patients with pulmonary fibrosis.  
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Lung function decreases as the normal architecture of the lung is replaced by fibrotic 
tissue. Tissue levels of both fibulin-1 and periostin were increased in patients with IPF 
compared to subjects without lung disease, but only fibulin-1 correlated with poorer 
lung function in patients with IPF. It is not hard to imagine why an interlacing, 
bridging protein like fibulin-1 would be found in greater amounts in the tissue of 
subjects whose lung function is poor. The physiological effect of increased collagen 
deposition is not only a consequence of excessive protein production, but also in its 
changed 3-D structure. A good example of this is the fact that increased collagen 
deposition is associated with both IPF (McKleroy et al. 2013) and emphysema 
(Martin-Mosquero et al. 2006), yet the physiological outcome on lung mechanics is 
drastically different (Faffe and Zin 2009).   
The ability of periostin to modulate collagen and fibronectin deposition has been 
shown in mice (Norris et al. 2007; Kudo 2011) and in this study, we showed that as 
tissue periostin increases so does tissue collagen and fibronectin in the tissue of 
patients with IPF. Similarly, the relationship between periostin and tenascin-C (Kii et 
al. 2010) was reproduced as the proteins correlated in the serum of patients with IPF. 
The effect size is used to describe the strength of the relationship between  two 
variables and in this case, the relationships between serum fibulin-1 and tenascin-C 
and between serum tenascin-C and periostin may be considered moderately correlated 
as the Pearson’s correlation coefficients were only 0.4. This effect size may not be 
accurately reflect the importance of the relationship in biological context as small 
changes in lung 3D structure may result in a pronounced effect on lung function . 
The biomechanics of lung parenchyma is largely determined by the structural 
arrangement of collagen, elastin and proteoglycans (Suki et al. 2005). The 
Page 160 of 252 
 
macromolecules collagen, elastin and fibronectin are capable of forming fibres thicker 
than several hundred nanometres which form a network that extends from the central 
airways to the alveolar ducts. The orientation of these large fibres is determined by 
the smaller interlacing proteins (Culav et al. 1999) and this is the first study to 
highlight correlations between fibulin-1, periostin, tenascin-C and fibronectin ECM 
proteins in the serum and tissue of patients with IPF.  
While increasing levels of tissue fibulin-1 moderately correlated with increasing 
levels of periostin, it did not correlate with fibronectin, as we might have expected. 
This may be due to insufficient power in this study to be able to correctly reject the 
null hypothesis. However, strong correlations were seen between tissue periostin and 
fibronectin and between periostin and total collagen as expected from the literature 
(Hamilton 2008; Kii et al. 2010; Kudo 2011). Interestingly, tissue fibronectin and 
total collagen did not correlate with each other. This may be explained by the 
replacement of fibronectin with collagen during fibre maturation as seen in various 
stages of development (Dessau et al. 1980).   
Expression of certain ECM proteins is limited in normal adult tissues, but increased 
during development/wound healing (Bosman and Stamenkovic 2003) and tenascin-C 
is one such ECM protein (Imanaka-Yoshida 2012). To our knowledge this is the first 
study to show that serum tenascin-C has potential as another biomarker in IPF, as it 
was decreased in the serum of patients with IPF compared to patients with HP, a 
disease of similar clinical presentation. Conversely, increases in tenascin-C have been 
shown in the BALF of patients with IPF (Kaarteenaho-Wiik et al. 1998). This may 
reflect a different source of tenascin-C as both the BALF and route of experimental 
fibrosis involve the epithelial cells.  
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However, except for fibulin-1, none of the other three ECM proteins tested were 
increased in the serum and had increased tissue levels that correlated with poorer lung 
function in patients with IPF. Those two factors (increased serum and tissue levels of 
the candidate protein) are central in being able to distinguish which patients exhibit an 
active fibrogenic state and therefore are an indication of the usefulness of that protein 
as a biomarker. 
Activated fibroblasts are known to be the mesenchymal cell most responsible for 
ECM deposition (Kisseleva and Brenner 2008). Fibroblasts are the key driver in the 
fibrotic process and the matrix they produce influences those fibrogenic changes 
(Klingberg et al. 2013). In pulmonary fibrosis, the diseased matrix is drastically 
altered (Booth et al. 2012; Tschumperlin et al. 2012) and this was reflected in the 
dysregulation of the ECM proteins in fibroblasts derived from patients with IPF.  In 
this study, basal mRNA expression of tenascin-C is decreased in IPF fibroblasts 
compared to both Non-IPF and COPD fibroblasts. In contrast, there was no difference 
in either periostin or fibronectin mRNA levels between patients with IPF and subjects 
without lung disease and this supports our hypothesis that fibulin-1 is a unique signal 
of fibrotic fibroblasts.  
In the search for a serum biomarker of active fibrogenesis it is important to establish a 
potential source of the serum protein for future targeted therapies. To complete this 
investigation, the levels of soluble ECM protein production secreted from the cultures 
of primary parenchymal fibroblasts were compared between Non-IPF, COPD and IPF 
fibroblasts. Neither cell-secreted periostin or tenascin-C production was increased in 
IPF fibroblasts compared to Non-IPF or COPD fibroblasts, results which strengthen 
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the conclusion that increased fibulin-1 production may be a unique target of activated, 
and resident, fibrotic fibroblasts. 
This study is the first to report that while it is likely that many ECM proteins are 
dysregulated in the context of idiopathic fibrotic disease, fibulin-1 is a better 
biomarker than three other ECM proteins that have been identified as participants in 
the fibrotic process. The variable clinical course in IPF emphasizes the need for serum 
biomarkers of disease progression that reflect active fibrogenic states in the lung and 
identify patients who are at a higher risk of lung function decline. In the search for a 
biomarker, measurements of fibulin-1 may be able to identify patients with IPF who 
are most likely to rapidly require lung transplantation. 
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Chapter 4. The effect of TGFβ1 stimulation on 
fibulin-1 production in fibroblasts 
4.1 Introduction 
An injury to the lung sets off a tightly regulated chain of events that under normal 
circumstances results in restoration of the lung architecture following closure of the 
wound. However, in the event of pathological fibrosis, the repair process becomes 
unrestrained and extracellular matrix (ECM) deposition becomes excessive.   
Mesenchymal cells are responsible for the production of most of the ECM and 
therefore the building blocks of fibrosis. Fibroblasts produce the vast majority of the 
matrix proteins and provide the basis of the ECM in the interstitium (Frantz et al. 
2010). Although pulmonary fibrosis is thought to be driven by an abnormal epithelial 
repair process that propagates throughout the interstitium (Crosby and Waters 2010), 
it is the dysregulated ECM production by lung fibroblasts that alters the physical 
architecture of the tissue and results in the loss of lung function (Faffe and Zin 2009).  
Impaired communication between epithelial cells and resident fibroblasts drives 
aberrant wound repair (Selman and Pardo 2002). Epithelial cells line the airways, 
cover the alveolar surface and airway epithelial cells can exhibit a thickened basement 
membrane, which is a specialized ECM, during fibrogenesis. Both epithelial cells and 
fibroblasts can also produce cytokines that further perpetuate the disease process 
(Lomas et al. 2012) by recruiting other cells to the injury site. For example, 
circulating fibrocytes, which are potential progenitors of fibroblasts, are recruited to 
the lung by chemo-attractant cytokines produced by alveolar epithelial cells and are a 
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potential source of the increased fibroblast numbers in IPF (Andersson-Sjoland et al. 
2008).  
The pro-fibrotic cytokine transforming growth factor (TGF)-β1 is a major driver in 
fibrogenesis and is overproduced in IPF (Lepparanta et al. 2012). TGFβ1 is also 
important in differentiation of the fibroblast into its pathological and contractile 
phenotype during pulmonary fibrosis (Kage and Borok 2012), which is characterized 
by the expression of alpha-smooth muscle actin (α-SMA) (Zhang et al. 1996).  
Stimulation of fibroblasts with TGFβ1 induces ECM proteins like fibronectin 
(Doerner and Zuraw 2009) and type I collagen (Kenyon et al. 2003).  TGFβ1 can also 
bind to other ECM components such as elastin and decorin (Prud'homme 2007), two 
ECM molecules that affect the overall physiology of the lung (Antunes et al. 2009). 
TGFβ1 is also known to induce production of periostin  (Naik et al. 2012) and 
tenascin-C (Fitch et al. 2011). Furthermore, latent TGFβ1 co-localizes with 
fibronectin, indicating that the storage of TGFβ1 and therefore availability are 
modulated in the fibrotic lung and emphasizing the role of the ECM as an active 
player in fibrogenesis (Lepparanta et al. 2012).  
The ECM protein fibulin-1 is increased following stimulation with TGFβ1 in airway 
smooth muscle (ASM) cells derived from patients with asthma (Lau et al. 2010). In 
the asthmatic airway, TGFβ1 is increased and associates with fibroblasts as well as 
ASM (Howell and McAnulty 2006). As part of the fibrogenic remodelling process in 
asthma, there is excessive subepithelial deposition of ECM molecules that result in 
increased basement membrane thickness and, importantly, stiffening of the 
tracheobronchial walls (Royce et al. 2009).  
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In the lung, as with other organs, mechanical forces can directly influence cellular 
behaviour, especially during embryonic development (Kubota et al. 2012). The 
mechanical properties of the lung parenchyma are in part determined by the structure 
of the alveolar walls (Suki et al. 2005) and in particular, fibulin-1 is necessary for the 
embryonic development of the alveolar septa (Figure 4.1) (Kostka et al. 2001).  
 
 
 
 
 
 
 
Figure 4.1 Fibulin-1 is necessary for proper lung development of mice.  
Hemotoxylin (blue, cell nuclei) and eosin (red, collagen/muscle) staining of 
mouse tissue sections show that mice which are homozygous-deficient for 
fibulin-1 exhibit improperly expanded sacculi and thickened septa in the lungs 
at mouse embryonic day 18.5 (E18.5) and one day after birth (P1) compared to 
heterozygous controls.  
Bar 100µm 
Adapted with permission from (Kostka et al. 2001). 
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Fibulin-1 also has an important role in elastic fibre formation (Roark et al. 1995) as it 
binds to tropoelastin (Sasaki et al. 1999) and several of the central proteoglycans 
involved in ECM structure such as nidogen (Kubota et al. 2006) and versican 
(Aspberg et al. 1999), the latter of which is increased in pulmonary fibrosis 
(Bensadoun et al. 1996). Elastic fibres are also important determinant fibres in the 
biomechanical properties of the lung and changes in ECM composition in the context 
of fibrotic disease often includes the dysregulation of elastic fibre molecules (Faffe et 
al. 2006).  
In the lung parenchyma, elastic properties are largely determined by the orientation of 
elastin fibres and the loosely-arranged collagen fibres that form a spring-like network 
around cells and vessels (Rocco et al. 2004). Tenascin-C, in concert with periostin, is 
largely responsible for the proper orientation of collagen fibres (Kii et al. 2010). 
Fibulin-1 binds fibronectin (Argraves et al. 1989) and is also known to alter the 
binding of tenascin-C to fibronectin (Williams and Schwarzbauer 2009). The nature 
of the interconnected relationship between large structural fibres (fibronectin and 
collagen) and smaller, bridging ECM proteins like fibulin-1 (as well as periostin, and 
tenascin-C) may be dysregulated within the fibroblasts themselves in the context of 
fibrotic disease, resulting in an overall stiffer lung because the fibroblasts that 
populate the ECM are also more stiff. Lung tissue from mice treated with bleomycin 
(an experimental model of pulmonary fibrosis in which interstitial collagen deposition 
is induced) is stiffer than lung tissue from saline-treated mice, as measured by atomic 
force microscopy (AFM) (Liu and Tschumperlin 2011)  but to date, there have been 
no investigations into the stiffness of primary lung fibroblasts derived from patients 
with and without pulmonary fibrosis.  
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AFM is a microscopy technique that has been used for decades in material science 
and has been used on organic materials since the late 1980’s (Marti et al. 1988). AFM 
first characterizes the topography of the material by measuring the deflection of a 
cantilever attached to a probe as it is passed over the cellular surface (Marti et al. 
1988). Secondly, it then estimates the stiffness of the tissue layer by measuring the 
resistance of the tissue to deformation by the cantilever/probe as it is indented into the 
tissue (Marti et al. 1988). A stiffer tissue would be more resistant to the pushing of the 
cantilever (Jalili and Laxminarayana 2004).  
Studies with lung fibroblast cell lines have demonstrated that TGFβ1 can increase 
fibroblast cell stiffness (Liu et al. 2010) and it is likely that a similar relationship can 
been seen in primary cells. Consequently, we were interested in using AFM to 
investigate the physical differences between individual primary fibroblast cells as they 
are grown in culture in both basal and fibrotic conditions using stimulation with 
TGFβ1.  
To this end, in this chapter we aimed to examine the effect of TGFβ1 on fibulin-1 
expression and production in fibroblasts derived from patients with IPF, COPD and 
from subjects without lung disease. Secondly, we aimed to confirm that TGFβ1 also 
increased the expression of the ECM proteins periostin, tenascin-C and fibronectin. 
Lastly we examined the morphology and stiffness of fibroblasts in the context of both 
a basal and TGFβ1-stimulated environment.  
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4.2 Methods  
4.2.1 Patient Data  
The patients from whom the fibroblasts were derived were previously described in 
Chapter 2 (Table 2.8) and Chapter 3 (Table 3.10).  
4.2.2 Fibroblast isolation and cell culture 
Primary parenchymal fibroblasts were cultured and set up for experiment as 
previously described in Chapter 2 (Methods 2.2.5, 2.2.6, 2.2.7). For atomic force 
microscope measurements, cells were washed twice with cold, sterile PBS and fixed 
for 20 minutes at room temperature with 10% neutral buffered formalin solution 
(Sigma Aldrich, Sydney, Australia). Cells were washed twice again with PBS as 
before. Cells were stored in sterile PBS at 4°C until probing.  
4.2.3 Stimulation with TGFβ1 
Activated TGFβ1 (R&D Systems, USA) recombinant protein was used in all 
experiments. For cell stimulation, TGFβ1 was diluted in quiescing media as described 
in Chapter 2 (Methods 2.2.7).   
4.2.4 RNA isolation 
RNA isolation was performed as described in Chapter 2 (Methods 2.2.7.1). 
4.2.5 Real-time reverse transcription polymerase chain reaction 
QPCR was performed as described in Chapter 2 (Methods 2.2.8). In addition to the 
primers that have been described in Chapter 2 (2.2.8.2) and Chapter 3 (Methods 
3.2.3), additional primers used in this chapter were for the specific isoforms of 
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fibulin-1 (A: custom made primer designed by previous PhD candidate Justine Lau 
((Lau et al. 2010)), B: Hs00972625_m1, C: Hs00242546_m1, D: Hs0019774_m1) 
and for IL-6 (Hs00174360_m1), α-SMA (Hs00426835_g1) and Fibulin-5 
(Hs00197064_m1).  
4.2.6 Secreted and cell-associated protein collection from cell cultures 
Cell secreted and cell-associated proteins were collected from primary parenchymal 
fibroblast cultures as described in Chapter 2 (Methods 2.2.7.2). 
4.2.7 Immunoblotting 
Immunoblotting was performed as previously described in Chapter 2 (2.2.9 and 
2.2.13) and analysed as described  in Chapter 2 (2.2.14).  
4.2.8 Sandwich ELISA 
The levels of periostin and tenascin-C were investigated by sandwich ELISA as 
previously described in Chapter 3 (3.2.4). Levels of the cytokines IL-6 and IL-8 were 
measured using antibody pairs from BD (Becton Dickinson & Co, USA), summarised 
in Table 4.1, using the ELISA method outlined in Chapter 3 (Methods 3.2.4). 
Table 4.1 Materials used in ELISAs for cytokine measurements 
 IL-6 set (BD cat#55520) IL-8 set (BD cat#555244) 
Primary antibody 1µg/mL  in 0.1M Na2HPO4 4µg/mL in PBS 
Blocking media 1% BSA/PBS 1% BSA/PBS 
Standard 1000pg/mL 0pg/mL 2000pg/mL  0pg/mL 
Samples Diluted as necessary Diluted as necessary 
Secondary antibody 0.5µg/mL 40ng/mL  
Detection antibody 1:200 (R&D cat#DY998) 1:200 (R&D cat#DY998) 
Substrate TMB (Zymed cat#00-2023) TMB (Zymed cat#00-2023) 
Stop solution 1M H3PO4 1M H3PO4 
Lower limit of detection 47pg/mL 31pg/mL 
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4.2.9 Light microscopy 
Images of fibroblasts in culture were taken using an Camedia C4000 Zoom (Olympus, 
USA) digital camera attached to a CK2 light microscope (Olympus, USA) at 10x 
magnification. 
4.2.10 Atomic Force Microscopy 
Atomic force microscopy (AFM) was performed under the supervision and tutelage of 
Dr. Wojciech Chrzanowski (Faculty of Pharmacy, The University of Sydney). The 
analysis of the results was performed by Jade Jaffar.  
For atomic force microscope measurements, cells were washed twice with cold, 
sterile PBS and fixed for 20 minutes at room temperature with 10% neutral buffered 
formalin solution (Sigma Aldrich, Sydney, Australia). Cells were washed twice again 
with PBS as before. Cells were stored in sterile PBS at 4°C until probing. 
AFM was performed using an atomic force microscope from Asylum Research (Santa 
Barbara, CA, USA) with the IGOR Pro software (Version 6.3.4.1, Wavemetrics, 
Oregon, USA). The cantilever (Asylum Research, Santa Barbara, CA, USA) used was 
a silicone-nitrate base with a cone-shaped tip. The model used to fit the force curves 
generated by AFM was the Derjaguin–Muller–Toporov (DMT) model with the invols 
set to 147nm/V and the spring constant of the cantilever was set to 12.8 piconewtons 
per nanometer (pN/nm) as per the manufacturer’s instructions.  
The Poisson ratio of all the samples was set to 0.5. When material is stretched in one 
direction it will get thinner in the other two directions. The Poisson ratio is a measure 
of deflection of the sample and relates to the amount of compression that the material 
can undergo. This compression leads to a larger change in volume in materials with a 
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higher Poisson’s ratio. Most metals have a Poisson’s ratio between 0.25 and 0.35 
whereas rubber has a Poisson’s ratio of 0.5. Biological materials have a Poisson’s 
ratio of 0.5 because the indentation of the cantilever does not produce a permanent 
change in volume (Buzard 1992). The Poisson’s ratio is limited between -1 and 0.5.  
 Surface topography of fibroblasts was measured in contact mode, where the surface 
of the sample remains in contact with the tip of the cantilever. The scan rate for 
topography was 0.2Hz. Cell stiffness of the fibroblasts was measured by contact-
indentation mode, where the surface is indented by the cantilever tip and then 
retracted before the tip moves along to the next measurement point. The scan rate for 
cell stiffness was also 0.2Hz. 
4.2.11 Statistical Analysis 
Graphs were made using GraphPad Prism 6 Software for Windows (Version 6 
GraphPad Software Inc. 1992-2007). Statistical analysis was done using SPSS 
Statistics (Version 21 IBM Corporation 1989-2012). 
The effect of different concentrations of TGFβ1 was assessed using paired t-tests. 
Differences in the basal levels of ECM proteins between groups of fibroblasts were 
assessed by one-way ANOVA with Tukey’s post test correction for multiple 
comparisons. Differences between groups before and after stimulation with TGFβ1 
were assessed by two-way ANOVA with Tukey’s post test correction for multiple 
comparisons. 
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4.3 Results 
The basal levels of fibulin-1, periostin, tenascin-C and fibronectin were reported in 
the previous Chapters (fibulin-1, Figure 2.12, Figure 2.13; periostin/ tenascin-C/ 
fibronectin, Figure 3.10, Figure 3.11) and have been reproduced in this Chapter for 
comparison purposes. Graphical mRNA data is presented using 1/∆Ct levels on the y-
axis. Equal amounts of mRNA from each fibroblast line were converted into cDNA 
and levels of mRNA were quantified by QPCR.  The comparative (or ∆∆Ct) method 
was used to calculate the relative abundance of mRNA compared to the housekeeping 
gene 18S. Samples with a high amount of a particular mRNA transcript have a 
smaller delta Ct value because fewer cycles of PCR are required to amplify the target 
gene to a pre-determined threshold value. 
4.3.1 Characterisation of the basal mRNA expression of fibulin-1 isoforms in 
primary parenchymal fibroblasts 
Alternative splicing of the fibulin-1 gene produces 4 isoforms that differ in their C-
terminal region (Tran et al. 1997). Isoforms C and D are the predominant forms 
expressed in adult human tissues and have been shown to have differing functions 
during tissue morphogenesis (Muriel et al. 2005). In Chapter 2, this study showed that 
fibroblasts from patients with IPF produced more fibulin-1 mRNA than fibroblasts 
from patients without IPF (Figure 2.12) however, whether there was differential 
expression of the four isoforms of fibulin-1 was not examined. In addition, the levels 
of fibulin-1 mRNA in fibroblasts derived from patients with COPD was not different 
compared to fibroblasts derived from patients with and without IPF (Figure 4.2). The 
basal expression levels of all 4 fibulin-1 isoforms followed the same pattern as shown 
in Chapter 2 in that fibulin-1A, C, and D were all significantly increased in fibroblasts 
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from patients with IPF compared to fibroblasts from subjects without lung disease 
(Two-way ANOVA, p<0.01) (Figure 4.2). Fibulin-1B expression was lower than the 
other fibulin-1 genes and there was no statistical difference in the expression levels in 
the fibroblasts derived from the three patient groups (patients with IPF, patients 
without IPF and patients with COPD).  
 
 
Figure 4.2 Basal mRNA levels of the four fibulin-1 isoforms in primary 
parenchymal fibroblasts. 
Primary parenchymal fibroblasts from patients with IPF (n=5) and age and gender 
matched patients without IPF (n=4) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM, quiesced in 0.1% FBS/DMEM for 24 hours and maintained 
in fresh 0.1% FBS/DMEM for a further 72 hours. Non-IPF fibroblasts were derived 
from the macroscopically normal tissue isolated from the tumour-free margin of 
resections from patients with non-small cell carcinoma. 500ng of mRNA was 
converted to cDNA for this comparison. Data are expressed as 1/delta cycle threshold 
to 18S (∆Ct) to enable a greater number to reflect more mRNA. The centre line is the 
population median. *p<0.05 one way ANOVA with Tukey’s post-test for between 
group comparisons.  
FBLN1 fibulin-1, COPD chronic obstructive pulmonary disease, IPF idiopathic 
pulmonary fibrosis, FBS foetal bovine serum, DMEM Dulbecco’s Modified Eagle 
Medium 
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Because this study was investigating the effect of TGFβ1 on these fibroblasts, the 
basal expression of IL-6 and α-SMA, two proteins known to be induced by TGFβ1, 
was also measured. 
In addition, fibulin-5, another member of the fibulin family which also plays a role in 
elastogenesis (Nakamura et al. 2002) and is also a TGFβ1 gene target (Lee et al. 
2008) was measured to elucidate if other fibulin family members were induced by 
TGFβ1 in primary parenchymal fibroblasts. 
There was no difference in basal mRNA expression of IL-6, α-SMA or fibulin-5 
between fibroblasts from subjects without IPF and fibroblasts from patients with IPF. 
Fibroblasts from patients with IPF produced significantly less IL-6 mRNA than 
fibroblasts from patients with COPD (one-way ANOVA, p<0.05) (Figure 4.3).  
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Figure 4.3 Basal mRNA levels of markers measured to gauge response to TGFβ1 
stimulation in primary parenchymal fibroblasts 
Primary parenchymal fibroblasts from patients with IPF (n=5) and age and gender 
matched patients without IPF (n=4) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep 
for 24 hours and maintained in fresh 0.1% FBS/DMEM/1% pen-strep for a further 72 
hours. Non-IPF fibroblasts were derived from the macroscopically normal tissue 
isolated from the tumour-free margin of resections from patients with non-small cell 
carcinoma. 500ng of mRNA was converted to cDNA for this comparison. Data are 
expressed as 1/delta cycle threshold to 18S (∆Ct) to enable a greater number to reflect 
more mRNA. The centre line is the population median. *p<0.05 one way ANOVA 
with Tukey’s post-test for between group comparisons.  
FBLN5 fibulin-5, COPD chronic obstructive pulmonary disease, IPF idiopathic 
pulmonary fibrosis, FBS foetal bovine serum, DMEM Dulbecco’s Modified Eagle 
Medium, IL interleukin, α-SMA alpha smooth muscle actin, Pen-Strep penicillin-
streptomycin 
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4.3.2 The dose related effect of TGFβ1 on fibulin-1 mRNA levels in 
parenchymal fibroblasts 
Initially, the study investigated the effect of different concentrations of TGFβ1 and 
different times of exposure on fibulin-1C and fibulin-1D mRNA in fibroblasts from 5 
subjects without lung disease (Figure 4.4). Fibulin-1C and fibulin-1D were examined 
as these are the majority isoforms of fibulin-1 in adult humans (Tran et al. 1997). 
Treatment with three concentrations of TGFβ1 (1, 3, 10ng/mL) significantly 
downregulated the expression of fibulin-1C and fibulin-1D mRNA at the three 
timepoints examined, 24 hours, 48 hours and 72 hours of stimulation, with no 
difference between the time points.  
To ensure that the fibroblasts were responding to TGFβ1, the change in fibronectin 
mRNA was also measured. As expected, TGFβ1 increased fibronectin mRNA at both 
the 24 hour and 48 hour timepoints, albeit only with the highest concentration of 
TGFβ1 (Figure 4.5).  
For these reasons, further experiments were carried out using 10ng/mL of TGFβ1 for 
72 hours. 
 
Page 177 of 252 
 
24 hours - FBLN1C
U
ns
tim
ul
at
ed
1n
g/
m
L
3n
g/
m
L
10
ng
/m
L
0.0
0.5
1.0
1.5 *
*
*
24 hours - FBLN1 D
U
ns
tim
ul
at
ed
1n
g/
m
L
3n
g/
m
L
10
ng
/m
L
0.0
0.5
1.0
1.5 *
*
*
U
ns
tim
ul
at
ed
1n
g/
m
L
3n
g/
m
L
10
ng
/m
L
48 hours - FBLN1 D
U
ns
tim
ul
at
ed
1n
g/
m
L
3n
g/
m
L
10
ng
/m
L
0.0
0.5
1.0
1.5
*
*
72 hours - FBLN1C
U
ns
tim
ul
at
ed
1n
g/
m
L
3n
g/
m
L
10
ng
/m
L
0.0
0.5
1.0
1.5
*
*
*
72 hours - FBLN1 D
U
ns
tim
ul
at
ed
1n
g/
m
L
3n
g/
m
L
10
ng
/m
L
0.0
0.5
1.0
1.5 *
*
 
Figure 4.4 Effect of TGFβ1 on fibulin-1C and fibulin-1D mRNA levels in primary parenchymal 
fibroblasts from subjects without IPF 
Primary parenchymal fibroblasts from patients without IPF (n=5) were grown for 72 hours in 5% 
FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep for 24 hours and maintained 
in fresh 0.1% FBS/DMEM/1% pen-strep or treated with 1, 3, 10ng/mL TGFβ1 in 0.1% 
FBS/DMEM/1% pen-strep for a further 24, 48 or 72 hours. Non-IPF fibroblasts were derived from the 
macroscopically normal tissue isolated from the tumour-free margin of resections from patients with 
non-small cell carcinoma. Values are expressed as fold change compared to time matched unstimulated 
control. 
(Paired t-test compared to unstimulated *p<0.05). 
TGFβ1 transforming growth factor-beta 1, IPF idiopathic pulmonary fibrosis, FBS foetal bovine serum, 
DMEM Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
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Figure 4.5 Effect of TGFβ1 on fibronectin mRNA levels in primary parenchymal 
fibroblasts from subjects without idiopathic pulmonary fibrosis (IPF) 
 
Primary parenchymal fibroblasts from patients without IPF (n=5) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep 
for 24 hours and maintained in fresh 0.1% FBS/DMEM/1% pen-strep or treated with 
1 or 10ng/mL TGFβ1 in 0.1% FBS/DMEM/1% pen-strep for a further 24 (left) or 48 
(right) hours. Non-IPF fibroblasts were derived from the macroscopically normal 
tissue isolated from the tumour-free margin of resections from patients with non-small 
cell carcinoma. Values are expressed as fold change compared to time matched 
unstimulated control. (Paired t-test compared to unstimulated *p<0.05) 
TGFβ1 transforming growth factor-beta 1, FBS foetal bovine serum, DMEM 
Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
 
 
  
4.3.3 The effect of TGFβ1 on fibulin-1 mRNA levels of primary parenchymal 
fibroblasts 
Treatment with 10ng/mL of TGFβ1 for 72 hours significantly downregulated all 
isoforms of fibulin-1, regardless of disease status of the fibroblasts (Figure 4.6).  
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Figure 4.6 The effect of 10ng/mL TGFβ1 on mRNA levels of fibulin-1 isoforms. 
 
Primary parenchymal fibroblasts from patients with IPF (n=5) and age and gender 
matched patients without IPF (n=4) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep 
for 24 hours and either left (●) unstimulated  in fresh 0.1% FBS/DMEM/1% pen-strep 
or (■) stimulated for a further 72 hours with 10ng/mL TGFβ1 in 0.1% 
FBS/DMEM/1% pen-strep  
(*two-way ANOVA, p<0.05) 
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from patients with non-small cell 
carcinoma. 500ng of mRNA was converted to cDNA for this comparison. Data are 
expressed as 1/delta cycle threshold to 18S (∆Ct) to enable a greater number to reflect 
more mRNA.  
COPD chronic obstructive pulmonary disease, IPF idiopathic pulmonary fibrosis, 
TGFβ1 transforming growth factor-beta 1, FBS foetal bovine serum, DMEM 
Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin  
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4.3.4 The effect of TGFβ1 on mRNA levels of other genes of interest in primary 
parenchymal fibroblasts 
Treatment with TGFβ1 significantly increased fibronectin mRNA and α-SMA 
expression in all 3 disease groups (Figure 4.7). TGFβ1 has been shown to increase α-
SMA expression in fibroblasts (Kage and Borok 2012),  Treatment with TGFβ1 
upregulated periostin mRNA in fibroblasts from patients with IPF (p<0.05) but had no 
effect in fibroblasts from patients without IPF or patients with COPD (Figure 4.7). 
TGFβ1 stimulation did not alter the mRNA levels of tenascin-C, IL-6 or fibulin-5. 
 A summary of the means and standard deviations (SD) for the mRNA results is 
shown in Table 4.2. 
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Figure 4.7 The effect of TGFβ1 on mRNA levels of ECM proteins, IL-6 and α-
SMA in fibroblasts. 
Primary parenchymal fibroblasts from patients with IPF (n=5) and age and gender 
matched patients without IPF (n=4) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep 
for 24 hours and either left (●) unstimulated in fresh 0.1%FBS/DMEM/1% pen-strep 
or (■) stimulated for a further 72 hours with 10ng/mL TGFβ1 in 
0.1%FBS/DMEM/1% pen-strep (*two-way ANOVA, p<0.05). Data are expressed as 
1/delta cycle threshold to 18S (∆Ct) to enable a greater number to reflect more 
mRNA. Non-IPF fibroblasts were derived from the macroscopically normal tissue 
isolated from the tumour-free margin of resections from patients with non-small cell 
carcinoma. 500ng of mRNA was converted to cDNA for this comparison.  
COPD chronic obstructive pulmonary disease, IPF idiopathic pulmonary fibrosis, 
TGFβ1 transforming growth factor-beta 1, FBS foetal bovine serum, DMEM 
Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin, IL 
interleukin, SMA smooth muscle actin, FBLN5 fibulin-5 
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Table 4.2 Summary of the effect of TGFβ1 on mRNA levels of genes of interest in 
primary parenchymal fibroblasts 
mRNA levels (1/∆Ct) Non-IPF COPD IPF 
Basal TGFβ1 Basal TGFβ1 Basal TGFβ1 
  (n) 4 4 4 4 5 5 
FBLN1 (pan) Mean  0.093 0.066 0.102 0.070 0.111 0.077 
SD 0.004 0.004 0.015 0.005 0.009 0.004 
Periostin Mean  0.098 0.117 0.099 0.114 0.099 0.128 
SD 0.013 0.006 0.013 0.004 0.015 0.008 
Tenascin-C Mean  0.094 0.087 0.096 0.087 0.082 0.085 
SD 0.004 0.005 0.005 0.003 0.006 0.003 
Fibronectin Mean  0.126 0.159 0.128 0.153 0.121 0.160 
SD 0.010 0.005 0.013 0.007 0.009 0.006 
FBLN1A Mean  0.071 0.048 0.075 0.050 0.081 0.053 
SD 0.003 0.003 0.009 0.002 0.006 0.002 
FBLN1B Mean  0.055 0.046 0.057 0.047 0.060 0.050 
SD 0.002 0.003 0.004 0.002 0.002 0.002 
FBLN1C Mean  0.091 0.065 0.097 0.067 0.110 0.074 
SD 0.005 0.005 0.013 0.005 0.006 0.003 
FBLN1D Mean  0.092 0.065 0.099 0.067 0.107 0.074 
SD 0.004 0.006 0.012 0.004 0.007 0.004 
IL-6 Mean  0.073 0.075 0.078 0.071 0.065 0.066 
SD 0.012 0.010 0.007 0.010 0.001 0.004 
α-SMA Mean  0.131 0.213 0.133 0.214 0.135 0.251 
SD 0.007 0.029 0.007 0.024 0.016 0.024 
FBLN5 Mean  0.075 0.077 0.077 0.079 0.080 0.084 
SD 0.003 0.005 0.003 0.002 0.002 0.002 
Primary parenchymal fibroblasts from patients with IPF (n=5) and age and gender matched 
patients without IPF (n=4) patients with COPD (n=4) were grown for 72 hours in 5% 
FBS/DMEM /1% pen-strep, quiesced in 0.1% FBS/DMEM /1% pen-strep for 24 hours and 
either left unstimulated in fresh 0.1% FBS/DMEM /1% pen-strep (Basal) or stimulated for a 
further 72 hours with 10ng/mL TGFβ1 in 0.1%FBS/DMEM /1% pen-strep.   
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated from the 
tumour-free margin of resections from patients with non-small cell carcinoma. 500ng of 
mRNA was converted to cDNA for this comparison.  
COPD chronic obstructive pulmonary disease , IPF idiopathic pulmonary fibrosis, n Number, 
TGFβ1 transforming growth factor-beta 1, FBS foetal bovine serum, DMEM Dulbecco’s 
Modified Eagle Medium, Pen-Strep penicillin-streptomycin, IL interleukin, SMA smooth 
muscle actin, FBLN5 fibulin-5 
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4.3.5 The effect of TGFβ1 on cell-derived ECM proteins in primary 
parenchymal fibroblasts 
The primary focus of this Chapter was the effect of TGFβ1 on cell-derived fibulin-1 
because of the hypothesis that increased TGFβ1 may be a driving factor leading to 
increased fibulin-1 found in the parenchyma tissue, which was shown to correlate 
with decreased lung function in patients with IPF (Figure 2.11, Table 2.7). Therefore, 
the effect of TGFβ1 on fibulin-1 protein production in fibroblasts was next examined. 
Figure 4.8 shows an example blot of cell supernatants probed for fibulin-1.  
Figure 4.9 shows the matching blot of cell lysates from the corresponding samples 
also probed for fibulin-1. 
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Figure 4.8 Example blots of supernatants probed for fibulin-1 from 
fibroblasts derived from patients with and without IPF 
Primary parenchymal fibroblasts from patients with IPF (n=3) and age 
and gender matched patients without IPF (n=3) were grown for 72 hours 
in 5% FBS/DMEM /1% pen-strep, quiesced in 0.1% FBS/DMEM/1% 
pen-strep,  for 24 hours and either leftunstimulated in 0.1% 
FBS/DMEM/1% pen-strep  (-) or stimulated for a further 72 hours with 
10ng/mL TGFβ1in 0.1%FBS/DMEM /1% pen-strep (+). 
 (+ve) indicates cell secreted fibulin-1 protein as a positive control. 
Non-IPF fibroblasts were derived from the macroscopically normal 
tissue isolated from the tumour-free margin of resections from resections 
from patients with non-small cell carcinoma. 
 IPF idiopathic pulmonary fibrosis, n Number, TGFβ1 transforming 
growth factor-beta 1, FBS foetal bovine serum, DMEM Dulbecco’s 
Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
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Figure 4.9 Example blots of cell lysates probed for fibulin-1 and GAPDH from fibroblasts derived from patients with and without IPF 
Primary parenchymal fibroblasts from patients with IPF (n=3) and age and gender matched patients without IPF (n=3) were grown for 72 hours 
in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep for 24 hours and either left (-) unstimulated in 0.1% 
FBS/DMEM/1% pen-strep or (+) stimulated for a further 72 hours with 10ng/mL TGFβ1in 0.1%FBS/DMEM/1% pen-strep. (+ve) indicates cell 
secreted fibulin-1 protein as a positive control. 
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated from the tumour-free margin of resections from resections 
from patients with non-small cell carcinoma. IPF idiopathic pulmonary fibrosis, n Number, TGFβ1 transforming growth factor-beta 1, FBS 
foetal bovine serum, DMEM Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin, GAPDH Glyceraldehyde 3-phosphate 
dehydrogenase 
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There was a differential effect of TGFβ1 on the cell-secreted ECM proteins that were 
measured. Treatment with TGFβ1 significantly decreased fibulin-1 levels and this 
effect was consistent across all the disease groups. Conversely, TGFβ1 increased 
periostin levels in fibroblasts from patients with IPF, but had no effect on periostin 
levels in fibroblasts from subjects without IPF or with COPD (Figure 4.10).   
TGFβ1 significantly increased the production of IL-6 in both fibroblasts from subjects 
without lung disease and from patients with IPF (Figure 4.11A) however, there was 
no significant effect on fibroblasts from patients with COPD.  
In the absence of stimulation, fibroblasts from patients with COPD produced a 
significantly higher level of both IL-6 and IL-8 cytokines compared to fibroblasts 
from subjects without IPF and from patients with IPF (Figure 4.11). Increased levels 
of IL-6 and IL-8 have been reported in fibroblasts derived from patients with COPD 
(Zhang et al. 2012). There was no effect of TGFβ1 on IL-8 production in any of the 
three disease groups (Figure 4.11B).  
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4.3.5.1 The effect of TGFβ1 in cell-secreted protein production of ECM 
proteins. 
Figure 4.10 The effect of TGFβ1 on cell-secreted ECM protein production in 
primary parenchymal fibroblasts. 
 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender 
matched patients without IPF (n=7) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS DMEM/1% pen-strep 
for 24 hours and either left unstimulated in fresh 0.1% FBS/ DMEM/1% pen-strep  
(●) or stimulated for a further 72 hours with 10ng/mL TGFβ1 in 0.1% FBS/ 
DMEM/1% pen-strep (■)  (*paired t-test, p<0.05). 
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from patients with non-small cell 
carcinoma..  
Values were normalized to the total protein content of the cell monolayer as measured 
by BCA assay.  
BCA Bicinchroninic Acid, ECM extracellular matrix, COPD chronic obstructive 
pulmonary disease, IPF idiopathic pulmonary fibrosis, TGFβ1 transforming growth 
factor-beta 1, FBS foetal bovine serum, DMEM Dulbecco’s Modified Eagle Medium, 
Pen-Strep penicillin-streptomycin 
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Figure 4.11 The effect of TGFβ1 on cell-secreted cytokine protein production in 
primary parenchymal fibroblasts. 
 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender 
matched patients without IPF (n=7) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM, quiesced in 0.1% FBS/DMEM for 24 hours and either left 
(●) unstimulated or (■) stimulated for a further 72 hours with 10ng/mL TGFβ1 in 
0.1% FBS/DMEM (*paired t-test, p<0.05). 
(A) IL-6 and (b) IL-8 in cell culture supernatants were measured by ELISA. Values 
(ng/mL) were normalized to the total protein content of the cell monolayer as 
measured by BCA assay.  
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from patients with non-small cell 
carcinoma.  
BCA Bicinchroninic Acid, COPD chronic obstructive pulmonary disease, IPF 
idiopathic pulmonary fibrosis, TGFβ1 transforming growth factor-beta 1, FBS foetal 
bovine serum, DMEM Dulbecco’s Modified Eagle Medium, 
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4.3.6 The effect of TGFβ1 on cell-associated fibulin-1 production by primary 
parenchymal fibroblasts 
Basal expression of cell-associated (containing intracellular and membrane bound 
proteins) fibulin-1 protein was increased in fibroblasts from patients with IPF 
(Chapter 2, Figure 2.8) compared to fibroblasts from patients without IPF and patients 
with COPD. Therefore the effect of TGFβ1was investigated in this system. Treatment 
with TGFβ1 significantly increased cell-associated fibulin-1 production by fibroblasts 
derived from patients with IPF (Figure 4.12). There was no effect of TGFβ1 in either 
of the other two groups. Figure 4.9 shows a representative western blot.  
4.3.7 Basal morphology of primary parenchymal fibroblasts 
The basal morphology of fibroblasts from patients with and without IPF was then 
qualitatively examined. Cultures of fibroblasts derived from three subjects without 
lung disease and three patients with IPF were used to generate data addressing the 
final aim of this Chapter. Cells were grown on uncoated plastic dishes. There were no 
macroscopic differences in gross morphology between the cultures of fibroblasts 
grown in basal conditions (Figure 4.13).  
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Figure 4.12 The effect of TGFβ1 on cell-associated fibulin-1 production by 
primary parenchymal fibroblasts. 
 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender 
matched patients without IPF (Non-IPF, n=7) patients with COPD (n=4) were grown 
for 72 hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS DMEM/1% 
pen-strep for 24 hours and either left unstimulated in fresh 0.1% FBS/ DMEM/1% 
pen-strep  (●) or stimulated for a further 72 hours with 10ng/mL TGFβ1 in 0.1% FBS/ 
DMEM/1% pen-strep (■). Cell lysates were collected and analysed by western blot. 
Blots were stripped and reprobed for GAPDH as loading control (*paired t-test, 
p<0.05) and data were normalised to these protein levels. 
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from patients with non-small cell 
carcinoma. 
COPD chronic obstructive pulmonary disease, IPF idiopathic pulmonary fibrosis, 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase, TGFβ1 transforming growth 
factor-beta 1, FBS foetal bovine serum, DMEM Dulbecco’s Modified Eagle Medium , 
Pen-Strep penicillin-streptomycin 
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Figure 4.13 Images of fibroblast monolayers from patients with and without IPF. 
Primary parenchymal fibroblasts from patients with IPF (n=3) and age and gender 
matched patients without IPF (n=3). Cells were grown for 72 hours in 5% 
FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep for 24 hours 
and maintained in fresh 0.1% FBS/DMEM/1% pen-strep for a further 72 hours. Non-
IPF fibroblasts were derived from the macroscopically normal tissue isolated from the 
tumour-free margin of resections from patients with non-small cell carcinoma.  
IPF idiopathic pulmonary fibrosis, FBS foetal bovine serum, DMEM Dulbecco’s 
Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
Magnification 10x 
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4.3.8 The effect of TGFβ1 on cell morphology 
Qualitative changes in morphology were seen in all fibroblast cultures when treated 
with 10ng/mL TGFβ1 for 72 hours (Figure 4.14). Regardless of disease status, 
fibroblasts responded to TGFβ1 treatment by assembling in tight colonies and losing 
their spindle-like extensions that are seen under basal conditions.  
Next, the effect of treatment with TGFβ1 on the surface topology and stiffness of the 
cells was quantified by AFM. Scans were performed on  two cell lines, one from a 
patient with IPF and one from a patient without IPF. Each cell line was either treated 
with TGFβ1 or left unstimulated and  a single area, measuring 50µm by 50µm, from 
each sample was investigated.  Areas of similar gross apperance were selected to 
undergo AFM scanning. The surface topography of the four samples is shown in 
Figure 4.15. 
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Figure 4.14 Fibroblasts treated with 
TGFβ1 undergo morphological changes. 
 Representative light microscopy images 
of primary parenchymal fibroblasts from 
patients without (top panels) or with 
idiopathic pulmonary fibrosis (IPF) 
(bottom panels) are shown. Cells were 
grown for 72 hours in 5% FBS/DMEM/ 
1% pen-strep, quiesced in 0.1% FBS/ 
DMEM/1% pen-strep for 24 hours and 
either left unstimulated in fresh in 0.1% 
FBS/DMEM/1% pen-strep or stimulated 
for a further 72 hours with 10ng/mL 
TGFβ1 in 0.1% FBS/DMEM /1% pen-
strep. Images are representative of three 
fibroblast lines per group. 
Arrows indicate places of spindle-like 
extensions of fibroblasts. Non-IPF 
fibroblasts were derived from the 
macroscopically normal tissue isolated 
from the tumour-free margin of resections 
from patients with non-small cell 
carcinoma. 
TGFβ1 transforming growth factor-beta 1, 
FBS foetal bovine serum, DMEM 
Dulbecco’s Modified Eagle Medium, Pen-
Strep penicillin-streptomycin. 
Magnification 10x 
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Figure 4.15 Surface morphology of fibroblasts derived from patients with and 
without idiopathic pulmonary fibrosis (IPF) as measured by atomic force 
microscopy. 
 
Cells were grown for 72 hours in 5% FBS/DMEM /1% pen-strep, quiesced in 0.1% 
FBS/DMEM /1% pen-strep for 24 hours and either left unstimulated in fresh 0.1% 
FBS/DMEM /1% pen-strep or stimulated for a further 72 hours with 10ng/mL TGFβ1 
in 0.1% FBS/DMEM /1% pen-strep. 
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from a patient with non-small cell 
carcinoma. 
Images are representative of 1-3 scans per patient. 
TGFβ1 transforming growth factor-beta 1, FBS foetal bovine serum, DMEM 
Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
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After scanning for surface topology, the same sample area was then probed for cell 
stiffness. A representative scan from one of the four samples is shown in Figure 4.16. 
 
Figure 4.16 Representative cell height and stiffness scan of fibroblasts as 
measured by atomic force microscopy. 
Fibroblasts were grown on plastic dishes and first scanned for surface topography. 
The “height” image was generated by measuring the deflection of the cantilever from 
a predetermined set point as the cantilever was moved across the surface. 
Subsequently, the same area was probed for “stiffness” by measuring the deflection of 
the same cantilever as the cantilever was indented into the cell surface. Points of red 
indicate where there was no measurement due to instrumental error. 
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These data suggest that there may be a difference in the response to TGFβ1 between 
cells derived from patients with IPF compared to cells derived from patients without 
IPF.  The summary of the force measurements of fibroblast stiffness is found in Table 
4.3. 
The maximum stiffness of fibrotic lung tissue has been reported to be approximately 
50kPa (Liu and Tschumperlin 2011) but this figure can change depending on which 
model is used to calculate the stiffness from the forces measured using AFM. 
Furthermore, where the cells are of minimal thickness, the influence of the underlying 
tissue culture plastic may skew the data. Tissue culture plastic has a stiffness of 
gigapascals (Wells 2008).  Therefore the median and interquartile range (IR) of  
stiffness measurements were initially used to compare the samples.  
Unstimulated cells from a patient without IPF had a median stiffness of 0.6kPa (IR 
0.2 – 1.1) whereas unstimulated cells from a patient with IPF had a median stiffness 
of 0.8kPa (IR 0.5 – 1.2). Under stimulation with TGFβ1, cells from a patient without 
IPF increased in median stiffness to 3.0kPa (IR 1.8 to 6.9), which was an increase of 
400%. Cells from a patient with IPF also increased median stiffness under stimulation  
with TGFβ1to 15.3kPa (IR 10.8 to 24.7), which was an increase of over 1700%.  
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Table 4.3 Summary of Force Measurements on human lung fibroblasts 
 
 Non-IPF 
unstimulated 
Non-IPF 
TGFβ1 
IPF 
unstimulated 
IPF 
TGFβ1 
Number of points measured* 6400 6368 6400 6338 
Number of points not 
analysed** 0 16 0 62 
Average stiffness (kPa) 4.97 26.45 0.99 22.53 
Standard Deviation 57.34 72.47 3.55 40.55 
Minimum Stiffness (kPa) 0.005 0.021 0.046 0.169 
Maximum Stiffness (kPa) 3460.4 514.6 158.7 700.1 
Median Stiffness (kPa) 0.551 3.046 0.839 15.349 
25th Percentile (kPa) 0.249 1.846 0.475 10.841 
75th Percentile (kPa) 1.128 6.855 1.184 24.737 
*Number of points measured in a 50 x 50µm area 
**Unable to analyse due to instrument error 
Primary parenchymal fibroblasts were grown for 72 hours in 5% FBS/DMEM /1% 
pen-strep, quiesced in 0.1% FBS/DMEM /1% pen-strep for 24 hours and either left 
unstimulated in fresh 0.1% FBS/DMEM /1% pen-strep or stimulated for a further 72 
hours with 10ng/mL TGFβ1 in 0.1% FBS/DMEM /1% pen-strep. Surface stiffness of 
cell cultures was measured using atomic force microscopy (AFM) and images were 
generated using Asylum Research software (Igor Pro Version 6.34A). Stiffness 
(Young’s modulus) was calculated using the Derjaguin–Muller–Toporov (DMT) 
model. Non-IPF fibroblasts were derived from the macroscopically normal tissue 
isolated from the tumour-free margin of resections from a patient with non-small cell 
carcinoma. 
Data are generated from a single scan on each cell line per treatment. 
IPF idiopathic pulmonary fibrosis, TGFβ1 transforming growth factor-beta 1, FBS 
foetal bovine serum, DMEM Dulbecco’s Modified Eagle Medium, Pen-Strep 
penicillin-streptomycin 
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The change in the proportions of stiffness measurements that fell between 0 and 
50kPa in the two different cell lines was examined. For this study, a measurement of 0 
to 1kPa was considered normal whereas a measurement of greater than 1kPa to less 
than or equal to50kPa was considered fibrotic. This range (0 to 50kPa) was chosen to 
encapsulate the biological range of stiffness measurements and to discount any 
potential influence of the underlying tissue culture plastic, which measures 
approximately 106kPa (Discher et al. 2005). This assumption was necessary as the 
maximum measured stiffness in the current experiments was 3460kPa. In all cases, 
the total number of points that was disregarded (eg. points that measured more than 
50kPa) was less than 10% of the total number of points that were measured. This 
indicates that the vast majority of each sample area contained cellular material and not 
plastic.  
Because the total number of points that was successfully measured differed and the 
influence of tissue culture plastic may also have differed between the samples the data 
was then expressed as percentages of the “Usable Total”. The Usable Total was 
defined as the total number of points that measured less than or equal to 50kPa. The 
data were normalised by dividing the number of points that fell into each of six 
consecutive and non-overlapping intervals of stiffness (bins) by the Usable Total. This 
gave the relative frequencies, or the proportion of cases that fell into each of the bins. 
The summary of the relative frequencies is found in Table 4.4. Untreated fibroblasts 
from a patient with IPF  exhibited more stiffness values in the fibrotic range than 
untreated fibroblasts from a patient without IPF. Fibroblasts from a patient with IPF 
cultured in non-stimulating conditions had 38% of points of stiffness measure over 
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1kPa whereas fibroblasts from a patient without IPF grown in the same manner had 
only 27% of points of stiffness measure over 1kPa.  
Treatment with TGFβ1 had a similar effect on fibroblasts from patients with and 
without IPF. When stimulated with TGFβ1, fibroblasts from a patient without IPF 
increased to 94% fibrotic (defined as points of stiffness greater than 1kPa) while 
fibroblasts from a patient with IPF were 100% fibrotic. In both groups of fibroblasts, 
cells that were treated with TGFβ1 increased the proportion of points that were in the 
higher stiffness bins. For example, the proportion of points that was greater than 
10kPa but less than or equal to 50kPa was 3% and 0% in unstimulated cells from a 
patient without IPF and from a patient with IPF respectively. Treatment with TGFβ1 
increased the proportion of points in that category to 10% and 80% respectively.  
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Table 4.4 Treatment with TGFβ1 increases the relative frequency of points in the categories of higher stiffness in lung fibroblasts. 
*Count indicates the number of points (x) that fell into each stiffness bin  
**Relative Frequency is the count of each stiffness bin divided by the Usable Total 
***The Usable Total is the number of points measured that fell between 0 and 50kPa. 
TGFβ1 transforming growth factor-beta 1, IPF idiopathic pulmonary fibrosis, kPa kilopascal
 
Non-IPF unstimulated Non-IPF TGFβ1 IPF unstimulated IPF TGFβ1 
Stiffness bin 
(kPa) Count* 
Relative 
Frequency** Count* 
Relative 
Frequency** Count* 
Relative 
Frequency** Count* 
Relative 
Frequency** 
0 > x ≤ 0.2 1253 20% 7 0.12% 276 4% 1 0.02% 
0.2 > x ≤ 0.5 1714 27% 65 1% 1406 22% 2 0.03% 
0.5 > x ≤ 1 1657 26% 259 5% 2280 36% 7 0.11% 
1 > x ≤ 5 604 10% 1506 27% 2294 36% 36 1% 
5 > x ≤ 10 882 14% 3232 57% 135 2% 1171 19% 
10 > x ≤ 50 177 3% 575 10% 3 0.00047% 4937 80% 
More than 50kPa 113 
 
581 
 
6 
 
184 
 
Total  points 
measured 6400 
% of total 
points 
measured 
6224 
% of total 
points 
measured 
6400 
% of total 
points 
measured 
6338 
% of total 
points 
measured 
Usable Total*** 6287 98% 5643 91% 6394 100% 6154 97% 
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4.4 Discussion 
The aim of this chapter was primarily to investigate if fibulin-1 levels in primary 
parenchymal fibroblasts were altered by treatment with TGFβ1, a pro-fibrotic 
pluripotent cytokine and a key driver of the fibrotic process. Previous studies had 
indicated that TGFβ1 had the ability to induce fibulin-1 production in the context of 
fibrotic airways disease (Lau et al. 2010) and therefore possibly played a role in 
interstitial fibrosis as many of the mechanisms driving fibrogenesis in lung diseases 
are shared (Hardie et al. 2009). Therefore, this study aimed to investigate the effect of 
TGFβ1 on lung fibroblast-derived fibulin-1 and the ECM molecules (periostin, 
tenascin-C and fibronectin) investigated in earlier chapters as TGFβ1 is known to 
induce these proteins in other mesenchymal cells (Horiuchi et al. 1999; Doerner and 
Zuraw 2009). Lung fibroblasts, regardless of disease status, change morphologically 
when treated with TGFβ1, and these results in turn suggest may result in increased 
cell stiffness. A summary of the results in Chapter 4 is found in 
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Table 4.5. 
This study provides evidence that stimulation with 10ng/mL TGFβ1 significantly 
decreases fibulin-1 mRNA at 24, 48 and 72 hours in fibroblasts derived from patients 
without IPF (Non-IPF fibroblasts), patients with emphysema (COPD fibroblasts), or 
patients with IPF (IPF fibroblasts).  This decline in fibulin-1 mRNA levels across all 
disease groups was consistent and the mRNA levels for all four isoforms of fibulin-1 
were reduced by the TGFβ1 treatment. This shows that although there were 
differences in basal levels of fibulin-1 isoforms between disease groups, these 
differences are negated in the presence of TGFβ1, resulting in similar levels of 
fibulin-1 mRNA in fibroblasts regardless of disease group. The depressive effect of 
TGFβ1 treatment on fibulin-1 mRNA is also seen in airway smooth muscle (ASM) 
cells derived from patients with and without COPD (Chen et al. 2013), indicating that 
this phenomenon is not limited to parenchymal fibroblasts.   
In contrast, treatment with TGFβ1 had a consistent inductive effect on both 
fibronectin and α-SMA mRNA across the board, a finding which is supported by 
previous reports in the literature (Thannickal et al. 2003; Dunkern et al. 2007) and 
indicates a successful response to TGFβ1 stimulation in our study. The effect of 
TGFβ1 on cytokine production in fibroblasts was also supported by the literature (Ge 
et al. 2012). Finally, in the absence of stimulation, COPD fibroblasts produced a 
significantly higher level of both IL-6 and IL-8 cytokines compared to Non-IPF and 
IPF fibroblasts, again consistent with previous reports in the literature (Zhang et al. 
2012). These data provide evidence that the differences in fibulin-1 production among 
fibroblasts from patients with different diseases are disease specific. 
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Messenger RNA and protein levels do not necessarily track with one another 
(Kalinichenko et al. 2008). As this study was investigating the fibrotic signal found in 
the circulation, the effect of TGFβ1 treatment on the soluble, cell-secreted form of the 
ECM molecules was examined. Differences in soluble protein regulation between the 
disease types examined were identified, consistent with earlier literature investigating  
tenascin-C and periostin  (Carey et al. 2010; Yamaguchi et al. 2013).  
This is the first study to show that TGFβ1 significantly decreased the amount of cell-
secreted fibulin-1 produced by fibroblasts in all the disease groups studied. In 
addition, a concomitant increase in cell-associated fibulin-1 levels was observed only 
in IPF fibroblasts. The simplest explanation for this is that TGFβ1 directly drives cell-
secreted fibulin-1 into the ECM although the source of the soluble fibulin-1 may in 
fact be coming from the cell culture media. However, in previous studies from our 
laboratory, treatment of ASM cells with TGFβ1 also decreased  cell-secreted fibulin-1 
levels derived from the cells while increasing cell-associated fibulin-1. Importantly, 
the subsequent increase in cell-associated fibulin-1 levels were not due to de novo 
synthesis of protein, but rather from requisition of cell-secreted fibulin-1 (Chen et al. 
2013).   
Many ECM proteins are likely to be dysregulated during fibrosis, therefore, due to the 
promiscuous nature of TGFβ1, this study investigated the effect on ECM proteins 
which were potential candidate biomarkers of disease progression in IPF. Periostin 
mRNA has been reported to be increased in IPF fibroblasts compared to Non-IPF 
fibroblasts (Naik et al. 2012). This finding was not confirmed in this study, albeit this 
may be explained by a difference in experimental timings between the studies. 
However, following reports in periodontal ligament fibroblasts (Wen et al. 2010), and 
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embryonic lung fibroblasts (Takayama et al. 2006), this study confirmed that TGFβ1 
increased periostin mRNA in lung IPF fibroblasts. Furthermore, this is the first study 
to report increases in periostin protein following TGFβ1 stimulation in adult lung 
fibroblasts, although TGFβ1 has been shown to induce cell-secreted periostin protein 
in transfected bone stromal cells previously (Oku et al. 2008).  
TGFβ1 did not upregulate either cell-secreted periostin or tenascin-C protein in Non-
IPF or COPD fibroblasts. However, in IPF fibroblasts, cell-secreted periostin but not 
tenascin-C was increased. In the literature, cell-associated periostin increases with 
TGFβ1 treatment in mouse osteoblast cells (Horiuchi et al. 1999), supporting the data 
generated in this study. Periostin has been identified as a potential biomarker of 
disease progression in IPF (Naik et al. 2012) and its significance as a protein that 
stabilises the ECM is shown through its interactions with tenascin-C and collagen (Kii 
et al. 2010). The current study indicates that periostin may also be an important 
contributor to the fibrotic process in the presence of increased levels of TGFβ1. 
Periostin, which is produced as a cytokine from airway epithelial cells (Sidhu et al. 
2010), can induce a TGFβ-dependent secretion of type I collagen by airway 
fibroblasts. Periostin is known to stimulate the TGFβ pathway itself (Sidhu et al. 
2010). It is possible that a similar mechanism of ECM modulation is at work in the 
distal parenchymal fibroblasts as well. In solution, periostin mixes with collagen and 
alters its cross-linking or fibrillogenesis (Sidhu et al. 2010) and may explain the 
increased lung tissue stiffness seen in fibrosis (Norris et al. 2007). This action of 
soluble ECM molecules affecting the 3-dimensional orientation of larger ECM fibres 
is a concept not fully explored in the context of IPF. Our study exposes the possibility 
that this increased deposition of fibulin-1 and the increased secretion of periostin may 
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be altering the physical properties of fibroblasts and by extension, the lung tissue. Our 
study does not distinguish between extracellular and  intracellular stores of fibulin-1, 
and therefore, further investigation  around  matrices from which cells have been 
removed is needed.   
ECM proteins determine the biomechanical properties of the lung (Faffe et al. 2006). 
In this Chapter, treatment with TGFβ1 altered both the gross morphology and surface 
stiffness of Non-IPF and IPF fibroblasts. The median stiffness measurements of the 
fibroblasts were higher than those reported in the literature for lung fibroblasts (Liu et 
al. 2010) but this is likely due to the effect of fixation which has been shown to 
increase overall cell stiffness (Codan et al. 2013). Because live cells could not be 
investigated in our experimental set up, all cultures were fixed for the same length of 
time. 
From the images of the fibroblast monolayer cultures morphological changes are 
visible following TGFβ1 stimulation in both Non-IPF and IPF fibroblasts. At this 
same timepoint (72 hours), there was an increase in fibulin-1 deposition only in the 
IPF fibroblasts. Furthermore, experiments with representative samples of Non-IPF 
and IPF fibroblasts indicate that treatment with TGFβ1 may increase the proportion of 
the cell’s surface that demonstrates a high level of stiffness in both groups. However, 
the increase in stiffness was far greater in IPF fibroblasts compared to Non-IPF 
fibroblasts.  
It is possible that the difference in the change of stiffness pattern is due to the 
increased deposition of fibulin-1. Further investigation, beyond the scope of this 
thesis is required to map the distribution of the fibulin-1 onto the stiffness maps of the 
fibroblasts to elucidate the potential relationship between the fibroblast stiffness and 
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fibulin-1 deposition. In addition, expanded experiments exploring the effect of TGFβ1 
on cell stiffness are needed. Increased cell stiffness may also be a result of increased 
periostin deposition (Sidhu et al. 2010), or altered cytoskeletal arrangements (Jester et 
al. 1999) but these aspects were not studied as part of this thesis.  
Experiments using fibulin-1 and/or periostin gene-silenced fibroblasts and stimulation 
with TGFβ1 could elucidate if these ECM proteins are playing a significant role in 
orchestrating the cell stiffness.  
TGFβ1 is increased in the tissue of patients with IPF (Lepparanta et al. 2012) and 
would therefore be continuously present in the context of the disease. Our 
experiments indicate that fibroblast-secreted fibulin-1 may be driven into the ECM by 
TGFβ1. In the context of IPF, where fibroblast-secreted fibulin-1 is increased, this 
may result in increased stiffness of parenchymal fibroblasts and consequently, a stiffer 
lung which then results in decreased lung function.  
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Table 4.5 Summary of results in Chapter 4 
Grey box indicates experiment not undertaken as part of this thesis 
Primary parenchymal fibroblasts from patients with IPF (n=8) and age and gender 
matched patients without IPF (n=7) patients with COPD (n=4) were grown for 72 
hours in 5% FBS/DMEM/1% pen-strep, quiesced in 0.1% FBS/DMEM/1% pen-strep 
for 24 hours and either left unstimulated (in fresh 0.1% FBS/DMEM/1% pen-strep) or 
stimulated for a further 72 hours with 10ng/mL TGFβ1 in 0.1% FBS/DMEM/1% pen-
strep. Significant results are shown with the direction of the relationship between 
unstimulated and TGFβ1 treated cells indicated by the arrows (paired t-test, p<0.05).  
 
Non-IPF fibroblasts were derived from the macroscopically normal tissue isolated 
from the tumour-free margin of resections from patients with non-small cell 
carcinoma. 
COPD chronic obstructive pulmonary disease, IPF idiopathic pulmonary fibrosis, ns 
not significant, TGFβ1 transforming growth factor-beta 1, FBS foetal bovine serum, 
DMEM Dulbecco’s Modified Eagle Medium, Pen-Strep penicillin-streptomycin 
 
 
 
 
 
What is the effect of TGFβ1 on 
ECM proteins in primary 
parenchymal fibroblasts? 
Non-IPF COPD IPF 
mRNA 
Fibulin-1 ↓ ↓ ↓ 
Periostin ns ns ↑ 
Tenascin-C ns ns ns 
Fibronectin ↑ ↑ ↑ 
Cell-secreted 
Fibulin-1 ↓ ↓ ↓ 
Periostin ns ns ↑ 
Tenascin-C ns ns ns 
Cell-associated Fibulin-1 ns ns ↑ 
Cell stiffness Stiffness ↑  ↑ 
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Chapter 5. General Discussion  
5.1 Summary and conclusions 
Although pulmonary fibrosis is a feature of many interstitial lung diseases (ILDs), a 
diagnosis of idiopathic pulmonary fibrosis (IPF) carries with it the poorest prognosis.  
For many patients, disease progression is a foregone conclusion as there is no 
effective treatment for this disease and there have been no improvements in drug-
based therapy in decades. At this moment in time, patients with IPF face a median 
survival time of 2-5 years but often without the knowledge of whether lung function 
decline will proceed rapidly or remain stable for years (Mura et al. 2012). 
The fibrotic extracellular matrix (ECM) is now recognized as an important initiator, 
and driver, of the fibrotic process, but the contribution of individual components of 
the ECM has not been fully investigated. The experiments described in this thesis 
have, for the first time, identified the ECM protein fibulin-1 as a biomarker of disease 
progression in patients with IPF. Importantly, serum fibulin-1 levels were able to 
accurately identify patients with IPF who experienced rapid lung function decline 
independent of other predictors of survival (eg. baseline lung function).   
IPF is a rare and heterogeneous disease. The diversity in the location from which 
patients’ samples were sourced, coupled with the multiple patient materials that have 
been studied in this thesis highlights the consistency of the findings that fibulin-1 may 
be an important factor in the fibrogenic process. This study involved patients from 
three continents and researchers from seven institutions. Through these extensive 
networks of collaborators, investigations on patterns of ECM expression in serum, 
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lung lysates, fixed tissue, as well as isolated fibroblasts of patients with and without 
lung diseases was performed. Studies comparing fibroblasts derived from patients 
with various lung diseases have shown that differences in protein expression are 
maintained in-vitro (Marinkovic et al. 2012; Habiel and Hogaboam 2014) and 
therefore may reflect important differences in disease pathogenesis in-vivo. Building 
an extracellular foundation in any organ requires that component proteins are secreted 
from resident or invading cells in a soluble form and are then cross-linked into a 
deposited network by a cell-driven process with the help of existing “helper” 
molecules (Frantz et al. 2010). Some of these helper ECM proteins can be detected in 
the peripheral blood and serve as biomarkers of active fibrogenesis (Inoue et al. 
2013).  
Experiments in this study showed that fibulin-1 was a better biomarker of disease 
progression in IPF than the ECM proteins fibronectin, periostin and tenascin-C. This 
is an important finding considering that there are over 300 ECM proteins that could be 
dysregulated in the context of fibrosis (Booth et al. 2012) but not all are predictive of 
the disease process. In our study we confirmed that periostin, being the only other 
ECM protein identified as a potential biomarker for IPF (Naik et al. 2012), was also 
increased in both the serum and tissue of patients with IPF, but periostin did not 
predict disease progression these patients with IPF.  
Fibulin-1 is secreted by lung fibroblasts and it is possible that the increased fibulin-1 
in the serum of patients with IPF is a reflection of increased fibulin-1 production by 
fibrogenic fibroblasts. The basal expression of fibulin-1 was increased in fibroblasts 
derived from patients with IPF (IPF fibroblasts) compared to fibroblasts derived from 
patients without IPF (Non-IPF fibroblasts). This may also explain the source of the 
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increased fibulin-1 found in the lung tissue of patients with IPF. However, fibroblasts 
are not the only cell type known to be dysregulated in fibrosis and therefore other 
cells may be contributing the increased serum fibulin-1 levels in patients with IPF. 
Parenchymal lung mechanics can be altered by increased ECM deposition (Faffe and 
Zin 2009) but it is the expression of α-smooth muscle actin (α-SMA) and stress fibres 
that determines the physical properties of fibroblasts themselves (Thoelking et al. 
2010). Both ECM deposition and  actin/stress fibre formation in fibroblasts are driven 
by transforming growth factor –β1 (TGFβ1) (Willis and Borok 2007) and therefore 
the effect of TGFβ1 on fibroblast-derived fibulin-1 was examined in the final Chapter 
of this thesis. 
In this study, the effect of TGFβ1 was highly varied, keeping with the pleiotropic 
nature of the cytokine. This study is also the first to demonstrate that TGFβ1-induced 
cell-associated fibulin-1 production was limited to IPF fibroblasts and not Non-IPF or 
COPD fibroblasts. TGFβ1 increased the stiffness of both Non-IPF and IPF fibroblasts, 
albeit much more dramatically in IPF fibroblasts. This increase in stiffness may be 
attributed to increased cellular fibulin-1 deposition in IPF fibroblasts compared to 
Non-IPF fibroblasts, but this remains to be investigated in future studies. 
5.2 Fibulin-1 is a biomarker of disease progression in IPF 
Biomarkers of disease progression in patients with pulmonary fibrosis are needed to 
aid in current clinical management and treatment. As shown in Chapter 2, fibulin-1 is 
an attractive candidate biomarker as its levels are elevated in the serum, whole lung 
lysates, fixed lung tissue and isolated parenchymal fibroblasts of patients with IPF 
compared to subjects without IPF. Furthermore, patients with IPF had higher serum 
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fibulin-1 levels compared to patients with sarcoidosis and in patients with “other” 
ILDs examined, of which 74% (26 out of 35) had connective-tissue disease related 
ILD.  In addition, patients with IPF were the only ILD category in this study to have 
serum fibulin-1 levels greater than subjects without lung disease, after adjustments for 
age, gender and smoking history were made.   
While it would be reasonable to conclude that elevated fibulin-1 levels were a feature 
of IPF alone, a wide range of serum fibulin-1 levels is shared between ILDs. It is 
possible that serum fibulin-1 levels are simply a reflection of the fibrotic environment 
in a particular ILD patient and relate to a general state of active lung fibrosis, not a 
specific feature of IPF. In support of this hypothesis, this study also showed that 
serum fibulin-1 levels were inversely correlated with disease severity (as measured by 
the extent of fibrosis represented by the composite physiologic index) in patients with 
ILDs, including IPF. The follow up period of the patients in this study was a 
minimum of one year from blood sampling. Patients with IPF are the most likely to 
experience lung function decline or death (Demedts et al. 2001), and therefore a 
longer period of follow up for patients with other ILDs may be necessary in order to 
investigate the utility of serum fibulin-1 as a marker of disease progression in other 
ILDs, something which was outside the scope of this thesis.  
The contribution of individual components of the ECM to lung mechanics is an area 
that is not well studied and this study was the first to recognize the correlation 
between increased levels of tissue fibulin-1 and decreased lung function in patients 
with IPF. Measuring the level of lung tissue fibulin-1 in two forms (whole lung 
lysates and fixed tissue sections) was important in determining the robustness of the 
results. The amount of elastic fibres, measured as the proportion of lung tissue that is 
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elastic fibre, predicts prognosis in IPF (Enomoto et al. 2013). Because fibulin-1 binds 
elastic fibres (Roark et al. 1995) it is possible that the increased levels of fibulin-1 are 
a manifestation of increased elastic fibre content.  
A correlation between increased elastic fibre content and decreased FVC% has 
recently been reported in patients with IPF (Enomoto et al. 2013). Increased elastic 
fibre content was also predictive of disease progression in IPF (Enomoto et al. 2013). 
However, the correlation between tissue fibulin-1 and FVC% (r = 0.9, p<0.05) was 
much stronger than the correlation reported between elastic fibre content and FVC% 
(r=0.5, p<0.01) leading to the hypothesis that fibulin-1 is not merely a “passenger 
along for the ride” but may be directly influencing lung mechanics. The level of 
fibulin-1 may also directly affect the compliance, or elasticity, of the lung, although 
further experiments are needed to confirm this hypothesis. 
The measured level of fibulin-1 in this study did not take into account any 
fragmentation that may have occurred post-translationally. Fibulin-1 in three types of 
patient materials was measured by western blot and therefore comparisons of the size 
of fibulin-1 between serum, whole lung lysates, and fibroblast-derived protein were 
possible. Western blots of serum showed four bands (weighing 100kDa, 73kDa, 
50kDa and approximately 28-30kDa) for fibulin-1 but blots of lung lysates, fibroblast 
cell-secreted and cell-associated fibulin-1 showed only one band of 100kDa size.  
All measurements of fibulin-1 in this study were based on the 100kDa size band. It is 
possible that the increase of fibulin-1 in the 100kDa band of the serum of patients 
with IPF is the contribution of fibulin-1 from the lung, in particular from the resident 
fibroblast. Previous studies of fibulin-1 in the literature have been measured by 
sandwich ELISA (Cangemi et al. 2011) and as a result, to our knowledge, this is the 
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first study to identify additional fragments of fibulin-1 in the serum that potentially 
could have bioactive properties of their own. Sequence analysis of the other size 
bands of fibulin-1 found in the serum are needed to identify these proteins in order to 
establish if they are fragments of fibulin-1, or artefacts of serum-derived proteins 
binding non-specifically to the fibulin-1 antibody used in the current studies. Should 
future studies determine that the bands of different sizes are fragments of fibulin-1, it 
would be interesting to determine if they also have roles in disease pathogenesis. 
Fibulin-1 can be subjected to degradation by cathepsin D, a protease tasked with 
regulating apoptosis, which generates a bioactive fragment of approximately 65kDa  
named Neostatin that exhibits tumour suppressor activity (Xie et al. 2008). Enhanced 
cathepsin D protein has been reported in the alveolar epithelium of fibrotic lungs, 
particularly in regions of active proliferation (Kasper et al. 1996) and an inverse 
relationship between fibulin-1 and cathepsin D is seen in breast cancer (Pupa et al. 
2004). Both fibrosis and cancer are instances of active ECM remodelling and 
therefore it would be interesting to investigate the consequences of fibulin-1 activity 
following degradation by other proteases involved in the lung fibrotic process such as 
matrix metalloproteinases (MMPs)(Song et al. 2013).  
Dysregulation of fibroblast-derived ECM proteins in IPF is an area ripe for further 
study. It is incredible to realise that in a lifetime, the cells that populate an 
individual’s organs are regenerated many times with little apparent loss of fidelity 
during normal homeostasis (Pellettieri and Sanchez Alvarado 2007). However, in the 
context of disease, studies of decellularized matrices indicate that there may be 
dozens of ECM proteins that are altered in the fibrotic lung (Booth et al. 2012) and in 
IPF, one of these dysregulated ECM proteins is periostin (Naik et al. 2012). 
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Therefore, it was important to investigate, in this study, whether other ECM proteins 
were also dysregulated in the context of IPF and could also be used as biomarkers of 
disease progression in addition to fibulin-1. 
5.3 Dysregulation of  ECM proteins in IPF 
It is now recognized that the ECM plays an active role in determining cell behaviour 
such as morphology (Royce et al. 2009), proliferation (Krimmer et al. 2012), 
migration (Perumpanani et al. 1998), and signalling (Chiquet et al. 2003). The ECM 
has been shown to drive the fibrotic process by producing a fibrogenic positive-
feedback loop by altering particular components of the ECM (Parker et al. 2014). It is 
critical to identify which of the nearly 300 proteins that constitute the ECM are the 
key players to target for future therapies. These proteins (fibulin-1, periostin, tenascin-
C, fibronectin) influence one another (Williams and Schwarzbauer 2009; Kii et al. 
2010) and in Chapter 3 it was demonstrated how relationships between these proteins 
may be important in understanding the pro-fibrotic environment in patients with 
fibrotic interstitial lung disease.   
The results presented in this thesis support a model in which patients with fibrotic 
lung diseases can be stratified by their level of “fibrotic potential” and in addition to 
fibulin-1, the ECM proteins periostin and tenascin-C were also dysregulated in 
patients with IPF. For the purposes of this discussion, the fibrotic potential as been 
defined as the probability that a patient will experience a progressive decline in lung 
function over the course of their disease.  
Within 5 years of diagnosis, 44% of all patients with IPF are expected to die, 
compared with only 2% of patients with sarcoidosis (Demedts et al. 2001) and 
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therefore, in keeping with our definition, patients with IPF have the highest fibrotic 
potential whereas those with sarcoidosis have the lowest. The fibrotic potential of a 
patient may be quantified by sampling serum levels of any number of ECM proteins 
in patients with ILD.  
In this study, 45% (75/167) of patients with ILD exhibited increased levels of at least 
one of the four serum ECM proteins studied.  Pearson’s chi-squared test was used to 
assess whether there was a relationship between  the number of patients who had a 
high level of at least 1 ECM protein and the particular ILD group. The proportion of 
patients who had high levels of serum ECM proteins differed between disease groups 
(Table 5.1). A high level of serum ECM protein was defined as greater than or equal 
to the mean + 2 standard deviations level of that protein measured in the healthy 
controls (n=17). If patients with IPF had the highest fibrotic potential, then it would 
make sense that more than half (52%) of the patients with IPF exhibited high levels of 
at least one of the four ECM proteins we studied (Table 5.1).  
Furthermore, patients with IPF that had a high level of at least one of the ECM 
proteins studied were also more likely to progress within one year of blood draw 
(Table 5.2).  
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Table 5.1 The number of patients with a high serum level of at least one ECM protein is greatest in IPF  
Disease Category (n) 
Fibulin-1 Periostin Tenascin-C Fibronectin At least 1 ECM* 
Count % Count % Count % Count % Count % 
Non-diseased 
Control 17 1 6% 1 6% 0 0% 1 6% 2 12% 
Sarcoidosis 12 0 0% 2 17% 6 50% 2 17% 4 33% 
HP 32 9 28% 6 19% 18 56% 5 16% 16 50% 
"Other" ILD 35 10 29% 6 17% 11 31% 4 11% 16 46% 
IPF 71 28 39% 15 21% 22 31% 14 20% 37 52% 
Total 167 48  30  57  26  75 45% 
The means and standard deviations (SD) of serum levels of the ECM proteins were calculated from n=17 non-diseased controls with no history 
of lung disease. A high level of ECM protein was defined as greater than or equal to the mean+ 2SD of that protein.  
Those patients who had a high level of serum ECM protein were counted individually.  
% is defined as the number of patients who had a high level of ECM protein expressed as a percentage of the total number of patients within 
each disease category. 
*At least 1 ECM is defined as the number of patients who had a high level of at least one of the four ECM proteins. 
Pearson Chi-Square value 9.771, degrees of freedom 4, p=0.044 
”Other” refers to patients with connective tissue-disease related ILD (n=26), Non-specific interstitial pneumonia (n=4), 
lymphangioleiomyomatosis (n=4), and drug-induced ILD (n=1). 
ECM extracellular matrix, ILD intersitital lung disease, IPF idiopathic pulmonary fibrosis, HP hypersensitivity pneumonitis
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Table 5.2 Patients with IPF who had a high ECM level were more likely to 
progress within 1 year of blood draw. 
 
 
The means and standard deviations (SD) of serum levels of fibulin-1, periostin, 
tenascin-C and fibronectin was calculated from n=17 non-diseased controls with no 
history of lung disease.  
A high level of an ECM protein was defined as greater than or equal to the mean + 
2SD level of that protein. A patient was considered to have high ECM levels if any 
one of the four ECM protein levels was high. 
Patients that did not have high serum levels of any of these ECM proteins were 
considered to have normal ECM levels. 
Progression was defined as having a significant fall in lung function (defined as ≥10% 
relative fall in FVC%, ≥15% relative fall in DLCO%, or death one year of blood draw). 
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, ECM extracellular 
matrix
  
Normal 
ECM 
levels 
High 
ECM 
levels 
Total 
patients 
Pearson 
Chi-
Square p-
value 
Non-IPF ILD 
Stable 9 11 20 
0.214 Progressed 4 12 16 
Total Non-IPF 
 
13 23 36 
IPF 
Stable 15 6 21 
0.025 Progressed 11 16 27 
Total IPF 
 
26 22 48 
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Serum levels of periostin and tenascin-C also inversely correlated with lung function 
parameters in patients with ILDs. Like a concentration gradient, it may be that 
increased systemic levels of ECM proteins act to tilt the patient’s circulatory 
microenvironment towards a state of enhanced ECM deposition, outside of de novo 
ECM production. Fibulin-1 incorporation into the ECM requires fibronectin, and 
increasing amounts of fibronectin in the matrix also increases the amount of fibulin-1 
deposited (Godyna et al. 1995). Increases in systemic levels of particular ECM 
proteins may drive the increased deposition of that ECM protein, and potentially also 
proteins that associate with the protein of increased levels, into the lung as more 
“fibrotic building blocks” are available for use during wound healing events. 
One of the mechanisms driving the progression of IPF is thought to be propagated 
through constant damage to the lung (Wilson and Wynn 2009), in which vascular 
homeostasis plays a critical role. The initial stage of wound healing is haemostasis 
and in concert with fibulin-1 (Godyna et al. 1996), it is fibronectin and fibrin that 
form the initial thrombus, or “plug”, that seals the wound (Stenman et al. 1980). 
Fibronectin fibre assembly is of particular importance because collagen fibres do not 
form without the presence of fibronectin (Sottile and Hocking 2002). This provisional 
matrix provides the seed structure for the deposition of collagen that follows (Hernnas 
et al. 1992). In this manner, it is possible that the increased amounts of fibulin-1, 
produced by IPF fibroblasts, could be contributing to fibrosis via the role of fibulin-1 
in the initial clot formation that underlies all fibrosis (Tran et al. 1995). In this study 
increased levels of fibronectin in the patients with ILDs were not seen. It is possible 
that whilst fibulin-1 and fibronectin are known to bind to each other in tissue (Godyna 
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et al. 1995), this does not necessarily mean that the two molecules bind in the 
circulation.   
In the later stages of wound healing, after the initial deposition of the individual 
subunits of collagen, cross-linking of the collagen strands occurs through the 
maturation process of the fibres. During this process, myofibroblasts replace the 
fibronectin in the provisional matrix with decorin. Decorin is a “C” shaped molecular 
bridge that is placed between collagen fibrils as a “spacer,” ensuring uniform distance 
between collagen fibres (Weber et al. 1996). Fibroblasts from patients with 
pulmonary fibrosis also produce more decorin than fibroblasts from non-fibrotic 
subjects (Westergren-Thorsson et al. 2004). This study did not investigate the role of 
decorin in the tissue of patients with IPF and future work is necessary to elucidate the 
relationship between decorin and the ECM proteins studied here. However, similarly 
to decorin, periostin functions as a molecular spacer in collagen fibrillogenesis (Norris 
et al. 2007) and can also alter fibronectin fibres by acting as a bridge linking multiple 
fibronectin fibres (Kudo 2011).   
An essential part of ECM remodelling is collagen fibril formation. Collagen fibril 
formation requires the correct intracellular formation of ECM component proteins in 
the endoplasmic reticulum in a process that involves many molecular chaperones for 
proper folding and secretion (Lamande and Bateman 1999).  Once in the extracellular 
space, the mechanisms involved in tissue-scale ECM formation are complex and often 
require the assistance of fibril-associated molecules that are targeted to the surface of 
collagen precursors (Canty and Kadler 2005).  The mechanisms driving collagen fibril 
formation are outside the scope of this thesis however this study highlighted a novel 
link between fibulin-1 and periostin in lung tissue from patients with IPF. Further 
Page 220 of 252 
 
investigation into the role of fibulin-1 in collagen fibril formation, via the shared 
correlation between fibulin-1 and periostin and periostin and collagen in lung tissue 
from patients with IPF are warranted.  
Whilst levels of tissue periostin and tissue total collagen were also increased in lung 
tissue from patients with IPF, levels did not correlate with lung function in these 
patients with IPF.  Interestingly, tissue periostin did correlate strongly with tissue total 
collagen, as would be expected from prior reports in the literature (Takayama et al. 
2006). Although collagen is a major determinant of lung function (Suki et al. 2005), it 
is possible that the increases seen in periostin/total collagen deposition in the tissue of 
patients with IPF was not as influential on lung function as the increases seen in 
fibulin-1 deposition. Fibulin-1 may have a strong role in determining lung function 
because of its role in elastic fibre formation (Sasaki et al. 1999). Elastic fibres are 
another major determinant of lung function (Faffe and Zin 2009).  
A greater mechanistic understanding of the processes regulating and driving site-
specific fibrogenesis would allow for the development of anti-fibrotic treatments 
potentially capable of “resetting” the dysregulated ECM and restoring normal lung 
architecture and function. Future studies investigating the precise manner in which the 
network of proteins that makes up the ECM are aligned relative to each other are 
needed.  
5.4 Fibulin-1 production in primary parenchymal fibroblasts is 
increased by TGFβ1 in patients with IPF 
Fibroblasts from patients with IPF inherently produce increased levels of fibulin-1, at 
both the gene and protein levels. Chapter 3 was concluded by showing that none of 
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the other three proteins studied in this thesis (periostin, tenascin-C, or fibronectin) 
shared this same characteristic. Fibroblasts are capable of altering specific ECM 
proteins in response to mechanical stress even in the presence of TGFβ1 (Chiquet et 
al. 2003), alluding to parallel production of ECM proteins, as well as growth factors, 
in response to mechanical stress.  
TGFβ1 is a potent inducer of ECM proteins (Zanotti et al. 2010). TGFβ1 is also 
released from activated platelets in the first stages of wound healing (Grainger et al. 
1995). The earlier hypothesis that increased circulating fibulin-1 was driven into the 
matrix during wound healing events was extended in Chapter 4 by including a study 
of TGFβ1 as an inducer of fibulin-1 deposition. The data presented here lead to the 
hypothesis that in a healthy individual, after an injurious event to the lung, in which 
blood vessels are damaged, TGFβ1, perhaps released from platelets, drives fibulin-1 
from the blood into the wound. In a patient with IPF, increased levels of fibulin-1 may 
be deposited in the tissue because of (1) increased levels of circulating fibulin-1, 
and/or (2) increased production of fibulin-1 by fibrotic fibroblasts. 
TGFβ1 increased fibronectin mRNA in lung fibroblasts this study (Chapter 3) and has 
been shown to increase fibronectin protein deposition by lung fibroblasts (Patel et al. 
2012). It is possible that TGFβ1-induced fibronectin deposition subsequently 
increases fibulin-1 deposition. Fibronectin regulates latent TGFβ1 by controlling the 
assembly of the latent-TGFβ1-binding protein-1 into the matrix (Dallas et al. 2005). 
There is extensive evidence that fibronectin is important in the context of fibrotic 
disease (White and Muro 2011) but its significance may actually be due in part to how 
it interacts with other proteins (Muro et al. 2008), for example fibulin-1.  
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Upon activation from its latent state, TGFβ1 stimulation increases other pro-fibrotic 
cytokines such as vascular endothelial growth factor (VEGF) and connective tissue 
growth factor (CTGF) (Lee 2012). Levels of CTGF in the serum have also been 
reported as a biomarker of disease progression in IPF (Kono et al. 2011) and another 
extension of this work could be to investigate the effect of CTGF on fibulin-1. Other 
cytokines such as the tumour cytokine CXCL1/GROα have been reported to decrease 
fibulin-1, resulting in increased cell migration of prostate cancer cells (Kuo et al. 
2012). Additional cytokines may prove to also regulate fibulin-1 deposition, the study 
of which could also broaden the results of this thesis. 
Gene levels of pro-inflammatory cytokines like interleukin (IL)-6 are increased in 
patients with IPF (Pantelidis et al. 2001) and predictive of disease progression (De 
Lauretis et al. 2013). Furthermore, although obvious inflammation is absent in 
patients with established IPF (Keane 2008), TGFβ1 has been shown to induce IL-6 
mRNA in primary human lung fibroblasts (Eickelberg et al. 1999), and in this study, 
also induced IL-6 protein. IL-6 contributes to proliferation and reduces apoptosis in a 
subpopulation of fibroblasts in patients with IPF and is therefore important in disease 
progression (Habiel and Hogaboam 2014).  
Most relevant to our study is that IL-6 can regulate ECM deposition in the context of 
an already disordered ECM. Mice with fibrillin-1 deficiency, a model of Marfan’s 
syndrome which is a connective tissue disorder resulting in heart defects, are 
protected from ECM degeneration when IL-6 is also knocked out (Ju et al. 2014). 
Fibrillin-1 binds fibulin-1 (El-Hallous et al. 2007), and therefore, it is possible for IL-
6 to indirectly affect fibulin-1 deposition into the ECM and could be explored as an 
extension of this study.  
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The deposition of particular ECM proteins gives each tissue ECM a unique 
topography that is generated by an exceedingly complex interaction between 
epithelial, endothelial, adipocyte and fibroblast cells (Frantz et al. 2010). This study 
concluded by examining morphological, and physical, changes in the topography of 
lung fibroblast cells after TGFβ1 stimulation, from which the importance of 
differences in ECM deposition was inferred. 
It was hypothesized that increased fibulin-1 deposition into the ECM decreased lung 
function due to the role that fibulin-1 plays in determining the orientation of larger 
structural fibres such as fibrillin-1, fibronectin (Cooley et al. 2008), and elastic fibres 
(Roark et al. 1995). This was supported by the results presented in Chapter 2, which 
indicated a strong correlation between the level of fibulin-1 deposited in lung tissue 
and the lung function of that patient with IPF. In addition it was concluded, from the 
data presented in Chapter 3, that the relationship between amount of ECM protein and 
lung function was not a feature of just any ECM protein, as periostin did not possess 
this characteristic despite being increased in the same tissue samples from patients 
with IPF. Differences in lung tissue levels of fibulin-1 between patients with and 
without IPF were mirrored in the fibroblasts derived from the aforementioned 
patients. 
Fibroblasts from a patient with IPF were stiffer than fibroblasts from a patient without 
IPF. Furthermore, while TGFβ1 stimulation increased the stiffness of both Non-IPF 
and IPF fibroblasts, TGFβ1 stimulation  increased fibulin-1 production in IPF 
fibroblasts but not in Non-IPF fibroblasts. The mechanism underlying fibulin-1 
deposition by fibroblasts may be regulated by TGFβ1. In support of this possibility, 
greater levels of TGFβ, co-localised with ECM proteins that bind fibulin-1, namely 
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fibronectin and fibrillin-1, are found in the lungs of patients with IPF (Lepparanta et 
al. 2012).  
In a healthy lung, an injury starts a chain of events that terminates in the restoration of 
the normal lung architecture and a return to normal lung function. Any number of 
control-points that lie along this chain of events may become dysregulated in the 
context of fibrotic ILDs that progress to lung failure. IPF is thought to be driven by 
activated fibroblasts that deposit excessive amounts of ECM in an aberrant wound 
response. Understanding this mechanism is of importance because IPF carries the 
greatest public burden due to its lack of treatment and high rate of mortality (Raghu et 
al. 2011).  
A summary of the results in this thesis is found in Table 5.3. The novel findings 
presented in this thesis are illustrated in Figure 5.1. Increased deposition of fibulin-1 
into the tissue ECM may result in decreased elasticity as fibulin-1 is a component of 
elastic fibres. Increased deposition of fibulin-1 may result in the overall stiffening of 
the lung, and eventual loss of function. Levels of circulating fibulin-1 predicted 
disease progression in patients with IPF and could be a useful clinical biomarker. 
Insights into the precise role of fibulin-1 in the ECM and its effect on fibroblasts 
could lead to new therapies for drug development and targeting.  
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 Table 5.3 Summary of thesis  
 
*indicates novel findings 
Grey boxes indicate research questions not undertaken as part of this thesis. 
mRNA messenger ribonucleic acid, IPF idiopathic pulmonary fibrosis 
Research Question     
Biomarker Study Fibulin-1 Periostin Fibronectin Tenascin-C 
1 
Is the biomarker increased 
in the serum of patients with 
IPF compared to controls? 
Yes* Yes No No 
2 
Does the biomarker predict 
progression in patients with 
IPF? 
Yes* No No No 
3 
Is the biomarker increased 
in the tissue of patients with 
IPF compared to controls? 
Yes* Yes No  
4 
Do fibroblasts from patients 
with IPF produce increased 
mRNA of the biomarker? 
Yes* No No No 
5 
In patients with IPF, do 
fibroblasts produce 
increased levels of the 
soluble biomarker protein? 
Yes* No  No 
6 
In patients with IPF, do 
fibroblasts produce 
increased levels of the 
cellular biomarker protein? 
Yes*    
7 
Does TGFβ1 increase the 
biomarker mRNA in 
fibroblasts from patients 
with IPF? 
No* Yes* Yes No 
8 
Does TGFβ1 increase the 
levels of deposited 
biomarker protein in 
fibroblasts from patients 
with IPF? 
Yes*    
Matrix Stiffness Study Non-IPF IPF 
9 Are fibroblasts from patients with IPF stiffer? n/a Yes* 
10 Does TGFβ1 increase the 
stiffness of fibroblasts? Yes Yes* 
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Figure 5.1 Summary of 
the results presented in 
this thesis.  
 
Five novel findings 
presented in this thesis 
are illustrated.  
 
High-resolution 
computed tomography 
scans from a patient 
without (http://www.ers-
education.org/media/836
51/ers_handbook_2nd_s
amplesection.pdf, 
accessed 02-06-14) and 
with IPF (reproduced 
with permission from 
(Raghu et al. 2011)) 
 were used to compare 
the differences in lung 
composition. Lighter 
areas are more solid. 
 
Double-lined black 
arrow represents a 
possible source of 
increased fibulin-1 in the 
serum of patients with 
IPF. 
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5.5 Future Directions 
The main limitation in this study was the inability to study serial samples of serum in 
patients with ILDs. Investigation of the stability of fibulin-1 levels would be 
necessary to confirm the findings presented in this thesis. Furthermore, the results 
described herein would be strengthened following validation in a second study of an 
alternate population of patients with IPF.  
Properties of ECM proteins differ between their soluble form and their cell-associated 
form and ECM proteins can alter collagen fibrogenesis (Flynn et al. 2010).  
Fibroblasts from subjects without IPF showed a different pattern of stiffness 
compared to fibroblasts from patients with IPF (Figure 5.1). Fibroblasts from subjects 
without IPF had a majority of points of stiffness on the normal end of the stiffness 
scale whereas fibroblasts from patients with IPF had a shift in the median towards 
fibrotic levels of stiffness. An additional limitation in the experimental set up required 
that the cells investigated using AFM in this thesis needed to be fixed prior to 
analysis. 
Further follow up work would be required to strengthen these observations. 
Fibroblasts derived  from fibrotic disease states are known to respond to matrices of 
differing stiffness (Marinkovic et al. 2012), but no study has investigated the inherent 
differences between IPF fibroblasts and normal fibroblasts.  
The differences described above may relate to the differential expression of ECM 
proteins, in particular fibulin-1. It would be interesting to see if knockdown of fibulin-
1 has an effect on the stiffness of the overall lung matrix. One way to study this would 
be the use of AFM on lung tissue from fibulin-1 heterozygous knockout mice. A 
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heterozygous knockout would be necessary as homozygous fibulin-1 knockouts are 
embryonically lethal (Kostka et al. 2001).  Mouse models with and without fibulin-1 
would also allow for the study of the effect of fibulin-1 on lung mechanics in vivo. 
Another way to study the effect of fibulin-1 in cell stiffness would be through the use 
of a transfected cell line such as the one that was used as a positive control in this 
study. The HT1080 fibrosarcoma line does not produce fibulin-1 and was transfected 
with the C-isoform of fibulin-1 to study the anti-angiogenic function of fibulin-1 (Xie 
et al. 2008). Differences in the stiffness between HT1080 cell lines transfected with 
and without the fibulin-1 gene would allow for a direct comparison of the impact of 
fibulin-1 on cell stiffness both in the presence and absence of cytokines like TGFβ1. 
TGFβ1 is not the only cytokine that induces fibulin-1. In the cancer literature, 
oestrogen (Nakamoto et al. 2005) and progesterone (Moll et al. 2002) both can induce 
fibulin-1 in ovarian cancer and endometrial stromal cells respectively. Furthermore, 
expression of fibulin-1 is increased in preeclampsia, a pregnancy-specific syndrome 
of which proteinuria (excess serum proteins in the urine) is characteristic (Liu et al. 
2011). Therefore, it would be worthwhile investigating if other cytokines can induce 
fibulin-1 in the context of fibrotic lung disease.  
Dysregulation of fibulin-1 may have subsequent effects on the deposition of other 
ECM proteins as the creation of this complex network involves many players. The 
relationship between ECM proteins has not been extensively studied and as shown in 
the preceding Chapters, ECM proteins correlate with each other. Future work could 
extend the aforementioned experiments of cell stiffness to include studies on the 
deposition patterns of other ECM proteins when fibulin-1 is knocked out. Such 
experiments would go towards elucidating if fibulin-1 is a driver of the fibrogenic 
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process or is merely a bystander, increased through association with some of the key 
players in the progression of fibrosis. Ultimately, a greater understanding of fibulin-1 
and the mechanisms that drive fibrosis would allow for more targeted treatments in 
pulmonary fibrosis.  
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